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ABSTRACT OF THE DISSERTATION
Identification, Development, and Evaluation of Small-Molecule Modulators of 
Nucleotide Metabolism
by
Ethan Wan Rosser
Doctor of Philosophy in Chemistry
University of California, Los Angeles, 2020
Professor Caius Gabriel Radu, Co-Chair
Professor Michael E. Jung, Co-Chair
This dissertation describes the identification, development, and evaluation of small-
molecule modulators of nucleotide metabolism. Nucleotides, well-known for their role as the 
“backbone” of DNA, are essential for a variety of cell processes including energy transfer, 
formation of lipid membranes, and DNA and RNA synthesis. Small molecule-mediated 
inhibition of enzymes involved in nucleotide metabolism has shown promise in various 
therapeutic settings, and our group has demonstrated that inhibition of deoxycytidine kinase 
combined with perturbations to other nucleotide-producing enzymes can effectively treat acute 
lymphoblastic leukemia in mouse models. 
Chapter One details the development and evaluation of inhibitors of deoxycytidine 
kinase. Expanding upon a scaffold previously identified by our group, structure-activity-
	 ii
relationship studies were undertaken in pursuit of a clinically-viable inhibitor. With the goal of 
eliminating the presence of a stereocenter within our lead compound while maintaining low-
nanomolar affinity for deoxycytidine kinase, a series of analogs containing a gem-dimethyl 
moiety was produced. In addition, the preclinical pharmacology of the lead compound, DI-87, 
was evaluated with the aid of PET imaging. 
Chapter Two describes the development and application of a cell-based metabolic 
modifier screening platform that leverages the redundancy in pyrimidine metabolism for the 
discovery of selective uridine monophosphate biosynthesis modulators. In evaluating a library of 
protein kinase inhibitors, multiple compounds which possess nucleotide metabolism modifying 
activity were identified. The JNK inhibitor JNK-IN-8 was found to potently inhibit nucleoside 
transport and engage ENT1. Additionally, the PDK1 inhibitor OSU-03012 and the RAF inhibitor 
TAK-632 were shown to inhibit the therapeutically relevant enzyme DHODH, and their affinities 
were unambiguously confirmed through in vitro assays and co-crystallization with human 
DHODH. 
	 iii
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CHAPTER ONE
Preclinical Pharmacological Evaluation and Further Development of Small Molecule 
Inhibitors of Deoxycytidine Kinase
1.1 Introduction
With critical  roles  in  fundamental  biological  processes  ranging from DNA and RNA 
synthesis  to  energy  transfer  to  lipid  synthesis,  the  importance  of  nucleotides  cannot  be 
overstated.1,2  Given their  essential  character,  levels of purine and pyrimidine nucleotides are 
highly regulated within mammalian systems, and their production is achieved through parallel 
and convergent  biosynthetic  pathways.3,4  The de novo  pathway (DNP) produces  nucleotides 
starting from glucose and simple amino acid precursors, while the nucleoside salvage pathway 
(NSP) recovers preformed nucleosides from the extracellular environment and phosphorylates 
them  to  generate  their  monophosphate  nucleotide  forms.4,5  The  action  of  the  key  enzyme 
ribonucleotide reductase (RNR) converts ribonucleotides (rNs), necessary for essential processes 
such as RNA synthesis and energy transfer,  to their deoxyribonucleotide (dN) forms through 
reduction of the ribose 2’-hydroxyl group, thus generating the dN building blocks required for 
DNA synthesis and repair.6 The salvage pathway for dN synthesis relies upon the action of two 
cytosolic kinases, thymidine kinase 1 (TK1) and deoxycytidine kinase (dCK), to phosphorylate 
deoxyribonucleosides  recovered  from the  extracellular  space  to  their  monophosphate  forms, 
which  are  subsequently  phosphorylated  by  other  kinases  to  produce  deoxyribonucleotide 
triphosphates  (dNTPs).7  Each  kinase  possesses  unique  substrate  specificities;  TK1 
phosphorylates thymidine (dT) and deoxyuridine (dU), while dCK phosphorylates deoxycytidine 
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(dC), deoxyadenosine (dA), and deoxyguanosine (dG).8 Though dCK has specificity for three 
out  of  the  four  dN  precursors  of  nucleic  acids,  it  is  able  to  indirectly  produce  the  fourth 
(deoxythymidine triphosphate, dTTP) by the action of dCMP aminase and thymidylate synthase 
upon the dCK product dCMP, thus generating dTMP.
dCK is a homodimer with monomeric units composed of ten α-helices surrounding a 
five-stranded parallel  β-sheet.9  The protein is  able to adopt several  distinct  conformations to 
accommodate varied nucleoside phosphoryl acceptors (dC, dA, dG) as well as both ATP and 
UTP phosphoryl  donors.10,11  dCK  is  constitutively  expressed,  though  expression  levels  are 
dependent upon tissue type – lymphocytic tissues have high expression, whereas proliferating 
cells such as those of the colon mucosa have intermediate expression, and differentiated tissues 
such as muscle have low expression.7 It has been demonstrated that dCK activity is modulated 
by reversible phosphorylation of Ser74, a residue in a flexible linker region between two of the 
ten α-helices of the monomeric unit.9
The  clinical  utility  of  dCK activity  is  well-established,  as  it  is  the  key  activator  of 
multiple nucleoside analog prodrugs used in antiviral and anticancer therapies.12 Prodrugs such 
as  gemcitabine  are  activated  through  dCK-mediated  phosphorylation  to  yield  their 
monophosphate forms, which are subsequently phosphorylated to their triphosphate forms by 
downstream kinases before incorporation into viral or cancer cell DNA. This incorporation leads 
to DNA damage, stalled replication forks, S-phase arrest, and can eventually lead to apoptosis.13 
Cancer,  viral,  and  other  rapidly-proliferating  cells  are  disproportionately  affected  by  this 
therapeutic  modality,  as  their  increased  rates  of  replication  lead  them  to  greater  levels  of 
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nucleotide-analog incorporation.  The role of  dCK in promoting apoptosis  in cancerous cells, 
albeit indirect,  serves as a preview for potential therapeutic applications of dCK inhibition – 
when confronted with high levels of DNA damage and replication stress, cancer cells undergo 
apoptosis.  DNA damage  can  result  from loss  of  genomic  integrity  through incorporation  of 
nucleotide analogs into newly synthesized DNA (i.e., gemcitabine therapy), or can result from an 
imbalance in cellular dNTP pools.13,14 The latter has been explored as a potential anticancer 
therapy through inhibition of the key NSP enzyme RNR, which as been an important target in 
anticancer therapy for decades. However, the use of RNR-inhibiting agents, such as hydroxyurea 
and  triapine  (3-AP),  has  so  far  proven  unsuccessful  in  clinical  trials,  potentially  due  to  the 
existence of the NSP which becomes upregulated upon DNP-inhibition and thus allows cells to 
maintain  control  over  dNTP  levels.13,15–17  An  appealing  response  to  this  compensatory 
mechanism is to destabilize pool levels through simultaneous inhibition of both the NSP and 
DNP, therefore inducing replication stress response and apoptosis. 
dCK is an intriguing target in anticancer therapy as it is a rate limiting enzyme within the 
salvage pathway of dNTP biosynthesis, and multiple cell lines and tumor samples in the Cancer 
Cell  Line Encyclopedia and The Cancer Genome Atlas,  respectively,  express this  enzyme at 
higher levels when compared to normal tissue.18 Among the cancers listed in these resources as 
having high expression levels of dCK, leukemias and lymphomas are most prominently featured. 
However, despite its ability to provide all four dNs necessary for DNA synthesis and repair, the 
potential clinical implications of inhibiting dCK activity have only recently become clear.  In 
previous  studies,  dCK  has  been  shown  to  play  important  roles  in  hematopoiesis  through 
regulation of dNTP biosynthesis in lymphoid and erythroid progenitors – hematopoiesis was 
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impaired in dCK-/- mice due to lack of dCTP, which resulted in replication stress, S-phase arrest, 
and DNA damage in these progenitors.8,19 dCK has also been demonstrated to activate the G2/M 
checkpoint  in  cells  responding  to  DNA damage.20  Given  its  roles  in  hematopoiesis  and  in 
regulation of cell division, as well as the potential for disruption in dNTP pool levels following 
its inhibition, our group became interested in developing small molecule inhibitors of dCK for 
use in novel anticancer therapies.
Following a high-throughput screening campaign in our lab, two hit compounds were 
identified as low-µM inhibitors of dCK (Figure 1.1A), and their activity was validated through 
inhibition  of  uptake  of  tritiated  deoxycytidine  (3H-dC).21  Subsequent  structure-activity 
relationship (SAR) studies, aided by crystallographic data of early inhibitors complexed with 
dCK, revealed that alkyl substitution of the thiazole 5-position led to increased dCK affinity. This 
knowledge eventually yielded the initial lead compounds DI-38 and DI-39, which had low-nM 
IC50 values in CEM cells (Figure 1.1B). The translational potential of this class of compounds 
was demonstrated by Nathanson et  al.,  who showed that  inhibition of  the DNP through dT-
mediated allosteric regulation of RNR led to upregulation of the NSP in order to avoid lethal 
replication  stress.17  Inhibiting  the  NSP-mediated  production  of  dNs  using  DI-39  while 
simultaneously blocking the DNP with dT proved to be an efficacious therapy against  acute 
lymphoblastic leukemia (ALL) models in mice, and no host toxicity was detected. The proposed 
mechanism involves the activation of cellular replication stress response upon insufficient levels 
of dCTP/dNs for proper DNA synthesis. This lack of dNs leads to S-phase arrest (stalled DNA-
replication), DNA damage, and apoptosis. 
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Figure  1.1  |  Discovery  and  development  of  small  molecule  inhibitors  of  deoxycytidine 
kinase. (A) Structures for initial hit compounds identified by high throughput screen and IC50 
values determined using a 3H-dC uptake assay in L1210 cells. (B) Former lead compound dCK 
inhibitors and IC50 values determined using 3H-dC uptake assay in CCRF-CEM human cells. (C) 
Distinct regions of dCK inhibitor molecular scaffold. (D) Former lead compound dCK inhibitor 
and IC50 value determined using 3H-dC uptake assay in CCRF-CEM human cells. (E) Schematic 
of dCK role in activation of 18F-CFA PET probe.
Despite  the  in  vivo  efficacy of  DI-39 against  models  of  ALL,  it  remained a  sub-par 
clinical candidate as it suffered from metabolic instability and was highly insoluble. In assessing 
the structure and potential areas suitable for modification, the scaffold can be divided into four 
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distinct sections: a substituted phenyl ring represents Part A, which is connected to the 2-position 
of the Part B thiazole ring, which in turn is bound at the 4-position to a Part C linker region 
which connects the thiazole to a Part D pyrimidine ring (Figure 1.1C).  The 2-mercapto-4,6-
diaminopyrimidine Part D of the initial lead compounds was found to be optimal for interaction 
with dCK by Nomme et al., while the 5-propyl moiety of the Part B thiazole was discovered to 
present a metabolic liability.22 It was previously shown that increasing the alkyl chain length at 
the 5-position of the thiazole led to increased dCK affinity,21 but with metabolic considerations 
in mind, a 5-methyl substituent was adopted as the appropriate substitution, despite its lower 
dCK affinity. To compensate for this loss of activity, modification of the Part C linker region was 
explored,  ultimately  leading  to  the  discovery  that  a  methyl  substituent,  specifically  the  R-
enantiomer, led to increased in vitro activity and metabolic stability. Subsequent exploration of 
substitutions of the Part A phenyl ring led to identification of a new lead compound, DI-82, 
which had low-nM affinity for dCK and promising metabolic stability (Figure 1.1D). 
While potent activity against the desired target is an important characteristic for small 
molecule therapeutics, it can mean nothing if the pharmacokinetic (PK) and pharmacodynamic 
(PD) properties of the lead compound are poor. Positron emission tomography (PET) is a widely-
used  non-invasive  imaging  technique  which  has  applications  within  diagnosis,  staging,  and 
therapeutic monitoring in cancer.23,24 Recently, PET imaging has emerged as a promising tool 
for use in drug discovery and development, specifically for PK/PD evaluation.25 In PET imaging, 
a positron-emitting isotope is incorporated into a molecule, and this so-called PET probe is then 
injected into the test subject. As the isotope within the PET probe decays, the emitted positrons 
collide with electrons,  thus initiating an annihilation event  and releasing two gamma rays.23 
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Using a PET scanner, clinicians and researchers are able to detect the gamma rays and track the 
distribution and concentration of the PET probe throughout the body. The first PET probe was 
[18F]-fluoro-2-deoxy-D-glucose (18F-FDG; FDG), a powerful imaging molecule by virtue of the 
Warburg effect in which cancer cells preferentially utilize aerobic glycolysis to meet their energy 
demands.26 FDG is recognized by the glucose transporters GLUT1 and GLUT3, which transport 
the glucose analog into the cell where it is phosphorylated to FDG-6-phosphate by hexokinase.24 
No  longer  a  substrate  for  glycolysis  and  unable  to  escape  the  cell,  the  FDG  PET  probe 
accumulates in all tissues but especially in cancer cells due to their increased levels of glycolysis, 
allowing for cancer imaging through PET scanning.23 
In the context of drug discovery, PET imaging may be used to evaluate the PK and PD of 
lead compounds through incorporation of a positron-emitting isotope into the lead compound, so 
long as isotope addition does not significantly alter the biological properties of the molecule. 
Following  injection,  PET  imaging  allows  for  visualization  and  quantification  of  target 
engagement, and when viewed as a function of time, provides invaluable information regarding 
clearance, metabolism, and kinetics.23 Early use of PET imaging in evaluating lead compounds 
can inform decision-making, accelerate the advancement of promising candidates, and reduce 
failure rates.25,27 PET tracers have been developed for many biological targets and processes, 
including  for  dCK  activity.28–30  The  recently  reported  dCK  PET  probe  [18F]Clofarabine 
( [18F]CFA; CFA) is a purine analog which is phosphorylated by dCK to form cell-retained CFA 
monophosphate, thereby generating a PET-detectable signal in dCK-expressing tissues (Figure 
1.1E). Such tracers can help determine dose-response relationships by directly interrogating the 
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target pathway being altered by the drug. Because of the importance of dCK to the nucleoside 
salvage pathway of healthy tissues, it is necessary to characterize dose-response relationships for 
dCK  inhibition  to  determine  the  optimal  inhibition  necessary  for  maximal  tumor  growth 
suppression without leading to excess toxicity. 
In  Section  One  of  Chapter  One,  the  development  of  lead  dCK  inhibitor  DI-87  is 
described, along with its subsequent preclinical pharmacological evaluation. These studies utilize 
PET  imaging  to  measure  dCK  inhibition,  and  PK-PD  modeling  to  quantify  dose-response 
relationship  between  drug  levels  and  tumor  growth  inhibition.  In  Section  Two,  the  further 
development of small molecule inhibitors of dCK is detailed, with attempts at producing achiral 
low-nM  dCK  inhibitors  detailed.  In  Section  Three,  the  evaluation  of  dCKi  as  nucleoside-
mimetics, or “nucleomimetics”, is detailed.
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Section One: Development and Preclinical Pharmacological Evaluation DI-87, a Novel 
Inhibitor of Deoxycytidine Kinase
Adapted from: Soumya Poddar, Edmund Capparelli, Ethan W. Rosser, Liu Wei, Thuc Le, 
Michael E. Jung, Caius G. Radu, Mina Nikanjam. Biochem. Pharmacol. 2019, 172, Article No. 
113742.
1.1.1  Development,  Synthesis,  and  In  Vitro  Activity  of  DI-87  –  a  Potent  Inhibitor  of 
Deoxycytidine Kinase
We previously  reported the  development  of  DI-3917  and DI-8222,  which were  potent 
inhibitors of dCK but possessed poor solubility and sub-optimal drug-like properties. In an effort 
to address the shortcomings of these compounds, we analyzed the crystal structures of human 
dCK complexed with our lead compounds which revealed that the sulfonamide moiety of DI-82 
formed  hydrogen  bonds  within  the  substrate  binding  pocket.  In  order  to  maintain  these 
interactions while potentially improving solubility, we sought to replace the sulfonamide moiety 
of DI-82 with a morpholine ring. Morpholines are a privileged scaffold in medicinal chemistry, 
with  documented  benefits  such  as  improved  pharmacokinetic  and  metabolic  profiles  for 
molecules bearing this heterocycle.31 Additionally, previous SAR studies upon the dCK inhibitor 
(dCKi) scaffold indicated that modifications within this region were well tolerated.21,22 DI-87 
was synthesized as follows: an SN2 reaction between 4-methoxy-3-hydroxybenzonitrile and 4-(2-
chloroethyl)morpholine  furnished  3  (Scheme  1.1).  Heating  with  an  aqueous  solution  of 
ammonium sulfide  gave  thioamide  4,  which  was  subjected  to  Hantzsch  thioazole  formation 
conditions to yield thiazole 5. Asymmetric Corey-Bakshi-Shibata (CBS) reduction of the ketone 
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resulted in the S-alcohol 6, which was converted into the trifluoroacetate 7 and directly displaced 
via SN2 reaction by 4,6-diamino-2-mercaptopyrimidine to furnish (R)-DI-87 (DI-87) (8).  The 
trifluoroacetate 7 was not isolated due to instability of this intermediate. 
Scheme 1.1 | Synthesis of DI-87a 
aReagents and conditions: (i) 4-(2-chloroethyl)morpholine hydrochloride, Cs2CO3, Acetone:DMF 
1:1, 70 °C, 12 hr, 91%; (ii) (NH4)2S (20% aqueous solution), pyridine, Et3N, 60 °C, 12 hr, 79%; 
(iii)  4-bromo-2,3-pentanedione,  ethanol,  reflux,  4  hr,  54%;  (iv)  (R)-(+)-2-methyl-CBS-
oxazaborolidine, Borane-THF complex, THF, -78 °C, 6 hr, 40%; (v) Trifluoroacetic anhydride, 
DCM, 0 °C, 0.5 hr; (vi) 4,6-diamino-2-mercaptopyrimidine, Cs2CO3, DMF, 80 °C, 3 hr, 27% (2 
steps).
The IC50 values for each enantiomer of DI-87 were determined using a dC uptake assay 
in CEM cells. (S)-DI-87 exhibited a much higher IC50 value (468 ± 2.1 nM) relative to (R)-DI-87 
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(3.15 ± 1.2 nM), consistent with previous studies which showed that the R-enantiomer was the 
active species (Figure 1.2A). (R)-DI-87 treatment rescued CEM cells from the anti-proliferative 
effects of gemcitabine, a dCK-dependent nucleoside analog prodrug used in anticancer therapy, 
with an EC50 of 10.2 nM (Figure 1.2B). Additionally, we observed that protein binding of (R)-
DI-87 (DI-87) is comparatively lower than its predecessor, (R)-DI-82 (DI-82), as measured by 
IC50 of the respective dCK inhibitor in presence of bovine serum albumin (BSA) (Figure 1.2C). 
Figure  1.2  |  DI-87  exhibits  potent  inhibition  of  deoxycytidine  kinase.  (A)  Ability  of 
enantiomeric dCK inhibitors (dCKi) (S)-DI-87 and (R)-DI-87 to inhibit uptake of [3H]-dC in 
CEM T-ALL cells. (B) Dose response of (R)-DI-87 in CEM T-ALL cells treated with 10 nM 
gemcitabine (Gem). (C) Protein binding of (R)-DI-87 and (R)-DI-82 assessed by comparing IC50 
values of the compounds in presence of 25 and 50 mg/ml bovine serum albumin (BSA). 
 
1.1.2 Pharmacokinetics of DI-87
DI-87 concentrations in plasma and tumor were determined for three dose levels: 10, 25, 
and  50  mg/kg,  and  were  obtained  at  a  single  time  point  from  each  mouse.  Plasma  DI-87 
concentrations peaked between 1 and 3 hr (Figure 1.3A). Tumor concentrations were lower than 
plasma by more than 3.5 fold and had a later, more sustained peak at 3–9 hr (Figure 1.3B). 
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Figure 1.3 | Plasma and tumor concentrations of DI-87 inform PK model. Plasma (A) and 
tumor  (B)  concentrations  of  DI-87.  Each  data  point  represents  the  plasma  and  tumor 
concentrations from a single mouse (n = 5 per  time point).  (C) PK-PD modeling parameter 
estimates.
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Table 1
predicted close to full dCK inhibition following 25 mg/kg DI-87 dosing.
Growth inhibition studies were performed using 25 mg/kg daily of DI-
87 in combination with a fixed dose of i.p. thymidine, since DI-87 alone
exhibits minimal growth inhibition. Oral DI-87 at 10 mg/kg was given
in combination with i.p. thymidine to demonstrate a dose–response
relationship with reduced dCK inhibition. Control mice received either
intraperitoneal saline injections alone, oral DI-87 with i.p saline injec-
tions, or thymidine alone. These results were validated in a repeat study
where we explored the effect of full dCK inhibition throughout the
dosing interval, with 25 mg/kg BID of DI-87 administered in combi-
nation with a fixed dose of thymidine as the highest dose. Tumor size
was measured every 3 days after the initiation of drug administration.
Mice administered thymidine alone or DI-87 alone had tumor growth
curves similar to the control (data not shown). Increasing DI-87 doses
resulted in reduced tumor growth, consistent with the dCK inhibition
seen in the PET scans. The changes in tumor size with time are shown in
Fig. 5A.
The tumor sizes from the two studies were used in a combined PK-
PD model. PK parameters from the final combined plasma-tumor model
were fixed and PD parameters were estimated in NONMEM. A super-
exponential function was found to describe the growth of the control
data the best: = eGrowth(t) k t1 k2. An Emax indirect response PD model 9
was found fit the growth inhibition data the best:
= +dA
dT
k k E k k TIME A(1 ) (56 ( ))in out max k1 2 2 1
Final parameter estimates from the model are shown in Table 1.
Emax was 1.06 and EC50 was 3.63 μg/mL. The final model was used for
simulations of two concentrations (10 mg/kg daily, and 25 mg/kg BID).
Fig. 5B demonstrates that the final model fit the experimental data well.
Thus, maximal dCK inhibition over the 24 hr dosing period results in
greater growth inhibition, consistent with the 25 mg/kg BID dose.
4. Discussion
dCK is an intriguing target in anti-cancer therapy as it is a rate
limiting enzyme within the salvage pathway of dNTP biosynthesis, and
multiple cell lines and tumor samples in the Cancer Cell Line
Encyclopedia and The Cancer Genome Atlas, respectively, express this
enzyme at higher levels when compared to normal tissue [10]. Among
the cancers listed in these resources, leukemias and lymphomas are
most prominently featured. While targeting the salvage pathway of
dNTP biosynthesis through dCK inhibition is a relatively new approach,
the key enzyme of the parallel de novo pathway, ribonucleotide re-
ductase (RNR), has been an important target in anticancer therapy for
decades. The RNR inhibitor hydroxyurea (HU) has been used clinically
for cancer treatment and is in clinical trials for novel applications. 3-AP
is also in clinical trials as an anti-cancer agent [11,12]. Although these
compounds are able to inhibit RNR, they each possess dose-limiting
toxicity and limited efficacy [13,14]. A major resistance mechanism to
RNR inhibition therapy is presence of an active dCK-mediated salvage
pathway, which may explain the failure of RNR inhibitors such as 3-AP
in clinical trials. In an effort to circumvent this resistance mechanism,
we developed inhibitors of dCK to be used in combination with RNR
inhibition. We previously reported the development of DI-39 [3] and
DI-82 [15], which were potent inhibitors of dCK but possessed poor
solubility and sub-optimal drug-like properties. To address these
shortcomings, we developed DI-87, a potent, specific, soluble, and
bioavailable dCK inhibitor which has recently gained FDA Investiga-
tional New Drug (IND) approval and will be evaluated in clinical trials
shortly.
In line with our previous studies, we determined that the R-en-
antiomer of DI-87 had a significantly higher affinity for dCK when
compared with the S-enantiomer. The affinity of DI-87 for dCK was
further confirmed through a rescue assay in which the growth of CEM
cells treated with gemcitabine with and without DI-87 supplementation
was monitored. Gemcitabine requires dCK for its cytotoxic effects, and
administration of DI-87 fully prevented cytotoxicity following gemci-
tabine treatment, thereby demonstrating the dCK inhibition of DI-87.
Previous generations of reversible dCK inhibitors developed by our
group had comp rable potency, but did not have optimal biochemical
properties. DI-87 improves upon these properties while maintaining
low-nM affinity for dCK. In particular, DI-82 was an effective dCK in-
hibitor but was heavily protein-bound. By comparison, DI-87 retained
its potency in the presence of albumin.
The preclinical pharmacology of DI-87 was also evaluated. Plasma
concentrations peaked 3 h after oral administration, while tumor con-
centrations maintained a peak between hours 3 and 9. Thus, the tumor-
to-plasma concentration ratio was dependent upon sampling time.
Tumor concentrations were significantly lower than plasma con-
centrations for all doses tested. The PET probe [18F]CFA was used to
quantify dCK activity in tumors, and thus effects of DI-87 upon the
target pathway. Given the differential peaks in plasma and tumor
concentrations, linking DI-87 tumor concentrations to dCK inhibition
provided a more physiologic and mechanistic approach. Our population
PK-PD modeling allowed us to describe limited tumor data and link
these concentrations to dCK inhibition. Full dCK inhibition occurred at
the 10 mg/kg dose and increasing doses led to a longer maintenance of
full inhibition. At the highest dose tested (25 mg/kg), full recovery of
enzyme activity occurred by 36 h, with full inhibition being maintained
at the 12 hr time point. Our PK-PD model suggested a threshold or rapid
switching on-off effect. When evaluated as a single agent, DI-87 was
well tolerated at higher doses, but had essentially no ability to inhibit
growth (data not shown). When DI-87 was administered as repeated
doses in combination with thymidine, full dCK inhibition was main-
tained at 12 h (25 mg/kg twice daily dose) and led to maximal tumor
growth inhibition. Lower doses led to diminished dCK inhibition with
predictable decreases in growth inhibition. Thus, DI-87 appears to have
potential as a cancer therapeutic when used in combination with thy-
midine.
The PET probe used in the current study is a tool to help provide
mechanistically-driven rational dosing of DI-87 and similar compounds
prior to clinical trials. The use of non-invasive PET probes and scans can
greatly aid in drug development. Imaging studies in early phase
Table 1
PK-PD modeling parameter estimates.
Plasma-Tumor PK model parameters
Parameter Estimate Standard Error
CL (L/hr/kg) 0.46 0.03
V (L/kg) 2.78 0.22
KA (hr) 0.66 (FIXED) .
Q (L/hr/kg) 0.0045 0.0013
Scalar 3.69 0.40
Half-life (hr)* 4.2 –
Eta1 (Scalar) 34.6% 0.08
Proportional Error 49.9% 0.04
DCK inhibition PK-PD model
Kout 0.12 0.00011
Emax 1.20 0.00200
EC50 0.31 0.00009
Gamma (Hill coefficient) 58.60 0.18500
Kin 0.76 0.00078
Additive Error 0.88 0.00025
Growth Inhibition PK-PD Model
Kout 0.372 0.0973
Emax 1.06 0.2030
Growth Function Exp 1 0.00498 0.0011
Growth Function Exp 2 1.47 0.0399
EC50 3.63 1.19
Intersubject Variability (Emax) 14.1% 2.65%
Additive Error 0.20 0.02
*Half-life: 0.693/(CL/V).
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Plasma and tumor pharmacokinetics (PK) was also evaluated in male mice following a 10 
mg/kg dose, with essentially identical results to those seen in female mice. A population PK 
model  was  initially  developed for  plasma concentrations,  with  a  one-compartment  structural 
model  fitting  the  data  well.  An  additional  compartment  was  added  to  model  tumor 
concentrations.  The  parameter  estimates  for  the  combined tumor  and plasma population  PK 
model are shown in Figure 1.3C, with actual tumor volumes used in the model. KA was fixed to 
the parameter estimate obtained from the plasma PK model. The typical clearance value was 
0.46 L/hr/kg and the plasma volume of distribution was 2.78 L/kg. Tumor sizes varied between 
experiments and it was thus difficult to determine whether tumor concentrations were linear.
1.1.3 dCK Inhibition Studies
DI-87 was administered to mice at three separate doses (5, 10, and 25 mg/kg) to establish 
a dose response curve. The [18F]CFA PET probe was administered three hr prior to imaging. 
Representative mice at each time point and concentration are shown in Figure 1.4A, and data 
from all mice is represented graphically in Figure 1.4B. The 25 mg/kg dose exhibited full dCK 
inhibition for 27 hr, with protein activity fully recovering by 36 hr. The 10 mg/kg dose resulted 
in full inhibition with recovery initiating at the 12 hr time point. The 5 mg/kg dose resulted in 
minimal dCK inhibition with rapid recovery. 
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Figure 1.4 | PET imaging reveals in vivo efficacy of DI-87. (A) dCK activity in CEM xenograft 
tumors, as visualized via PET imaging using [18F]CFA, from representative mice at DI-87 doses 
of 5 mg/kg, 10 mg/kg, and 25 mg/kg. (B) dCK activity as measured by PET quantified for all 
mice. NT; no treatment.
The  quantitative  data  generated  from  PET signal  intensity  was  used  in  a  combined 
population PK-PD model. PK parameters from the final combined plasma-tumor model were 
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fixed and PD parameters were estimated in NONMEM. A sigmoid Emax indirect response PD 
model32 was found to fit the dCK inhibition data the best: 
Final parameter estimates from the model are shown in Figure 1.3C. Emax was 1.20 and 
EC50 was 0.31 μg/mL. The Hill coefficient of 58.6 was consistent with the full dCK inhibition 
seen at the six hr time point for the 25 and 10 mg/kg doses, demonstrating that dCK inhibition is 
essentially a step function at higher concentrations with the transition from no inhibition to full 
inhibition being achieved over a relatively narrow range of concentrations. 
1.1.4 Growth Inhibition Studies
Based on the results from the dCK inhibition experiments, we predicted close to full dCK 
inhibition following 25 mg/kg DI-87 dosing. Tumor growth inhibition studies were performed in 
CEM xenograft tumors using 25 mg/kg daily of DI-87 in combination with a fixed dose of i.p. 
thymidine, since DI-87 alone exhibits minimal growth inhibition (Figure 1.5A). Oral DI-87 at 10 
mg/kg was given in combination with i.p. thymidine to demonstrate a dose–response relationship 
with reduced dCK inhibition. Control mice received either intraperitoneal saline injections alone, 
oral DI-87 with i.p saline injections, or thymidine alone; mice administered DI-87 or thymidine 
alone had tumor growth curves similar to control (data not shown). Tumor size was measured 
eery  three  days  after  the  initiation  of  drug  treatment.  Increasing  DI-87  doses  resulted  in 
significantly reduced tumor growth over the course of the experiment, consistent with the dCK 
inhibition observed in the PET scans. These results were validated in a repeat study where we 
explored the effect of full dCK inhibition throughout the dosing interval, with 25 mg/kg of DI-87 
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Plasma concentrations were more than 3.5-fold higher than tumor
concentrations.
3.3. dCK inhibition studies
DI-87 was administered to mice at three separate doses (5, 10, and
25 mg/kg) to establish a dose response curve. The [18F]CFA PET probe
was administered 3 h prior to imaging. Representative mice at each
time point and concentration are shown in Fig. 4A, and data from all
mice is represented graphically in Fig. 4B. The 25 mg/kg dose exhibited
full dCK inhibition for 27 hrs, and enzyme activity fully recovered by 36
hrs. The 10 mg/kg dose resulted in full inhibition with recovery in-
itiating at the 12 hr time point. The 5 mg/kg dose resulted in minimal
dCK inhibition with rapid recovery.
The quantitative data generated from PET signal intensity was used
in a combined population PK-PD model. PK parameters from the final
combined plasma-tumor model were fixed and PD parameters were
estimated in NONMEM. A sigmoid Emax indirect response PD model [9]
was found to fit the dCK inhibition data the best:
=dA
dT
k Sigmoid E k A(1 )in max out
Final parameter estimates from the model are shown in Table 1.
Emax was 1.20 and EC50 was 0.31 μg/mL. The Hill coefficient was 58.6
which was consistent with the full dCK inhibition seen at the 6 hr time
point for the 25 and 10 mg/kg doses, and demonstrating that dCK in-
hibition is essentially a step function at higher concentrations with the
transition from no inhibition to full inhibition being achieved over a
relatively narrow range of concentrations. Fig. 4C is a simulation of the
final model to demonstrate PET signal intensity and the dose response
curve for dCK inhibition seen with the 5, 10, and 25 mg/kg doses.
3.4. Growth inhibition studies
Based on the results from the dCK inhibition experiments, we
Fig. 2. Synthesis and in vitro activity of DI-87. (A)
Structure of DI87. (B) Synthetic route of DI-87. (C)
IC50 values determined using 3H-dC uptake assay in
CEM T-ALL cells to measure inhibition of dCK ac-
tivity. (D) Dose response of DI-87 in CEM T-ALL cells
treated with 10 nM Gemcitabine (n = 4;
mean ± SD) for 72 h determined using Cell Titer
Glo. (E) Protein binding of DI-87 and (R)DI-82 as-
sessed by comparing IC50 of the compounds in pre-
sence of 25 and 50 mg/mL BSA (n = 2; mean ± SD).
Fig. 3. Plasma and tumor concentrations. Each data
point represents the plasma and tumor concentra-
tions from a single mouse (n = 5 per time point).
Plasma concentrations are higher than tumor con-
centrations and have an earlier peak Tumor sizes
varied between experiments thus it was difficult to
determine if the tumor concentrations were linear.
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The quantitative data generated from PET signal intensity was used in a combined population PK-PD model.
administered twice daily (BID) in combination with a fixed dose of thymidine as the highest dose 
(Figure 1.5B). BID administration of 25 mg/kg DI-87 with thymidine resulted in near complete 
arrest of tumor growth.
Figure 1.5 | DI-87 co-administered with thymidine inhibits tumor growth in vivo, with PK 
model accurately predicting tumor growth outcomes. (A) Growth of CEM xenograft tumors 
during DI-87 and thymidine treatment. DI-87 administered at 10 mg/kg or 25 mg/kg daily in 
combination with thymidine (n = 5 per dose). (B) Tumor growth inhibition following 25 mg/kg 
BID DI-87 with thymidine (n = 5 per dose). (C, D) Growth inhibition simulation of daily (C) or 
BID (D) 25 mg/kg DI-87 administration using final PK-PD model.
The  tumor  sizes  from the  two  studies  were  used  in  a  combined  PK-PD model.  PK 
parameters from the final combined plasma-tumor model were fixed and PD parameters were 
estimated in NONMEM. A super-exponential function was found to describe the growth of the 
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control data the best: Growth(t) = ek1*tk2. An Emax indirect response PD model32 was found fit 
the growth inhibition data the best:
The final model was used for simulations of two concentrations – 10 mg/kg daily, and 25 
mg/kg BID – which demonstrated that the final model fit the experimental data well (Figures 
1.5C and 1.5D). Thus, maximal dCK inhibition over the 24 hr dosing period results in greater 
growth inhibition, consistent with the 25 mg/kg BID dose. 
1.1.5 Discussion
Following its synthesis, inhibition of [3H]-dC uptake confirmed that DI-87 was a potent 
inhibitor of dCK, with an IC50 of 4.3 nM. The affinity of DI-87 for dCK was further confirmed 
through a rescue assay in which the growth of CEM cells treated with gemcitabine with and 
without  DI-87  supplementation  was  monitored.  Gemcitabine  requires  dCK for  its  cytotoxic 
effects,  and  administration  of  DI-87  fully  prevented  cytotoxicity  following  gemcitabine 
treatment, thereby demonstrating the dCK inhibition of DI-87. Previous generations of reversible 
dCK inhibitors  developed  by  our  group  had  comparable  potency,  but  did  not  have  optimal 
biochemical properties. DI-87 improves upon these properties while maintaining low-nM affinity 
for dCK. In particular, DI-82 was an effective dCK inhibitor but was heavily protein-bound. By 
comparison, DI-87 retained its potency in the presence of albumin. 
The  preclinical  pharmacology  of  DI-87  was  also  evaluated.  Plasma  concentrations 
peaked 3 hr after oral administration, while tumor concentrations maintained a peak between 
hours 3 and 9. Thus, the tumor-to-plasma concentration ratio was dependent upon sampling time. 
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 Growth(t) = ek1*tk2. An Emax indirect response PD model 9 was found fit the growth inhibition data the best
predicted close to full dCK inhibition following 25 mg/kg DI-87 dosing.
Growth inhibition studies were performed using 25 mg/kg daily of DI-
87 in combination with a fixed dose of i.p. thymidine, since DI-87 alone
exhibits minimal growth inhibition. Oral DI-87 at 10 mg/kg was given
in combination with i.p. thymidine to demonstrate a dose–response
relationship with reduced dCK inhibition. Control mice received either
intraperitoneal saline injections alone, oral DI-87 with i.p saline injec-
tions, or thymidine alone. These results were validated in a repeat study
where we explored the effect of full dCK inhibition throughout the
dosing interval, with 25 mg/kg BID of DI-87 administered in combi-
nation with a fixed dose of thymidine as the highest dose. Tumor size
was measured every 3 days after the initiation of drug administration.
Mice administered thymidine alone or DI-87 alone had tumor growth
curves similar to the control (data not shown). Increasing DI-87 doses
resulted in reduced tumor growth, consistent with the dCK inhibition
seen in the PET scans. The changes in tumor size with time are shown in
Fig. 5A.
The tumor sizes from the two studies were used in a combined PK-
PD model. PK parameters from the final combined plasma-tumor model
were fixed and PD parameters were estimated in NONMEM. A super-
exponential function was found to describe the growth of the control
data the best: = eGrowth(t) k t1 k2. An Emax indirect response PD model 9
was found fit the growth inhibition data the best:
= +dA
dT
k k E k k TIME A(1 ) (56 ( ))in out max k1 2 2 1
Final parameter estimates from the model are shown in Table 1.
Emax was 1.06 and EC50 was 3.63 μg/mL. The final model was used for
simulations of two concentrations (10 mg/kg daily, and 25 mg/kg BID).
Fig. 5B demonstrates that the final model fit the experimental data well.
Thus, maximal dCK inhibition over the riod results in
greater growth inhibition, consistent with the 25 mg/kg BID dose.
4. Discussion
dCK is an intriguing target in anti-cancer therapy as it is a rate
limiting enzyme within the salvage pathway of dNTP biosynthesis, and
multiple cell lines and tumor samples in the Cancer Cell Line
Encyclopedia and The Cancer Genome Atlas, respectively, express this
enzyme at higher levels when compared to normal tissue [10]. Among
the cancers listed in these resources, leukemias and lymphomas are
most prominently featured. While targeting the salvage pathway of
dNTP biosynthesis through dCK inhibition is a relatively new approach,
the key enzyme of the parallel de novo pathway, ribonucleotide re-
ductase (RNR), has been an important target in anticancer therapy for
decades. The RNR inhibitor hydroxyurea (HU) has been used clinically
for cancer treatment and is in clinical trials for novel applications. 3-AP
is also in clinical trials as an anti-cancer agent [11,12]. Although these
compounds are able to inhibit RNR, they each possess dose-limiting
toxicity and limited efficacy [13,14]. A major resistance mechanism to
RNR inhibition therapy is presence of an active dCK-mediated salvage
pathway, which may explain the failure of RNR inhibitors such as 3-AP
in clinical trials. In an effort to circumvent this resistance mechanism,
we developed inhibitors of dCK to be used in combination with RNR
inhibition. We previously reported the development of DI-39 [3] and
DI-82 [15], which were potent inhibitors of dCK but possessed poor
solubility and sub-optimal drug-like properties. To address these
shortcomings, we developed DI-87, a potent, specific, soluble, and
bioavailable dCK inhibitor which has recently gained FDA Investiga-
tional New Drug (IND) approval and will be evaluated in clinical trials
shortly.
In line with our previous studies, we determined that the R-en-
antiomer of DI-87 had a significantly higher affinity for dCK when
compared with the S-enantiomer. The affinity of DI-87 for dCK was
further confirmed through a rescue assay in which the growth of CEM
cells treated with gemcitabine with and without DI-87 supplementation
was monitored. Gemcitabine requires dCK for its cytotoxic effects, and
administration of DI-87 fully prevented cytotoxicity following gemci-
tabine treatment, thereby demonstrating the dCK inhibition of DI-87.
Previous generations of reversible dCK inhibitors developed by our
group had comparable potency, but did not have optimal biochemical
properties. DI-87 improves upon these properties while maintaining
low-nM affinity for dCK. In particular, DI-82 was an effective dCK in-
hibitor but was heavily protein-bound. By comparison, DI-87 retained
its potency in the presence of albumin.
The preclinical pharmacology of DI-87 was also evaluated. Plasma
concentrations peaked 3 h after oral administration, while tumor con-
centrations maintained a peak between hours 3 and 9. Thus, the tumor-
to-plasma concentration ratio was dependent upon sampling time.
Tumor concentrations were significantly lower than plasma con-
centrations for all doses tested. The PET probe [18F]CFA was used to
quantify dCK activity in tumors, and thus effects of DI-87 upon the
target pathway. Given the differential peaks in plasma and tumor
concentrations, linking DI-87 tumor concentrations to dCK inhibition
provided a more physiologic and mechanistic approach. Our population
PK-PD modeling allowed us to describe limited tumor data and link
these concentrations to dCK inhibition. Full dCK inhibition occurred at
the 10 mg/kg dose and increasing doses led to a longer maintenance of
full inhibition. At the highest dose tested (25 mg/kg), full recovery of
enzyme activity occurred by 36 h, with full inhibition being maintained
at the 12 hr time point. Our PK-PD model suggested a threshold or rapid
switching on-off effect. When evaluated as a single agent, DI-87 was
well tolerated at higher doses, but had essentially no ability to inhibit
growth (data not shown). When DI-87 was administered as repeated
doses in combination with thymidine, full dCK inhibition was main-
tained at 12 h (25 mg/kg twice daily dose) and led to maximal tumor
growth inhibition. Lower doses led to diminished dCK inhibition with
predictable decreases in growth inhibition. Thus, DI-87 appears to have
potential as a cancer therapeutic when used in combination with thy-
midine.
The PET probe used in the current study is a tool to help provide
mechanistically-driven rational dosing of DI-87 and similar compounds
prior to clinical trials. The use of non-invasive PET probes and scans can
greatly aid in drug development. Imaging studies in early phase
Table 1
PK-PD modeling parameter estimates.
Plasma-Tumor PK model parameters
Parameter Estimate Standard Error
CL (L/hr/kg) 0.46 0.03
V (L/kg) 2.78 0.22
KA (hr) 0.66 (FIXED) .
Q (L/hr/kg) 0.0045 0.0013
Scalar 3.69 0.40
Half-life (hr)* 4.2 –
Eta1 (Scalar) 34.6% 0.08
Proportional Error 49.9% 0.04
DCK inhibition PK-PD model
Kout 0.12 0.00011
Emax 1.20 0.00200
EC50 0.31 0.00009
Gamma (Hill coefficient) 58.60 0.18500
Kin 0.76 0.00078
Additive Error 0.88 0.00025
Growth Inhibition PK-PD Model
Kout 0.372 0.0973
Emax 1.06 0.2030
Growth Function Exp 1 0.00498 0.0011
Growth Function Exp 2 1.47 0.0399
EC50 3.63 1.19
Intersubject Variability (Emax) 14.1% 2.65%
Additive Error 0.20 0.02
*Half-life: 0.693/(CL/V).
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Tumor concentrations were significantly lower than plasma concentrations for all doses tested. 
The PET probe [18F]CFA was used to quantify dCK activity, and thus effects of DI-87 upon the 
target  pathway,  in  tumors.  Given the  differential  peaks  in  plasma and tumor concentrations, 
linking  DI-87  tumor  concentrations  to  dCK  inhibition  provided  a  more  physiologic  and 
mechanistic approach. Our population PK-PD modeling allowed us to describe limited tumor 
data and link these concentrations to dCK inhibition. Full dCK inhibition occurred at the 10 mg/
kg dose and increasing doses led to a longer maintenance of full inhibition. At the highest dose 
tested (25 mg/kg), full recovery of enzyme activity occurred by 36 h, with full inhibition being 
maintained at the 12 hr time point. Our PK-PD model suggested a threshold or rapid switching 
on-off effect. When evaluated as a single agent, DI-87 was well tolerated at higher doses, but had 
essentially no ability to inhibit growth in CEM xenograft tumors (data not shown). When DI-87 
was administered as repeated doses in combination with thymidine,  full  dCK inhibition was 
maintained at 12 hr (25 mg/kg twice daily dose) and led to maximal tumor growth inhibition. 
Lower doses led to diminished dCK inhibition with predictable decreases in growth inhibition. 
Thus, DI-87 appears to have potential as a cancer therapeutic when used in combination with 
thymidine. 
The PET probe used in the current study is a tool to help provide mechanistically-driven 
rational dosing of DI-87 and similar compounds prior to clinical trials. The use of non-invasive 
PET probes  and scans  can greatly  aid  in  drug development.  Imaging studies  in  early  phase 
development can confirm that molecules reach the target tissue and do not accumulate in target 
sites, can determine dose-target occupancy, and can be used to help critically evaluate similar 
drug  candidates  based  on  responses.33  Our  group  developed  [18F]FAC  (1-(2ʹ-deoxy-  2ʹ-
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[18F]fluoro-β-D-arabinofuranosyl)cytosine)  as  the  first  dCK-specific  PET  probe,  and  the 
compound has subsequently been used in the preclinical drug development of small molecule 
dCK inhibitors.21,30 A more specific probe, [18F]CFA, was later developed by our group and was 
used in the current study to evaluate dCK activity in tumors when treated with a small molecule 
dCK inhibitor. This probe was also scheduled for study in a clinical trial at UCLA to evaluate 
changes in dCK activity following cancer immunotherapy, though the trial was terminated due to 
slow  accrual.34  PET  probes  in  preclinical  and  clinical  studies  can  additionally  aid  in 
understanding  how drug  distribution  in  target  tissues  and  response  of  the  target  pathway is 
modified in the presence of multiple drugs, as compared to single agent therapy. They can also 
help evaluate the degree of synergy, appropriate timing of therapies, and dosing amount. 
Our growth inhibition studies utilized a fixed dose of thymidine with varying doses of 
DI-87,  and  dual  inhibition  of  salvage  and  de  novo  pathways  led  to  effective  tumor  growth 
inhibition when full dCK inhibition was achieved throughout the dosing interval. PET imaging 
provided valuable information, namely the quantification of dCK inhibition, which enabled a 
more efficient methodology for dose optimization as it allowed us to determine optimal dosing 
and  schedules  without  testing  a  multitude  of  doses  in  growth  inhibition  studies.  The  DI-87 
plasma half-life of 4 hr suggests the need for more frequent dosing to maintain dCK and growth 
inhibition, however our mechanistic approach which included evaluation of tumor PK and PET 
imaging allowed us to determine that the 25 mg/kg dose twice daily would be appropriate to 
maintain dCK inhibition.  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Section Two: 
Further Development of Novel Deoxycytidine Inhibitors
1.2.1 Basis for Further Structure-Activity Relationship Studies of dCKi Scaffold
Despite the promising in vitro and in vivo data of DI-87, it remained apparent that this 
clinical candidate had further room for improvement. Though the addition of the morpholine ring 
in  Part  A of  the  scaffold  had  improved  its  solubility  when  compared  with  previous  lead 
compound  DI-82,  DI-87  remained  relatively  insoluble.  Furthermore,  previous  dCKi  analogs 
produced by our group had never strayed from a substituted phenyl ring in Part A of the scaffold. 
Additionally, the methyl stereocenter within the Part C linker posed a synthetic challenge – while 
the stereoselective Corey-Bakshi-Shibata reduction of the ketone intermediate led to the desired 
S-enantiomer of the alcohol intermediate in >99% ee, the subsequent SN2 reaction to install the 
pyrimidine ring resulted in degradation of enantiopurity, most likely due to a competing SN1 
reaction pathway. This necessitated the use of chiral HPLC chromatography for purification to 
obtain a suitably enantiopure product. Attempts at achieving an asymmetric synthesis that did not 
require  the  use  of  chiral  purification  methods  were  unsuccessful,  and  previous  work  had 
established that the Part C methyl substituent was necessary for maintaining low-nM activity 
against dCK.22,35 However, based upon co-crystal structures of previous lead compound DI-82 
complexed with dCK, it was known that the chiral methyl substituent occupied a hydrophobic 
pocket within the substrate binding site of dCK. Taken together, these considerations revealed 
further opportunities for structure-activity relationship studies, specifically within Part A and Part 
C of the dCKi scaffold.
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1.2.2 Synthesis and Evaluation of Novel dCKi – Modifications to Parts A, B and C
Based  upon the  hit  compounds  that  emerged  from the  initial  high-throughput  screen 
conducted against dCK, as well as the subsequent SAR guided by both in vitro activity as well as 
co-crystallization studies, all dCKi synthesized by our group bore a substituted phenyl moiety in 
Part A. Upon examining the previous SAR, it was clear that Part A of the scaffold was able to 
accommodate a variety of modifications, in contrast to Parts B, C and D, which had much less 
flexibility  in  terms  of  retaining  dCK  affinity  upon  introducing  diverse  chemical  moieties. 
Previous decisions regarding the nature of phenyl ring substitutions revolved around promoting 
additional favorable non-covalent interactions within the dCK binding site, as well as adding 
moieties which may have improved the overall solubility of the molecule, or incorporation of 
fluorine to enable the synthesis of dCK-specific PET probes.21,36 However, co-crystal structures 
provided evidence that the pocket within which our dCKi were binding was able to tolerate 
groups other than substituted phenyl rings. As such, we set out to determine whether we could 
improve the activity and/or solubility of our dCKi, while also improving Lipinski’s “rule of five” 
metrics,37,38 through diversifying Part A of the scaffold. Our general synthetic scheme began 
with  an  appropriate  nitrile-bearing  thioamide  precursor  (A)  or  starting  directly  from  the 
thioamide (B), followed by a Hantzsch thiazole synthesis reaction with an appropriate α-bromo 
ketone  (commonly  4-bromo-2,3-pentanedione)  which  yielded  the  ketone-substituted  thiazole 
intermediate (C) (Scheme 1.2). The ketone was was then reduced to the secondary alcohol (D) 
via  DIBAL-H-mediated  reduction.  Activation  of  the  alcohol  via  reaction  with  trifluoroacetic 
anhydride yielded a trifluoroactate intermediate (E),  which was displaced by 2-mercapto-4,6-
diaminopyrimidine under thermal conditions in the presence of base to produce the desired dCKi 
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compound (F).  All  compounds were synthesized in  their  racemic form for  initial  evaluation 
purposes. 
Scheme 1.2 | General synthetic strategy for synthesis of dCK inhibitorsa
aReagents  and  conditions:  (i)  (NH4)2S  (20%  aqueous),  Et3N,  Pyridine,  60  °C,  12  hr;  (ii) 
Appropriate  α-bromo  ketone,  ethanol,  reflux,  3  hr;  (iii)  DIBAL-H,  THF,  0  °C,  1  hr;  (iv) 
Trifluoroacetic anhydride, THF, 0° C, 0.5 hr; 4,6-diamino-2-mercaptopyrimidine, Cs2CO3, DMF, 
70°.
Former  lead  compounds  DI-39,  DI-82,  and  DI-87  each  had  substituted  phenyl  rings 
meant to improve drug-like properties such as solubility, and crystallographic studies showed 
that the sulfonamide extending from the meta position of DI-82 made key hydrogen-bonding 
interactions within the dCK protein binding site (Figure 1.6).21,22,39 Thus, the first compound 
synthesized in this study, NMc-1, stood in stark contrast to our group’s previously synthesized 
dCKi as it possessed an unsubstituted phenyl ring (Figure 1.7). Compounds NMc 2–5, bearing 
alkyl  and  heterocyclic  moieties  in  Part  A,  continued  the  trend  of  straying  from  previously 
synthesized  analogs.  dCK  inhibitory  activity  of  all  compounds  was  assessed  in  vitro  as 
previously reported.21,22
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Figure 1.6 |  Former lead dCK inhibitor compounds DI-39 and DI-82, and current lead 
compound DI-87. IC50 values measured through inhibition of [3H]-dC uptake in CEM T-ALL 
cells.
Figure 1.7 | Structures and IC50 values of dCK inhibitors possessing varied Part A moieties. 
IC50 values measured through inhibition of [3H]-dC uptake in CEM T-ALL cells.
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Encouragingly, compound NMc-1 showed high affinity for dCK, with an IC50 of 36.5 
nM. The low-nM activity buttressed the hypothesis that Part A of the dCKi scaffold was able to 
accommodate a variety of functional groups, and that groups adorning the phenyl ring may play 
only modest roles in promoting affinity for dCK. Further modifications to Part A had varied 
results in terms of dCK binding ability. The pyridine-containing NMc-2 had an IC50 of 113 nM, 
indicating that aromatic heterocycles may not be as well-tolerated as phenyl rings. Non-aromatic 
compounds  NMc 3–5  had  surprising  activities  –   the  adamantyl-containing  NMc-3  had  very 
strong affinity for dCK, with an IC50 of 11.1 nM, which was essentially identical to the racemic 
sample of previously identified lead compound DI-87. The propyl-substituted NMc-4 saw a ten-
fold decrease in activity, relative to NMc-3, while the morpholino NMc-5 was more than 180-
fold less active. The surprising affinity of NMc-3  was hypothesized to stem from its overall 
decrease in polarity, which would allow for greater cell permeability and greater opportunity for 
inhibition of dCK. The decrease in dCK affinity displayed by NMc-4 may stem from a non-polar 
character which was insufficient to enable the same level of cell permeation, and therefore dCK 
inhibition, as NMc-3. While NMc-3 was more straightforward in its synthesis when compared 
with  DI-87  and  just  as  active,  it  was  less  soluble.  The  morpholino  NMc-5,  which  was 
synthesized with the hope that the morpholine ring would improve solubility while maintaining 
low-nM activity, accomplished neither – the compound displayed the lowest IC50 of any of the 
five compounds synthesized, and did not possess noticeably improved solubility when compared 
with DI-87.
While Part A of our dCKi scaffold had proven itself amenable to modification, Parts B 
and C had shown a lower degree of flexibility in our previous studies. The 5-position of the 
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thiazole ring could accommodate short alkyl chains and maintain strong affinity for dCK, with 
propyl chains leading to the highest affinity. However, this affinity came at the cost of metabolic 
stability  –  propyl  and  ethyl  substitutions  correlated  with  rapid  metabolism,  while  a  smaller 
methyl substituent at the 5-position was more stable, albeit less active. The low-nM affinity for 
dCK was not recovered until a methyl group was incorporated into Part C of the scaffold, with 
the R-enantiomer being the more active species. Crystallography studies revealed that the methyl 
group  occupied  a  hydrophobic  pocket  of  the  dCK  substrate  binding  site.  However, 
enantioselective synthesis of dCKi compounds proved to be elusive,35  and enrichment of the 
desired enantiomer could only be realized through chiral chromatography. In an effort to address 
this issue, we sought to incorporate an achiral alkyl moiety within Part C of the dCKi scaffold, 
specifically a gem-dimethyl. We envisioned that the gem-dimethyl would be able to optimally fill 
the hydrophobic pocket while simultaneously eliminating the chirality of our dCKi. Extensive 
efforts were undertaken in order to identify methodology which would enable construction of the 
desired  gem-dimethyl-mercaptopyrimidine  connection.  However,  installation  of  this  moiety 
proved  to  be  non-trivial,  as  attempts  commonly  afforded  the  alkene  elimination  product. 
Eventually, a procedure was adapted in which the ketone-substituted thiazole intermediate 9 was 
converted to the tertiary alcohol 10 by reaction with methyl Grignard reagent (Scheme 1.3A). 
Subsequent  stirring  of  10  in  diethyl  ether  in  the  presence  of  thionyl  chloride  and  sodium 
carbonate at 0 °C yielded the tertiary chloride 11,40 which after filtration and concentration using 
low  temperature  roto-evaporation  was  not  isolated  due  to  instability  and  instead  directly 
displaced  by  4,6-diaminopyrimidine  thiolate.  This  yielded  12,  which  bore  the  desired  gem-
dimethyl-mercaptopyrimidine connection.41 
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Scheme 1.3 | Synthesis of dCK inhibitors bearing gem-dimethyl Part C moietya
aReagents  and  conditions:  A;  (i)  methyl  magnesium bromide,  THF,  0  °C,  1  hr;  (ii)  SOCl2, 
Na2CO3, ether, 0 °C, 0.25 hr; (iii) sodium 4,6-diaminopyrimidine-2-thiolate, Cs2CO3, DMF, 65 
°C, 4 hr. B; (i) ethyl bromopyruvate, ethanol, reflux, 3 hr; (ii) methyl magnesium bromide, THF, 
0 °C,  1  hr;  (iii)  SOCl2,  Na2CO3,  ether,  0  °C,  0.25 h;  (iv)  sodium 4,6-diaminopyrimidine-2-
thiolate, Cs2CO3, DMF, 65 °C, 4 hr.
With a dCK IC50 of 924.5 nM, the initial gem-dimethyl dCKi analog synthesized using 
this methodology, NMc-6,  proved to be significantly less potent against dCK than its mono-
methylated analog NMc-1 (Figure 1.8A). It was hypothesized that this loss of activity was the 
result  of  steric  interactions  between  the  gem-dimethyl  moiety  and  the  5-methyl  substituted 
thiazole which prevented the dCKi from adopting an optimal conformation for binding to dCK 
within the substrate binding site. To nullify this interaction, ethyl bromopyruvate was utilized in 
the Hantzsch thiazole synthesis reaction step of our synthetic scheme instead of 4-bromo-2,3-
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pentanedione,  which  resulted  in  a  5-hydrido  thiazole  (14)  rather  than  the  5-methyl  analog 
(Scheme  1.3B).  By  utilizing  this  substrate  for  construction  of  the  thiazole,  NMc-7  was 
generated, which demonstrated three-fold higher dCK affinity than the 5-methylthiazole NMc-6. 
Based upon this  improvement  in  dCK affinity,  compounds bearing the gem-dimethyl  and 5-
hydrido thiazole moieties but retaining Part A groups from previous analogs were synthesized 
(Figure 1.8A). Unfortunately, these compounds were not able to recapitulate the low-nM activity 
of our lead compound DI-87. The gem-dimethyl and adamantyl-containing NMc-8 was roughly 
15-fold  less  active  than  its  potent  mono-methyl  analog  and  constitutional  isomer  NMc-3. 
Likewise, the gem-dimethyl analog and constitutional isomer of DI-87, NMc-9, demonstrated a 
similar decrease in activity. 
Using the previously outlined methodology,  dCKi analogs were synthesized in which 
Parts A, B and C were simultaneously altered in order to differ from the structure of DI-87 
(Figure 1.8B).  Gem-dimethyl compounds explored included those bearing fluorinated phenyl 
rings (NMc-12, NMc-13), compounds bearing alkyl groups at the 2-position of the thiazole ring 
(NMc-14, NMc-15), and a compound possessing an oxadiazole ring extending from the thiazole 
2-position (NMc-16). The most potent compound, NMc-10, had an IC50 of 37.2 nM, and may 
have benefited from favorable hydrogen bonding interactions within the substrate binding site of 
of dCK due to the phenolic alcohol moiety. However, no other analogs generated in this portion 
of our synthetic campaign showed sub-100 nM activity against dCK. 
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Figure 1.8 |  dCK inhibitors bearing gem-dimethyl moiety in Part C. (A) dCK inhibiting 
compounds bearing gem-dimethyl moieties in Part C while maintaining Part A substituents of 
previously-synthesized  compounds.  (B)  dCK  inhibiting  compounds  bearing  gem-dimethyl 
moieties in Part C and previously unexplored Part A moieties. IC50 values determined through 
inhibition of [3H]-dC uptake in CEM T-ALL cells.
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1.2.3  gem-Dimethyl  dCKi  Analogs  Adopt  Unfavorable  Gauche  Conformation  While 
Binding dCK
While the decreased dCK affinity of our gem-dimethyl analogs was disappointing, it was 
not entirely unpredictable.  The chiral  methyl substituting in Part  C of lead compound DI-87 
occupied  a  small  hydrophobic  pocket  within  the  substrate  binding  site  of  dCK,  and  it  was 
hypothesized  that  the  gem-dimethyl  group  was  too  large  to  similarly  occupy  this  space. 
Additionally,  the  difference  in  affinity  between  NMc-1,  NMc-6,  and  NMc-7  indicated  that 
conformational differences engendered by the gem-dimethyl moiety were affecting the affinity of 
our newly synthesized analogs. In order to better understand the origins of the decreased affinity 
our gem-dimethyl analogs had for dCK, we utilized molecular dynamics (MD) simulations to 
examine the binding modes of selected dCK inhibitors within the substrate binding pocket of the 
protein.  Lead  compound  DI-87  served  as  the  positive  control,  while  the  gem-dimethyl 
compounds NMc-7,  NMc-9,  and NMc-10  were evaluated (Figure 1.9A).  The initial  binding 
conformations chosen for the MD simulations emulated those which were reported for previous 
lead compound DI-82.36 In our simulations,  the achiral  gem-dimethyl compounds underwent 
large conformational changes. In the initial binding conformation, the dihedral [C-S-C-C] angle 
between the pyrimidine and thiazole rings is near 150°, with the pyrimidine ring oriented far 
away from the thiazole (Figure 1.9B). As the simulation progressed, the binding conformations 
of the gem-dimethyl compounds change from an anti to a gauche conformation, with a dihedral 
angle  of  50°  (Figure  1.9C).  Conversely,  DI-87  maintains  the  anti  conformation,  with  the 
dihedral angle remaining near 150° throughout the duration of the MD simulation.
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Figure 1.9 | Molecular dynamics (MD) simulation of dCK inhibitor conformations in dCK 
binding pocket. (A) Structures of examined dCK inhibitors. (B) Representation of investigated 
dihedral C-S-C-C bond angle. (C) MD simulation of dCK inhibitor conformation within dCK 
binding  pocket,  with  representational  anti  and  gauche  conformer  structure  snapshots  for 
NMc-10. 
We further computed the energies of the dCKi conformations and scanned the energy 
surface along the dihedral angle using the density functional theory (DFT) method. For lead 
compound DI-87,  the most  stable  conformer is  the anti  with a  dihedral  angle  of  150°–210° 
(Figure 1.10A).  The energy increases monotonically as the dihedral  angle decreases beyond 
150°. For NMc-7, the energy surface has two minima at 180° and 60°, which correspond to the 
anti and gauche conformations, respectively, which were observed in the MD simulations. The 
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conformations change from this anti conformation to a gauche conformation, with a dihedral angle of 50˚ 
(figure 2). (R)-DI-87 keeps an anti conformation with the dihedral angle near 150˚ in the MD simulation.  
 
Figure 2. The dihedral angle [C-S-C-C] of different inhibitor compounds in MD simulations; gauche conformer and anti 
conformer from MD snapshots are shown in the right. 
 We further computed the energies of the conformations of the inhibitor compounds and scanned 
the energy surface along the dihedral [C-S-C-C] angle with density fu ction theory (DFT) method. F r (R)-
DI-87, the most stable conformer is the anti conformer at dihedral angle of 150-210˚. The energy increases 
monotonically as the dihedral angle decrease after 150˚. For DI-99, the energy surface has two minima at 
180˚ and 60˚ respectively, which corresponds to the anti conformation and the gauche conformations we 
observed in MD. 
Molecular Angles
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gauche conformation of DI-87 is 1.6 kcal/mol higher in energy than the anti, which is a result of 
the steric effects between an amine group of the pyrimidine ring and the 5-position methyl of the 
thiazole (Figure 1.10B). In NMc-7, which lacks a methyl group at the 5-position, the gauche 
conformation is 0.7 kcal/mol lower in energy than the anti (Figure 1.10C). Due to the absence of 
the thiazole methyl, this conformation lacks the steric effects observed in DI-87, leading to the 
lower energy of the gauche versus anti conformation. 
Figure 1.10 | Energy scan reveals conformational preferences of dCK inhibitors. (A) The 
conformation energies of DI-87 and NMc-7 were computed and the energy surface along the 
dihedral  [C-S-C-C]  angle  scanned  with  density  functional  theory  (DFT)  method.  (B,  C) 
Conformational energies of  DI-87 (B) and NMc-7 (C). 
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Figure 10
 
Figure 4. Energy scan along the bending angle; anti and gauche conformations of DI-87 and DI-99. 
 We compared the anti and gauche conformations of (R)-DI-87 and DI-99. The gauche 
conformation of (R)-DI-87 is 1.6 kcal/mol higher in energy, which is caused by the steric effect between 
the amine group and the methyl group. In DI-99, the gauche conformation is 0.7 kcal/mol lower in energy. 
In the gauche conformation, the steric effect is eliminated because there is no methyl group in the thiazole 
ring.  
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The gauche  and  anti  conformations  of  the  gem-dimethyl  compounds  bind  differently 
within  the  substrate  binding  site  of  dCK.  In  the  anti  conformation  of  NMc-10,  three  key 
hydrogen bonds are formed between the amino groups of the pyrimidine ring and Q97, D133, 
and E53 of the dCK substrate binding pocket. However, only one hydrogen bond with Q97 is 
maintained  in  the  gauche  conformation  (Figure  1.11).  These  hydrogen  bonding  interactions 
between the pyrimidine and amino acid residues within the binding site were demonstrated to be 
key to our scaffold’s ability to inhibit dCK in our previous SAR studies.22 Removal of one or 
both amino groups from the pyrimidine ring led to substantial or near-complete loss of activity, 
respectively. Because the MD simulations demonstrated that NMc-10 and other gem-dimethyl 
compounds evaluated transition between the two conformations,  we concluded that the gem-
dimethyl dCKi compounds displayed lower affinity for dCK due to fewer key hydrogen bonding 
interactions  within  the  binding  site,  which  was  the  result  of  a  more  energetically  favorable 
gauche conformation enabled by the absence of a 5-methyl substituted thiazole ring. 
Figure 1.11 | Hydrogen bonding interactions of anti and gauche conformations of NMc-10 
within dCK binding site. 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Figure 11
 
Figure 5. Hydrogen bonding of anti and gauche conformations with dCK. 
 The gauche and anti conformations bind differently in dCK. In the anti conformation, the 
compound forms three hydrogen bonds with Q97, D133 and E53 of dCK. In the gauche conformation, only 
the hydrogen bond with Q97 is maintained. As the achiral compounds switch from the anti conformation 
to the gauche conformation back and forth, the hydrogen bonding with dCK is weaker compared to (R)-
DI-87.  
 Combined MD simulations and DFT study reveals the relationship between the conformations and 
the binding affinity to dCK. Small changes in structure alter the conformational preference, leading to 
different binding affinities.  
Computational Methods: 
Docking and Molecular dynamics: 
The inhibitor compounds are docked into the binding pocket of dCK crystal structure manually. Classical 
molecular dynamics (MD) were performed using the GPU code (pmemd) of the Amber 12 package on the 
substrate conformations and the transition states for 500 ns in enzyme. The FF99SBildn force field was 
used for the protein residues. Parameters for the substrate conformations and transition states were 
generated within the antechamber module using the general Amber force field (gaff), with the partial 
charges set to fit the electrostatic potential calculated at the HF/6-31G(d) level by the RESP model. The 
Anti Gauche
Section Three: 
Evaluation of dCK Inhibitors as Nucleoside Mimetics
1.3.1 dCKi Scaffold as a Nucleoside Mimetic
The first  kinase inhibitor,  reported in 1984,  engaged its  target  through binding at  the 
phosphoryl donor (ATP) binding site of Cyclic Nucleotide Dependent Protein Kinase and Protein 
Kinase C.42 Since this discovery, the majority of kinase inhibitors utilized across all indications 
have adopted this same targeting strategy, namely binding to the ATP binding site of a kinase by 
mimicking the hydrogen bonding interactions between the kinase and the adenosine ring of ATP.
43,44  This  common targeting modality is  enabled by a highly conserved ATP binding region 
located in a cleft formed between two lobes of the kinase secondary structure.45,46 Due to the 
conserved nature  of  this  ATP binding region,  small  molecule  ATP-competitive inhibitors  are 
commonly discovered through high throughput screening and synthetic campaigns. The obvious 
obstacle posed by the conserved nature of this binding region is the similarity between kinases, 
which  can  lead  to  significant  off-target  effects  for  a  given  kinase  inhibitor.  It  is  therefore 
advantageous to develop inhibitors which bind at sites other than the ATP-binding site, thereby 
imbuing a potential for greater kinase-specificity upon the molecule. For this reason, our group 
was encouraged by the serendipitous discovery of inhibitors of dCK which bound not at the 
phosphoryl donor site, but at the substrate binding site.21,36 dCK phosphorylates dC, dA, and dG 
nucleosides into their monophosphate nucleotide forms, and the dCKi scaffold identified through 
our  high-throughput  screen  prevents  these  nucleosides  from  binding  through  competitive 
inhibition. For this reason, our dCKi can be classified not simply as kinase inhibitors, but as 
	 33
nucleoside mimetics (nucleomimetics). Through this frameshift, we came to envision our dCKi 
as having the potential for broader effects within nucleotide metabolism. 
1.3.2 Evaluation of Nucleomimetic dCK Inhibitors as Modulators of Pyrimidine Nucleotide 
Metabolism
In order to assess the potential of our nucleomimetic dCK inhibitors as having broader 
effects, we designed a phenotypic screening platform for the identification of novel modulators 
of  pyrimidine  nucleotide  metabolism.47  The  design  and  technical  details  of  this  screening 
platform  are  expounded  upon  in  Chapter  Two  of  this  dissertation,  though  an  overview  is 
provided  here.  While  dCK is  able  to  phosphorylate  multiple  nucleosides,  it  has  the  highest 
affinity  for  the  pyrimidine  nucleoside  dC.  All  pyrimidine  nucleotides  arise  from a  common 
precursor;  uridine  monophosphate  (UMP).  UMP  is  produced  by  separate  but  convergent 
biosynthetic pathways – the de novo pathway (DNP), which assembles UMP from amino acids 
and glucose in a six-step process, and the nucleoside salvage pathway (NSP), which salvages 
preformed uridine from the extracellular space and phosphorylates it to UMP. The general design 
of  our  screen  involved  forcing  cells  to  rely  upon  only  one  of  these  pathways  for  UMP 
production, and then incubating the cells with our dCKi and identifying which compound(s) 
caused  a  decrease  in  UMP production  in  the  studied  pathway  (Figure  1.12A).  In  order  to 
promote conditions in which UMP could only be produced via the DNP – a condition termed 
DNP-only – cells were incubated in media without uridine (rU) supplementation. With no rU 
present, the NSP lacks its substrate and cells must rely upon the DNP for UMP production. To 
force  cells  to  rely  upon  the  NSP –   termed  NSP-only  –   they  were  incubated  with  rU  and 
NITD-982, a potent and specific inhibitor of dihydroorotate dehydrogenase (DHODH), a key 
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enzyme of the DNP pathway. Baseline conditions were those in which both the DNP and NSP 
were active – achieved by incubating cells in the presence of rU and absence of NITD-982. 
Figure 1.12 |  Design of a phenotypic metabolic modifier screen to evaluate ability dCK 
inhibitor compounds to disrupt pyrimidine nucleotide metabolism. (A) Schematic of screen 
design. (B) Schematic of media conditions which lead to pyrimidine starvation. (C) Proliferation 
rates while incubated in pyrimidine starvation conditions for a panel  of cancer cell  lines.  % 
proliferation values were calculated using Cell Titer Glo (CTG) following 72 hr treatment (7-
point dose response; n=2). (D) Proliferation of JURKAT cells in baseline (DNP + NSP), DNP-
only, NSP-only, and pyrimidine starvation media conditions, normalized to baseline. (E) LC-MS/
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Figure 12
Fig. 9?Differential responses to pyrimidine starvation (defined as a condition in which both the DNP and USP are inactivated) 
in a panel of cell lines. (a) Proliferation rate normalized to number of cell division in the panel of cell lines treated with 1 µM NITD-982 
for 72 h (mean ± SD, n = 4). All cell lines were directly purchased from ATCC or authenticated by Laragen using tests that complies with 
ANSI/ATCC ASN-0002-2011 guidelines; ALL acute lymphoblastic leukemia; PDAC pancreatic ductal adenocarcinoma; SCLC small cell 
lung cancer
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Fig. 13? Chemogenomics platform to identify modulators of pyrimidine nucleotide metabolism.
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A panel of cancer cell lines was screened in order to identify those which displayed a 
decrease in proliferation when unable to produce pyrimidine nucleotides through either the DNP 
or NSP, conditions termed “pyrimidine starvation” (Figure 1.12B, 1.12C). Identifying such cell 
lines  enabled  our  screen  to  have  a  phenotypic  readout  –  namely  a  quantifiable  decrease  in 
proliferation upon concurrent inhibition of the DNP and NSP. Cell  Titer Glo was utilized to 
evaluate  proliferation  impairment.  Following  this  initial  survey  of  cancer  cell  lines,  the  T 
lymphocyte  cell  line  JURKAT was  chosen  for  the  screening  platform as  it  showed  a  large 
decrease in proliferation under pyrimidine starvation conditions,  but  was able to recapitulate 
baseline (DNP and NSP both active) proliferation levels when reliant upon either the DNP or 
NSP alone (Figure 1.12D).
To carry out the screen, JURKAT cells were incubated in three conditions – DNP-only, 
NSP-only, and baseline. dCKi which inhibited growth in DNP-only conditions were categorized 
as DNP inhibitors, while dCKi which inhibited growth in NSP-only conditions were categorized 
as NSP inhibitors and those which inhibited growth in baseline conditions were categorized as 
non-specific inhibitors. 65 nucleomimetic dCK inhibitor compounds synthesized by our group 
were screened for activity and subsequently ranked by pathway-specific index scores, calculated 
as the ratio of compound IC50 values against baseline conditions versus pathway-specific. Higher 
index  scores  correlated  with  higher  pathway  specificity.  Following  the  screen,  the  two  top 
scoring compounds against the DNP were resynthesized and tested again, only to reveal that the 
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initial  hits  were  a  false-positives.  The  top-scoring  compound  against  the  NSP,  NMc-9, 
demonstrated an IC50 of 11.4 µM which correlated with an index score of 8.77. LC-MS/MS 
analysis of incorporation of radiolabeled nucleotides into newly synthesized DNA showed that 
NMc-9  significantly  limited  the  amount  of  rU-derived  CTP compared  to  baseline  (Figure 
1.12E). 
It was reasoned that in order to exert its NSP-inhibitory action, NMc-9 was acting at one 
of two levels  of  the NSP –  either the nucleoside transport  level  or  the kinase level  (Figure 
1.12F). In the NSP of UMP biosynthesis, uridine nucleosides are salvaged from the extracellular 
space and transported into the cell via specialized nucleoside transporters (JURKAT cells express 
the equilibrative nucleoside transporter 1 (ENT1) gene SLC29A1).48 Once inside the cell, they 
are  phosphorylated  to  UMP by  uridine-cytidine  kinase  (UCK),  a  pyrimidine  ribonucleoside 
kinase which exists in two primary isoforms –  UCK1 and UCK2. UCK2 has been shown to 
possess a significantly higher catalytic efficiency when compared with UCK1.49 In addition to 
catalyzing the first  step of the pyrimidine NSP, UCK also phosphorylates several  nucleoside 
analog prodrugs which have found investigational interest as chemotherapeutic agents.12,49,50 
To determine at which level NMc-9 was acting, we first profiled its ability to prevent the 
uptake  of  [3H]Uridine  in  intact  cells.  The  FDA-approved  nucleoside  transport  inhibitor 
dipyridamole was included as a positive control, and NMc-1, which had no effect upon the NSP 
in our screen, was included as a negative control. Both NMc-9 and dipyridamole treatment led to 
a significant decrease in [3H]Uridine uptake, while NMc-1 did not impact uptake at all. Next, we 
assayed the ability of NMc-9  to inhibit the phosphorylation of [3H]Uridine to UMP in lysed 
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cells. Cytidine triphosphate (CTP), a negative allosteric regulator of UCK, was included as a 
positive  control  for  UCK  inhibition.  Treatment  with  NMc-9  or  CTP showed  a  significant 
decrease in [3H]Uridine phosphorylation,  relative to no treatment  or  treatment  with negative 
control. Together, these results indicate that NMc-9 is disrupting the NSP through inhibition of 
UCK. 
Figure 1.13 |  NMc-9 is a putative UCK inhibitor.  (A) Inhibition of [3H]Uridine uptake in 
JURKAT cells following 2 hr incubation ± 1 µM NMc-9, NMc-1, or dipyridamole (DPA). (B) 
Inhibition of [3H]Uridine phosphorylation to [3H]Uridine-monophosphate by NMc-9, NMc-1, 
and cytidine triphosphate (CTP). NT; no treatment. Mean±SD; n=3; one-way ANOVA corrected 
for multiple comparisons by Bonferroni adjustment; ** P<0.01; *** P<0.001.
1.4 Discussion
The importance of dCK in anticancer therapy has been recognized for decades, as this 
enzyme is the key activator of chemotherapeutic nucleoside analog drugs such as gemcitabine. 
However, despite our group having demonstrated the efficacy of inhibiting dCK function for the 
treatment of leukemia in mouse models, as well as defining its roles in hematopoiesis and cell 
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division,  the  potential  clinical  utility  of  dCK inhibition  remains  incompletely  defined.  As  a 
constitutively expressed protein and key enzyme of the nucleoside salvage pathway, dCK and 
inhibition of its function have the potential to be leveraged in a number of therapeutic settings. 
For instance, our proposed mechanism of action against leukemic cells in which inhibition of 
both the de novo and salvage nucleotide biosynthetic pathways leads to unsustainable levels of 
replication stress in cancerous cells may be extended to other cancers such as pancreatic ductal 
adenocarcinoma  (PDAC).  Patients  suffering  from  PDAC  are  in  desperate  need  of  new 
therapeutic options, as five year survival rates are <9%.51 In part due to a dense and fibrous 
stroma,  the  PDAC  tumor  microenvironment  is  particularly  unforgiving,  and  PDAC  tumors 
undergo  extensive  metabolic  reprogramming.52  Part  of  this  reprogramming  involves  the 
upregulation of cellular processes such as autophagy, which recycles and provides tumor cells 
with  the  nutrients  and biomolecules  necessary for  proliferation.53  Given the  role  of  dCK in 
salvaging extracellular  nucleosides,  and the role  of  autophagy in providing tumor cells  with 
deoxynucleosides  for  DNA replication,  there  may be opportunities  for  dCK inhibition to  be 
utilized in therapy against PDAC.54 This application is under active study within our research 
group. 
dCK also plays a vital role in the nucleotide metabolism of macrophages and monocytes, 
which play roles in immune response and activation of pro-inflammatory signaling. These white 
blood cells can contribute to exuberant immune responses at late stages of infectious disease and 
lead  to  cytokine  storms,  a  potentially  deadly  condition  marked  by  excessive  production  of 
inflammatory cytokines which can lead to multi-organ failure and death. Cytokine storms are 
associated with increased mortality in patients suffering from viral illnesses such as influenza, 
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and  has  been  documented  as  a  contributing  factor  to  mortality  in  the  ongoing  COVID-19 
pandemic caused by SARS-CoV-2. Interestingly, macrophages and monocytes lack the capacity 
to synthesize nucleotides de novo, meaning they rely upon dCK and the salvage pathway for 
biosynthesis of the nucleotides necessary for DNA replication and repair.55 This reliance upon 
dCK is heightened upon monocyte and monocyte-derived macrophage activation, as this process 
leads to production of reactive oxygen species (ROS) which necessitate the function of dCK to 
repair ROS-mediated DNA damage. Accordingly, dCK inhibition is associated with defects in 
monocyte/macrophage  effector  functions,  strongly  suggesting  that  dCK  inhibitors  could  be 
exploited therapeutically to attenuate excessive inflammation causing/caused by cytokine storm.
With demonstrated efficacy against leukemia and potential applications in PDAC therapy 
and  in  reducing  the  impact  of  cytokine  storms,  the  development,  pharmacological 
characterization, and evaluation of dCK inhibitors is an important area of research. Our lead 
compound  DI-87  possesses  low-nM affinity  for  dCK and  is  well-tolerated  in  mice  with  no 
observed adverse effects. Thus, preclinical evaluation studies were warranted. Due to technical 
and  kinetic  considerations,  there  were  multiple  limitations  within  our  preclinical 
pharmacological profiling studies of DI-87. Because the half-life of the [18F]CFA PET probe did 
not allow for multiple images within the same animal across a time course experiment, each time 
point represented a reading from a separate mouse. Additionally, the PET probe required time for 
optimal diffusion within the tumor; thus we were unable to quantify dCK inhibition at very early 
time points. PK in the tumor was evaluated in separate mice rather than using a probe to follow 
drug levels  over time.  However,  this  likely does not  represent  a major limitation,  as similar 
results were obtained between replicate experiments and results between mice were similar at 
each time point. Given small sample sizes in the PK studies and differing tumor studies between 
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experiments, it was difficult to determine whether the PK was linear; however, the plasma and 
tumor PK models fit the data well without evidence of non-linear PK. While a fixed dose of i.p. 
thymidine was used for growth inhibition in the current study, either an IV or oral RNR inhibitor 
will be necessary for combination therapy in further clinical development.
Our PET-aided pharmacological profiling of the novel DI-87 provides further evidence of 
the value of PET probes in assisting with preclinical drug development. By using a probe specific 
for dCK activity, we were able to accurately and efficiently predict appropriate dosing for growth 
inhibition  studies  by  determining  a  DI-87  dose  that  resulted  in  maximal  dCK  inhibition 
throughout the dosing interval. This also aided in the development of PK-PD models for both 
dCK inhibition and growth inhibition which can be used to optimize dosing schedules for further 
preclinical  studies.  The  optimal  dosing  schedule  of  25  mg/kg  BID,  predicted  to  completely 
inhibit dCK, led to near total arrest of tumor growth. Taken together, DI-87 is a potent dCK 
inhibitor with in vivo efficacy that demonstrates promise as a new compound for combination 
therapy against tumors expressing dCK, with additional potential applications as a single-agent 
therapy.  This  promise  is  further  evidenced  by  its  recent  Investigational  New  Drug  (IND) 
approval by the Federal Drug Administration. 
While the potency and favorable PK/PD profile of DI-87 remains encouraging, we still 
sought to make improvements through rational structure-activity relationship studies. Two areas 
of the molecular scaffold emerged as targets for modification – the substituted phenyl ring of Part 
A and the  methyl  stereocenter  of  Part  C.  Part  A,  composed of  a  substituted  phenyl  ring  in 
previous dCKi analogs, was identified as being able to accommodate a wide range of substituents 
while maintaining steady dCK inhibitory ability. By removing substitutions at phenyl positions 
2–6 in NMc-1, we generated a novel dCK analog which maintained nanomolar affinity for dCK, 
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providing credence to our hypothesis that this portion of the inhibitor scaffold was amenable to 
modification. We were encouraged by the potency of racemic and adamantyl-containing NMc-3, 
as  its  IC50  was  equal  to  that  of  racemic  DI-87  against  dCK.  Previous  dCKi  analogs  had 
incorporated various phenyl ring substitutions in order to encourage and take advantage of non-
covalent interactions within the dCK substrate binding site,  to incorporate fluorine atoms for 
potential  PET probe development,  and to  improve solubility.  While  the  adamantyl  group of 
NMc-3 does not address concerns regarding solubility or enable PET probe development, it does 
demonstrate that hydrophobicity and its potential impacts upon cell penetration can promote high 
dCK affinity and make up for  lost  non-covalent  hydrogen bonding interactions.  The 10-fold 
decrease in activity demonstrated by NMc-4 when compared with NMc-3 provided evidence that 
substantial hydrophobicity may be required to sustain any benefit over loss of hydrogen bonding 
interactions promoted by substituted phenyl rings. The severe loss of activity seen in NMc-5 
versus other analogs remains puzzling, as the Part A morpholine was incorporated by virtue of 
the privileged status of morpholine rings within medicinal chemistry and our data indicating that 
such a substituent may maintain dCK affinity.
With  progress  towards  improved  dCK  inhibitors  through  modifications  to  Part  A 
appearing incremental at best, we sought to explore the incorporation of a gem-dimethyl moiety 
within Part C of the molecular scaffold. We hypothesized that this moiety would optimally fill 
the  small  hydrophobic  pocket  within  the  dCK  substrate  binding  site  which  was  previously 
occupied by the chiral methyl group of DI-87. While the initial construction of the key mercapto-
tertiary carbon bond proved difficult,  conditions were identified in which the tertiary alcohol 
intermediate 10 (Scheme 1.3) could be converted to the desired gem-dimethyl containing final 
product in a telescoped reaction procedure. However, the gem-dimethyl NMc-6 was nearly 30-
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fold less potent than its mono-methyl containing analog NMc-1, leading us to hypothesize that 
steric interactions between the gem-dimethyl and 5-methyl substituted thiazole were preventing 
the compound from properly orienting within the substrate binding site of dCK. Compounds 
NMc-7–16,  which lacked the 5-position methyl were synthesized,  though none were able to 
recapitulate single-digit nanomolar affinity for dCK. We assessed the origins of this decrease in 
potency through MD simulations and discovered that the gem-dimethyl compounds lacking a 
methyl  in  the  5-position  of  the  thiazole  preferentially  adopted  a  “gauche”  orientation.  This 
orientation resulted in two fewer hydrogen bonding interactions, when compared with the “anti” 
orientation of DI-87. This loss of key hydrogen bonding contacts between the diaminopyrimidine 
and amino acids within the dCK substrate binding pocket was determined to be the predominate 
contributing factor to loss of activity observed in NMc-7–16. 
While the synthetic campaign failed to substantially improve upon lead compound DI-87, 
evaluation of our compounds against nucleotide metabolism proteins other than dCK led to the 
development of a phenotypic screening platform for the identification of novel modulators of 
pyrimidine nucleotide metabolism. Screening of a small library of dCK-inhibiting compounds 
developed  by  our  group  led  to  the  discovery  of  NMc-9  as  a  putative  UCK inhibitor.  Such 
inhibitors  have  been  studied  for  decades,  as  UCK  plays  a  critical  role  in  the  salvage  of 
extracellular  ribonucleosides  and  its  upregulation  in  certain  cancers  is  associated  with  poor 
prognosis and increased disease aggressiveness.56 As the key kinase of the salvage pathway, 
which  functions  alongside  the  de  novo  pathway,  the  development  of  UCK  inhibitors  has 
implications  for  the  function  of  other  small  molecule  drugs  and  drug  candidates  such  as 
inhibitors of the key de novo pathway enzyme  dihydroorotate dehydrogenase (DHODH).57,58 
Such  compounds  have  found  varied  applications  in  multiple  sclerosis,  rheumatoid  arthritis, 
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anticancer,  antiviral,  and  antibacterial  indications,  but  their  efficacy  can  be  limited  by  a 
functioning salvage pathway mediated by UCK.59–61 Despite its clinical relevancy, development 
of viable UCK inhibitors has remained elusive and there are no such compounds used clinically. 
Taken together,  the  ability  of  NMc-9  to  diminish  uridine  uptake  in  intact  cells  and prevent 
uridine phosphorylation in lysed cell provides evidence that it is directly inhibiting UCK, rather 
than preventing the transport of uridine into cells. 
In  summary,  we  have  developed  a  potent  dCK  inhibitor  with  favorable  pre-clinical 
pharmacology data, and have developed models which will inform proper dosing regimens in 
future clinical studies. We expanded upon this molecular scaffold to address shortcomings in 
solubility, as well as to generate achiral inhibitors while maintaining low-nanomolar affinity for 
dCK. While the last two goals were not met, it led to the development of a phenotypic metabolic 
modifier screening platform which was utilized to identify a novel putative UCK inhibitor, and 
whose utility is further expounded upon in Chapter 2 of this dissertation.
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1.5.1 Methods and Materials
dCK Uptake Assay Performed in Cell Culture 
The human cell line CCRF-CEM (C) was purchased from American Type Culture Collection 
(ATCC) with passage number 2–20 used for all experiments. Cells were seeded at a density of 
50,000 cells/ well in Millipore MultiScreen GV 96 well plates. 0.25 μCi of 3H-dC (Moravek 
Biochemicals) were added to the cells simultaneously with varying concentrations of the dCK 
inhibitor at a final volume of 100 μL/ well. After 1 hr at 37 °C, cells were washed four times with 
ice cold phosphate-buffered saline (PBS) using the Millipore Vacuum Manifold. The amount of 
incorporated probe was measured by scintillation counting with the PerkinElmer Microbeta.
Drugs
Drug stocks were prepared in DMSO or H2O and diluted fresh in cell culture media for 
treatments so as to ensure no in situ drug degradation occurred between treatments and/or assays. 
Cell Proliferation Assay 
CEM cells were plated at 1 × 10 cells/well in at 50 μL/well in white opaque 384-well plates and 
treated  as  described.  Following  incubation  with  increasing  concentrations  (2  nm-10  μM) of 
gemcitabine ± 1 μM DI-87 for 72 hr, 50 μL of CellTiter-Glo reagent (Diluted 1:5 in deionized 
H2O) was added to each well, plates incubated at room temperature for 5 min and luminescence 
was measured using a BioTek microplate luminescence reader. 
Animals
Animal studies were conducted under the approval of the UCLA Animal Research Committee 
and were performed in accordance with the guidelines from the Division of Laboratory Animal 
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Medicine  at  UCLA.  All  NOD  scid  gamma  (NSG)  mice  were  purchased  from  the  UCLA 
Radiation Oncology breeding colony. 
Mouse Xenograft Tumor Models and Treatments
Mice had three separate evaluation protocols which included pharmacokinetics, dCK activity, 
and growth inhibition studies. CEM cells were maintained in 10% FBS in RPMI-1640 and were 
grown at 37 °C, 20% O2, and 5% CO2. CEM tumor xenografts were developed in 8–12 week-old 
male or female NSG mice by implanting 2 ×  106  CEM cells in 100 μL of a 50/50 (vol/vol) 
mixture of PBS and matrigel (BD Biosciences) for subcutaneous injections in left shoulders (for 
imaging,  PK,  and  growth  inhibition  studies).  DI-87  (dCKi,  in-house  production  and  Sundia 
Pharmaceuticals) was administered by oral gavage to recipient animals. For oral administration 
of DI-87, the drug was solubilized in the formulation containing PEG-200: Transcutol: Labrasol: 
Tween-80 mixed in 5:3:1:1 ratio. For imaging studies, the mice were treated with indicated doses 
of  DI-87 after  the tumor size reached 250 mm3.  For growth inhibition and pharmacokinetic 
studies, treatments were started after the tumors reached 50 mm3. 
Phenotypic screen of dCK inhibitors against pyrimidine nucleotide metabolism
A library of 65 dCK inhibitors developed by our group was arrayed in polypropylene 384-well 
plates  at  200x  concentrations  covering  a  7-point  concentration  range  (corresponding  to  1x 
concentrations: 5 µM, 1.65 µM, 550 nM, 185 nM, 61.5 nM, 20.6 nM, 6.85 nM). 25 µl per well 
of condition-specific growth media (DNP + NSP (baseline): media +10 µM rU; DNP: media 
alone; NSP: media +10 µM rU + 1 µM NITD-982) was plated in opaque-white 384-well plates 
using a BioTek multidrop liquid handler. dCK inhibitors were added by 250 nL pin-tool transfer 
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(BioMek  FX,  Beckman-Coulter)  and  inhibitor/media  mixtures  were  incubated  at  room 
temperature for 30 m. 25 µL of a 40,000 cells/mL JURKAT suspension (for 1000 cells / well) 
was subsequently added to each well. After 72 h, 50 µL of Cell Titer Glo reagent diluted 1:4 in 
deionized H2O was added to each well and luminescence was measured using a Wallac plate 
reader (Perkin Elmer). Each condition was assayed in duplicate (n=2) and % proliferation values 
were  calculated  by  normalizing  experimental  wells  to  plate  negative  controls  and  averaging 
replicate values.  Composite pathway selectivity synergy scores for each test  compound were 
defined  as  the  sum  of  the  excess  over  additivity  (%  proliferation  inhibition  observed  -  % 
proliferation  inhibition  expected)  between  individual  protein  kinase  inhibitor  concentrations 
across the 7-point concentration range. Z factor scores for individual assay plates were calculated 
using eight positive and eight negative control wells on each plate. All plates gave a Z factor > 
0.5.
Cell Titer Glo viability analysis
Cells were plated at 1x103 cells / well at 50 µl / well in white opaque 384-well plates and treated 
as described. Following incubation 50 µl of Cell Titer. Glo reagent (Diluted 1:5 in deionized 
H2O) was added to each well, plates incubated at room temperature for 5 min and luminescence 
was  measured using a  BioTek microplate  luminescence  reader.  Proliferation  rate  normalized 
growth inhibition was calculated using the GR metric.
Mass spectrometry
For  analysis  of  stable  isotope-labeled  metabolite  incorporation  into  newly  replicated  DNA, 
JURKAT cells were cultured in glucose-free RPMI media supplemented with 10% dialyzed FBS, 
4 mM glutamine, 1 g/L [13C6]glucose, 10 µM [13C9; 15N2]rU and treated as indicated.
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Genomic DNA was extracted using the Quick-gDNA MiniPrep kit and hydrolyzed to nucleosides 
using the DNA Degradase Plus kit,  following manufacturer-supplied instructions. In the final 
step of DNA extraction, 50 μL of water was used to elute the DNA into 1.5 mL microcentrifuge 
tubes. A nuclease solution (5 μL; 10X buffer/DNA Degradase PlusTM/water, 2.5/1/1.5, v/v/v) 
was added to 20 μL of the eluted genomic DNA in an HPLC injector vial. The samples were 
incubated overnight at 37 ºC.
Hydrolyzed DNA was diluted 1/1 with solvent A (water/acetonitrile/formic acid, 95/5/0.1, v/v) 
and analyzed using a modified version of a previously reported method2,45 in which aliquots of 
the solution (15 µL) were injected onto a porous graphitic carbon column (Thermo Hypercarb, 
100 x 2.1 mm, 5 micron particle size) equilibrated in solvent A and eluted (300 µL/min) with an 
increasing  concentration  of  solvent  B  (acetonitrile/water/formic  acid,  90/10/0.1).  The  HPLC 
timetable, in terms of min/%B, is the following: 0/0, 5/0, 12/20, 15/30, 17/50, 19/50, 20/0, 24/0. 
The effluent from the column was directed to Agilent Jet Stream connected Agilent 6460 QQQ 
operating in the positive ion MRM mode. After verification of retention times using authentic 
standards, the peak areas of the protonated nucleoside/protonated base fragment ion transitions 
for each of the nucleosides were recorded with instrument manufacturer-supplied software.
Pharmacokinetic Studies of DI-87 in Mice
DI-87 plasma and tumor concentrations were assessed at 1, 3, 6, 9 and 24 hr following oral 
administration of 10, 25, or 50 mg/kg of DI-87 to female NSG mice with CEM tumors (N = 5 
mice per time point). At each time point, a cohort of mice was sacrificed by cervical dislocation; 
thus, a single plasma and tumor concentration were obtained from each mouse. Blood samples 
were collected in heparin-EDTA tubes by the retro-orbital technique and spun at 6000×g for 15 
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min prior to collecting the plasma supernatants. All plasma samples were frozen at −20 °C before 
sample processing. The stock solutions of DI-87 and DI- 82 (internal standard) were prepared by 
dissolving  the  appropriate  amount  of  each  drug  in  a  known  volume  of  dimethyl  sulfoxide 
(DMSO) to  a  10  mM concentration  and  were  stored  at  –20  °C before  use.  DI-82  (internal 
standard)  was diluted to  200 nM in methanol  to  make the internal  solution.  The calibration 
standards were prepared by spiking working stock solutions of DI-87 in plasma from untreated 
mice to give 0.01–10 pmol/μL range. Each 20 μL calibration standard sample was mixed with 60 
μL of  internal  solution  (methanol  with  200  nM  internal  standard)  and  vortexed  for  30  s. 
Following centrifugation at 15,000 × g for 10 min, approximately 60 μL of sample was carefully 
transferred  into  HPLC  injector  vials  for  LC-MS/MS-MRM  analysis.  Plasma  samples  were 
processed the same way as the calibration standard samples. 20 μL samples were injected onto a 
reverse  phase  column,  (Thermo Scientific  Hypersil  GOLD column 3.0  μm; 2.1  ×  100 mm) 
equilibrated  in  0.1%  water/formic  acid,  and  eluted  (200  μL/min)  with  an  increasing 
concentration of solvent B (acetonitrile/formic acid, 100/0.1, v/v: min/% acetonitrile; 0/0, 5/0, 
15/60, 16/100, 19/100, 20/0, and 25/0). The effluent from the column was directed to the Agilent 
Jet  Stream ion  source  connected  to  the  triple  quadrupole  mass  spectrometer  (Agilent  6460) 
operating in the multiple reaction monitoring (MRM) mode using previously optimized settings. 
The  following  drug  precursor  →  fragment  ion  transitions  were  used:  DI-82  (511  →  369), 
DI-87(503 →  361).  The peak areas for  each drug (precursor  →  fragment ion transitions)  at 
predetermined  retention  times  were  recorded  using  the  software  supplied  by  the  instrument 
manufacturer  (Agilent  MassHunter).62  The  intraday  precision  based  on  the  coefficient  of 
variation of replicates of the lower limit of quantification (LLOQ) and for quality control (QC) 
samples are within 15% and the accuracy of LLOQ and QC samples are within 10%. 
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Tumors were harvested after dissection of mice, weighed, and snap-frozen in liquid nitrogen. 
PBS containing internal standard (200 μL for 50 mg tumor) was added to the excised tumor and 
homogenized  using  a  bead  beater  (BioSpec).  The  samples  were  spun  down  to  collect 
supernatants. The supernatant was further diluted 5 times in PBS (with internal standard), and 
four parts of methanol (with internal standard) was added and incubated −80 °C overnight to 
precipitate  proteins.  The  samples  were  spun  at  maximum  speed  (16000  g)  at  4  °C,  and 
supernatant  collected.  Twenty  μL  samples  were  injected  onto  a  reverse  phase  column 
equilibrated in water 0.1% formic acid for LC-MS/ MS-MRM analysis in positive ion mode as 
above and compared to calibration standards. 
dCK Activity with MicroPET/CT
dCK activity was evaluated following oral administration of 5, 10, or 25 mg/kg of DI-87 to male 
NSG mice implanted with CEM tumors (N = 4 mice per  time point).  The NSG mice were 
anesthetized 3 hr prior to imaging and intravenously administered 740 kBq of [18F]CFA PET 
probe.28  Thus,  each  mouse  was  representative  of  a  single  time  point  and  concentration. 
MicroPET/CT experiments were conducted using G8 microPET/CT system.30,63 The mice were 
then positioned in an imaging chamber and data was acquired with the G8 microPET/CT system 
(Sofie Biosciences). MicroPET data was acquired for 10 min and reconstructed with a statistical 
maximum a posteriori probability algorithm (MAP) into multiple frames. The spatial resolution 
of  PET is  ~1.5 mm with 0.4 mm voxel  size.  CT images are a  low-dose 400 μm resolution 
acquisition with  200 μm voxel  size.  MicroPET and CT images  were  co-registered and then 
quantified by manually drawing three-dimensional regions of interest using Osirix software. The 
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color scale was proportional to tissue concentration, with red being the highest and yellow, green 
and blue corresponding to the lower values. 
Growth Inhibition Studies
Male NSG mice implanted with CEM tumors as above were used for growth inhibition studies. 
Combination therapy of DI-87 with thymidine was used. Treatments of DI-87 and/or thymidine 
were started after  tumor volume reached 50 mm3.  DI-87 was administered at  varying doses 
orally once a day (QD) or twice a day (BID) for 16–18 days while thymidine (2 g/kg) solubilized 
in  saline  was administered intraperitoneally  BID after  start  of  treatment.17  Three cohorts  of 
control mice were administered either: (i) intraperitoneal (i.p.) thymidine alone, (ii) Oral DI-87 
with  i.p  saline  injections,  or  (iii)  vehicle  for  oral  DI-87  and  saline  i.p.  Tumor  growth,  as 
measured by CT,  was compared amongst  different  treatment  groups (n = 5 mice,  5  tumors/
group). Tumor growth was monitored daily by caliper measurements ([(length × width2)/2]) and 
bi-weekly by CT measurements. 
Pharmacokinetic and Pharmacodynamic Modeling
Using the computer program NONMEM (version 7.3) with a GNU Fortran G77 Compiler, DI-87 
concentration-time data were modeled using first-order conditional estimation (FOCE) method 
with interaction. Plasma concentrations were assessed with standard PK models which included 
a  depot  compartment  representing  the  gut.  Tumor  concentrations  were  evaluated  with  the 
addition of a separate tumor compartment once plasma concentrations had been characterized 
(ADVAN6, TRANS1 subroutine). An exponential-normal distribution error model was used for 
inter-subject variability. 
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A combined pharmacokinetic-pharmacodynamic (PK-PD) model was developed using the final 
DI-87 plasma-tumor PK parameter estimates. The effect compartment (dCK inhibition or growth 
inhibition) was linked to the tumor concentrations. Linear (slope), Emax, and sigmoid Emax 
models were tested to determine which were the best fits to the data (see equations below).64 The 
final model was used to simulate dCK inhibition and growth inhibition from a representative 
mouse for each of the tested DI-87 concentrations. 
PD models: 
Docking and Molecular Dynamics: 
The inhibitor compounds are docked into the binding pocket of dCK crystal structure manually. 
Classical molecular dynamics (MD) were performed using the GPU code (pmemd) of the Amber 
12 package on the substrate conformations and the transition states for 500 ns in enzyme. The 
FF99SBildn  force  field  was  used  for  the  protein  residues.  Parameters  for  the  substrate 
conformations and transition states were generated within the antechamber module using the 
general  Amber force field (gaff),  with the partial  charges set  to fit  the electrostatic  potential 
calculated at the HF/6-31G(d) level by the RESP model. The charges were computed according 
to the Merz-Singh-Kollman scheme using the Gaussian 09 package. Each enzyme complex was 
immersed  in  a  pre-equilibrated  truncated  cuboid  box  with  a  10  Å  buffer  of  TIP3P water 
molecules using the tleap module. The systems were neutralized by addition of explicit counter 
ions (Na+ or Cl-). The systems were optimized for total 10000 steps, followed by gentle heating 
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to imaging and intravenously administered 740 kBq of [18F]CFA PET
probe [4]. Thus, each mouse was representative of a single time point
and concentration. MicroPET/CT experiments were conducted using G8
microPET/CT system [6,7]. The mice were then positioned in an ima-
ging chamber and data was acquired with the G8 microPET/CT system
(Sofie Biosciences). MicroPET data was acquired for 10 min and re-
constructed with a statistical maximum a posteriori probability algo-
rithm (MAP) into multiple frames. The spatial resolution of PET is
~1.5 mm with 0.4 mm voxel size. CT images are a low-dose 400 μm
resolution acquisition with 200 μm voxel size. MicroPET and CT images
were co-registered and then quantified by manually drawing three-di-
mensional regions of interest using Osirix software. The color scale was
proportional to tissue concentration, with red being the highest and
yellow, green and blue corresponding to the lower values.
2.14. Growth inhibition studies
Male NSG mice implanted with CEM tumors as above were used for
growth inhibition studies. Combination therapy of DI-87 with thymi-
dine was used. Treatments of DI-87 and/or thymidine were started after
tumor volume reached 50 mm3. DI-87 was administered at varying
doses orally once a day (QD) or twice a day (BID) for 16–18 days while
thymidine (2 g/kg) solubilized in saline was administered in-
traperitoneally BID after start of treatment 3. Three cohorts of control
mice were administered either: (i) intraperitoneal (i.p.) thymidine
alone, (ii) Oral DI-87 with i.p saline injections, or (iii) vehicle for oral
DI-87 and saline i.p. Tumor growth, as measured by CT, was compared
amongst different treatment groups (n = 5 mice, 5 tumors/group).
Tumor growth was monitored daily by caliper measurements
([(length × width2)/2]) and bi-weekly by CT measurements.
2.15. Pharmacokinetic and pharmacodynamic modeling
Using the computer program NONMEM (version 7.3) with a GNU
Fortran G77 Compiler, DI-87 concentration-time data were modeled
using first-order conditional estimation (FOCE) method with interac-
tion. Plasma concentrations were assessed with standard PK models
which included a depot compartment representing the gut. Tumor
concentrations were valuated with the addition of a separate tumor
compartment once plasma concentrations had been characterized
(ADVAN6, TRANS1 subroutine). An exponential-normal distribution
error model was used for inter-subject variability.
A combined pharmacokinetic-pharmacodynamic (PK-PD) model
was developed using the final DI-87 plasma-tumor PK parameter esti-
mates (Fig. 1). The effect compartment (dCK inhibition or growth in-
hibition) was linked to the tumor concentrations. Linear (slope), Emax,
and sigmoid Emax models were tested to determine which were the best
fits to the data (see equations below) [8]. The final model was used to
simulate dCK inhibition and growth inhibition from a representative
mouse for each of the tested DI-87 concentrations.
PD models:
A Linear slope Slope Conc. ( ): .
+B E E ConcEC Conc. : .max max 50
+C Sigmoid E E ConcEC Conc. :max max ExpExp Exp50
3. Results
3.1. D velopment of a h ghly potent, rally bioavail ble dCK inhibitor, DI-
87
While our group had previously developed the dCK inhibitors DI-39
and DI-82, each had drawbacks, including poor solubility and sub-op-
timal PK. In an effort to improve upon previous generation inhibitors,
DI-87 (Fig. 2A) was synthesized, with the morpholine moiety specifi-
cally incorporated to increase solubility. DI-87 was synthesized as fol-
lows: an SN2 reaction between 4-methoxy-3-hydroxybenzonitrile and 4-
(2-chloroethyl) morpholine furnished 1 (Fig. 2B). Heating with an
aqueous solution of ammonium sulfide gave thioamide 2, which was
subjected to Hantzsch thioazole formation conditions to yield thiazole
3. Asymmetric Corey-Bakshi-Shibata (CBS) reduction of the ketone re-
sulted in the S-alcohol 4, which was converted into the trifluoroacetate
5 and displaced via SN2 reaction by 4,6-diamino-2-mercaptopyrimidine
to furnish (R)-DI-87 (6). The IC50 values for each enantiomer of DI-87
were determined using a dC uptake assay in CEM cells. (S)-DI-87 ex-
hibited a much higher IC50 value (468 ± 2.1 nM) relative to (R)-DI-87
(3.15 ± 1.2 nM) (Fig. 2C). (R)-DI-87 treatment rescued CEM cells from
the anti-proliferative effects of gemcitabine, a dCK-dependent nucleo-
side analog prodrug, with an EC50 of 10.2 nM (Fig. 2D). Additionally,
we observed that protein binding of (R)-DI-87 (DI-87) is comparatively
lower than its predecessor, (R)-DI-82 (DI-82), as measured by IC50 of
the respective dCK inhibitor in presence of bovine serum albumin (BSA)
(Fig. 2E).
3.2. Pharmacokinetics of DI-87
DI-87 concentrations in plasma and tumor were determined for 3
dose levels: 10, 25, and 50 mg/kg (Fig. 3). Plasma and tumor con-
centrations were obtained at a single time point from each mouse.
Plasma DI-87 concentrations peaked between 1 and 3 h (Fig. 3A).
Tumor concentrations were lower than plasma and had a later, more
sustained peak at 3–9 h (Fig. 3B). Plasma and tumor PK was also
evaluated in male mice following a 10 mg/kg dose, with essentially
identical results to those seen in female mice (data not shown).
A population PK model was initially developed for plasma con-
centrations, with a one-compartment structural model fitting the data
well. An additional compartment was added to model tumor con-
centrations. The parameter estimates for the combined tumor and
plasma population PK model are shown in Table 1. KA was fixed to the
parameter estimate obtained from the plasma PK model. The typical
clearance value was 0.46 L/hr/kg and the plasma volume of distribu-
tion was 2.78 L/kg. Actual tumor volumes were used in the model.
Fig. 1. Schematic of population PK-PD model. DI-87 is an oral drug which is
absorbed from the gut with an absorption constant (KA). It distributes between
the plasma volume (Vp) and tumor volume (Vt) with an intercompartmental
clearance Q and is eventually cleared from the plasma compartment (CL).
Tumor DI-87 concentrations lead to drug effect (dCK inhibition or growth in-
hibition). DCK inhibition with modeled with a sigmoid Emax indirect response
model while growth inhibition was modeled with an Emax indirect response
model.
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from 0 K to 300 K under constant-volume and periodic-boundary conditions. Each system was 
then  equilibrated  for  2  ns  with  a  2  fs  time  step.  Production  trajectories  were  then  run  for 
additional 500 ns under the same simulation conditions. 
DFT Calculation:
Density  functional  theory  computations  were  performed  using  Gaussian09.  Geometry 
optimizations were performed at the B3LYP/6-31G(d) level of theory, which has been shown to 
yield accurate conformational energetics. The energy is scanned along the dihedral angle with 
Opt=ModRedundant option.  Reported energies are Gibbs free energies.  The 3D rendering of 
stationary  points  were  generated  using  CYLview.  GaussView  and  Avogadro  were  used  to 
construct the structures used in our computations. 
Statistical analyses
Data are presented as mean ± SD with number of biological replicates indicated. Comparisons of 
two groups were calculated using indicated unpaired two-tailed Student’s t-test and P values less 
than 0.05 were considered significant. Comparisons of more than two groups were calculated 
using one-way ANOVA followed by Bonferroni’s multiple comparison tests, and P values less 
than 0.05/m, where m is the total number of possible comparisons, were considered significant.
1.5.2 General Chemistry Methods
All chemicals,  reagents and solvents were obtained from commercial  sources and were used 
without further purification. Unless otherwise noted, reactions were carried out in oven-dried 
glassware  under  an  atmosphere  of  argon  using  commercially  available  anhydrous  solvents. 
Tetrahydrofuran (THF) was distilled from sodium under an argon atmosphere. Dichloromethane 
was distilled from calcium hydride. Solvents used for extractions and chromatography were not 
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anhydrous. Analytical TLC was carried out on precoated silica gel (Merck silica gel 60, F254) 
and visualized with UV light. Column chromatography was performed with silica (Fisher, 230–
400 mesh). 1H NMR, 13C NMR, and 19F NMR spectra were measured in CDCl3 or DMSO-d6 
on Bruker AV spectrometers at 400 or 500 MHz. Chemical shifts were reported in parts per 
million (δ) relative to residual solvent signals. The signals observed were described as follows: s 
(singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublets), dt (doublet of triplets), ddd 
(doublet of doublet of doublets), tt  (triplet of triplets), tdd (triplet of doublet of doublets), m 
(multiplet), br s (broad singlet), br m (broad multiplet). Mass spectra were obtained on a Waters 
LCT Premier with ACQUITY UPLC mass spectrometer under electrospray ionization (ESI) or 
Thermo Fisher Scientific Exactive Plus with direct analysis in real time (DART) ionization. All 
microwave-assisted  reactions  were  carried  out  in  a  CEM  Discover  908005  Microwave 
synthesizer system.
1.5.3 General Method A – Synthesis of Thioamide Intermediates 
With  appropriate  carbonitrile  starting  materials,  all  thioamide  intermediate  compounds  were 
synthesized  using  the  following  General  Method  A  for  synthesis  of  4-methoxy-3-(2-
morphlinoethoxy)benzothioamide:
To  a  homogenous  solution  of  4-methoxy-3-(2-morpholinoethoxy)benzonitrile  (1.52  g,  5.79 
mmol) in pyridine (12 mL) was added Et3N (1 mL, 7.17 mmol) and ammonium sulfide solution 
(20 wt% in water, 5.93 mL, 17.4 mmol). The reaction solution was heated to 60 °C and stirred 
for 12 hr. The reaction solution was then cooled to room temperature and concentrated in vacuo. 
The resulting residue was taken up in ethyl acetate and washed with deionized water and brine. 
The organic layer was dried over anhydrous MgSO4, concentrated in vacuo, and purified by flash 
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chromatography  over  silica  gel  (1:2  to  2:1  ethyl  acetate/hexanes)  to  yield  the  desired  4-
methoxy-3-(2-morpholinoethoxy)benzothioamide  (1.35  g,  79%  yield).  1H  NMR  (300  MHz, 
CDCl3) δ 7.75 (br s, 1H), 7.65 (d, J = 2.2 Hz, 1H), 7.41 (dd, J = 8.5, 2.2 Hz, 1H), 7.36 (br s, 1H), 
6.81 (d, J = 8.5 Hz, 1H), 4.21 (t, J = 5.9 Hz, 2H), 3.88 (s, 3H), 3.72 (t, J = 4.7 Hz, 4H), 2.85 (t, J 
= 5.9 Hz, 2H), 2.59 (t, J = 4.6 Hz, 4H). DART-MS: m/z calcd. for C14H21N2O3S [M + H]+, 
297.12729; found 297.12241.
1.5.4 General Method B – Synthesis of 2-substituted 1-(5-methyl-thiazol-4-yl)-ethan-1-one 
Intermediates
With appropriately substituted thioamide precursors, all 2-substituted 1-(5-methyl-thiazol-4-yl)-
ethan-1-one intermediate compounds were synthesized using the following General Method B 
for synthesis of 1-(2-(4-methoxy-3-(2-morpholinoethoxy)phenyl)-5-methylthiazol-4-yl)ethan-1-
one:
To a  solution of  4-methoxy-3-(2-morphlinoethoxy)benzothioamide (276 mg,  0.931 mmol)  in 
ethanol (3 mL) at room temperature was added 4-bromopentane-2,3-dione (200 mg, 1.12 mmol) 
and  the  reaction  solution  was  heated  to  reflux  for  3  hr.  The  reaction  solution  was  then 
concentrated in vacuo, and the resulting residue was directly purified by trituration with ethyl 
acetate and hexanes to yield the desired thiazole  (190 mg, 54% yield). 1H NMR (500 MHz, 
CDCl3) δ 7.50 (d, J = 2.0 Hz, 1H), 7.47 (dd, J = 8.4, 2.1 Hz, 1H), 6.90 (d, J = 8.4 Hz, 1H), 4.66 
(t, J = 4.4 Hz, 2H), 4.30 (br m, 2H), 4.02 (br m, 2H), 3.88 (s, 3H), 3.72 (br m, 2H), 3.55 (t, J = 
4.3 Hz, 2H), 3.22 (br m, 2H), 2.74 (s, 3H), 2.68 (s, 3H). DART-MS: m/z calcd. for 377.15350 [M 
+ H]+; found 377.15920.
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1.5.5  General  Method  C  –  Synthesis  of  2-substituted  ethyl-4-carboxylate  Thiazole 
Intermediates
With  appropriately  substituted  thioamide  precursors,  all  2-substituted  ethyl-4-carboxylate 
thiazole intermediates were synthesized using the following General Method C for synthesis of 
ethyl 2-methylthiazole-4-carboxylate:
To a solution of ethanethioamide (230 mg, 3.06 mmol) in ethanol (12 mL) was added ethyl 
bromopyruvate (0.46 mL, 3.67 mmol). The reaction solution was heated to reflux and stirred for 
2 hr. The reaction solution was then diluted with deionized water and extracted three times with 
ethyl  acetate.  The  combined  organic  layers  were  washed  with  brine,  dried  over  anhydrous 
MgSO4,  and  concentrated  in  vacuo.  The  residue  was  then  purified  by  flash  column 
chromatography with 35% ethyl acetate in hexanes as the eluent. The product was obtained as a 
crystalline solid (380 mg, 73% yield). 1H NMR (400 MHz, CDCl3) δ 8.03 (s, 1H), 4.41 (q, J = 
7.1 Hz, 2H), 2.76 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 166.9, 161.6, 
147.0,  127.4,  61.6,  19.5,  14.5;  HRMS-ESI  (m/z)  [M+H]+  calcd  for  C7H10NO2S  [M+H]+ 
171.03540, found 171.03738.
1.5.6  General  Method  D  –   Synthesis  of  2-substituted  1-(thiazol-4-yl)-ethan-1-ol 
Intermediates
With appropriate 2-substituted 1-(5-methyl-thiazol-4-yl)-ethan-1-one precursors, all 2-substituted 
1-(thiazol-4-yl)-ethan-1-ol thiazole intermediates were synthesized using the following General 
Method D for synthesis of 1-(5-methyl-propylthiazol-4-yl)-ethan-1-ol:
To a homogenous solution of 1-(5-methyl-propylthiazol-4-yl)-ethan-1-one (407 mg, 2.22 mmol) 
in THF at 0 °C was added DIBAL-H (1.0 M solution in THF, 3.11 mL, 3.11 mmol) dropwise. 
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The reaction solution was stirred at 0 °C for 15 min and then at room temperature for 75 min. 
Upon reaction completion,  the solution was then cooled to 0 °C and carefully quenched by 
addition of Rochelle’s Salt. This mixture was stirred for 30 min, diluted with deionized water, 
and extracted three times with ethyl acetate. The organic layers were then combined and dried 
over  anhydrous  MgSO4  and  concentrated  in  vacuo.  The  resulting  oil  was  purified  by  flash 
column chromatography over silica gel with 10% ethyl acetate in hexanes as the eluent. The 
desired alcohol was obtained as an oil (468 mg, 98% yield). 1H NMR (400 MHz, CDCl3) δ 4.88 
(m, 1H), 2.87 (d, J = 15.3 Hz, 1H), 2.85 (d, J = 15.3 Hz, 1H), 2.77 (br s, 1H), 2.35 (s, 3H), 1.75 
(m, 2H), 1.48 (d, J = 6.5 Hz, 3H), 0.99 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
168.1,  153.8,  125.5,  64.6,  35.4,  24.2,  23.5,  13.8,  10.9;  HRMS-ESI  (m/z)  [M+H]+  calcd  for 
C9H16NOS 186.09526, found 186.09952.
1.5.7  General  Method  E  –   Synthesis  of  2-substituted  2-(thiazol-4-yl)-propan-2-ol 
Intermediates
With  appropriate  2-substituted  ethyl-4-carboxylate  substituted  thiazole  precursors,  all  2-
substituted  2-(thiazol-4-yl)-propan-2-ol  intermediates  were  synthesized  using  the  following 
General Method E for synthesis of 2-(2-phenylthiazol-4-yl)propan-2-ol:
To a solution of ethyl 2-phenylthiazole-4-carboxylate (740 mg, 3.17 mmol) in THF (20 mL) at 0 
°C was added methyl magnesium bromide (3.0 M in THF, 4.2 mL, 12.7 mmol). The reaction 
solution was stirred for 30 min before warming to room temperature. Once the starting material 
was consumed, the reaction solution was quenched by carefully pouring into a saturated NH4Cl 
solution. The aqueous solution was extracted three times with ethyl acetate and the combined 
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organic layers were dried over MgSO4, concentrated in vacuo, and resulting residue was purified 
by flash column chromatography over silica gel  using 15 % ethyl  acetate in hexanes as the 
eluent. Desired alcohol obtained as an off-white solid (536 mg, 77% yield). 1H NMR (400 MHz, 
CDCl3) δ 7.95 (m, 2H), 7.42 (m, 3H), 7.08 (s, 1H), 3.04 (br s, 1H), 1.65 (s, 6H); 13C NMR (100 
MHz, CDCl3) δ 168.0, 165.0, 133.7, 130.1, 129.0, 126.7, 111.3, 71.3, 30.2; HRMS-ESI (m/z) 
[M+H]+ calcd for C12H14NOS 220.07961, found 220.08266.
1.5.8 General Method F – Synthesis of 2-substituted 1-(5-methyl-thiazol-4-yl)-ethyl 2,2,2-
trifluoroacetate Intermediates
With  appropriate  2-substituted  1-(thiazol-4-yl)-ethan-1-ol  precursors,  all  2-substituted  1-(5-
methyl-thiazol-4-yl)-ethyl  2,2,2-trifluoroacetate  intermediates  were  synthesized  using  the 
following  General  Method  F  for  the  synthesis  of  (S)-1-(2-(4-methoxy-3-(2-
morpholinoethoxy)phenyl)-5- methylthiazol-4-yl)ethyl 2,2,2-trifluoroacetate:
To a solution of (S)-1-(2-(4-methoxy-3-(2-morpholinoethoxy)phenyl)-5- methylthiazol-4-
yl)ethan-1-ol (47 mg, 0.124 mmol) in DCM (5 mL) at 0 °C was added trifluoroacetic anhydride 
(TFAA, 0.07 mL, 0.5 mmol) dropwise. After stirring for 30 min at 0 °C the reaction solution was 
warmed to room temperature prior to quenching with a saturated aqueous solution of sodium 
bicarbonate. The resulting aqueous solution was extracted with DCM three times, the combined 
organic layers washed with brine, concentrated in vacuo and used directly in next step due to the 
instability of the trifluoroacetate product. HRMS-ESI (m/z) calcd for C21H26F3N2O5S [M+H]+ 
475.15145, found 475.15481.
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1.5.9  General  Method  G  –  Synthesis  of  2-substituted  2-(1-(5-methyl-thiazol-4-yl)-ethyl) 
thiopyrimidine-4,6-diamine Final NMc Compounds (NMc 1–4)
With appropriate 2-substituted 1-(5-methyl-thiazol-4-yl)-ethyl 2,2,2-trifluoroacetate precursors, 
final NMc compounds 1–4 were synthesized using the following General Method E for synthesis 
of  (R)-2-((1-(2-(4-methoxy-3-(2-morpholinoethoxy)-phenyl)-5-methylthiazol-4-
yl)ethyl)thio)pyrimidine-4,6-diamine (DI-87): 
To a solution of crude (S)-1-(2-(4-methoxy-3-(2-morpholinoethoxy)phenyl)-5-methylthiazol-4-
yl)ethyl 2,2,2-trifluoroacetate (71 mg, 0.15 mmol) and Cs2CO3 (195 mg, 0.60 mmol) from the 
previous step in DMF (3 mL) was added 4,6-diamino-2-mercaptopyrimidine (43 mg, 0.30 mmol) 
and the reaction solution was stirred at 80 °C. After 3 hr, the reaction solution was filtered 
through a pad of Celite, concentrated in vacuo, and purified by flash chromatography over silica 
gel (1:20 to 1:10 methanol/DCM). Final product obtained as a pale brown solid (20 mg, 27% 
yield (two steps)). 1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 2.0 Hz, 1H), 7.37 (dd, J = 8.4, 2.0 
Hz, 1H), 6.86 (d, J = 8.4, 1H), 5.24 (s, 1H), 5.22 (q, J = 7.0 Hz, 1H), 4.60 (s, 4H), 4.24 (t, J = 5.9 
Hz, 2H), 3.88 (s, 3H), 3.76 (t, J = 4.7 Hz, 4H), 2.87 (t, J = 5.9 Hz, 2H), 2.61, (t, J = 4.5 Hz, 4H), 
2.50 (s, 3H), 1.80 (d, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 170.5, 163.8, 163.3, 
153.5, 150.8, 148.4, 127.4, 126.9, 119.9, 111.6, 111.3, 80.7, 67.0, 66.7, 57.6, 56.1, 54.2, 37.7, 
22.1, 11.7; HRMS-ESI (m/z) calcd for C23H31N6O3S2 [M+H]+ 503.18991, found 503.18727.
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1.5.10 General Method H – Synthesis of 2-substituted 4-(2-chloropropan-2-yl) Thiazole 
Intermediates
With appropriate 2-substituted 2-(thiazol-4-yl)-propan-2-ol precursors, all 2-substituted 4-(2-
chloropropan-2-yl) intermediates were synthesized using the following General Method H for 
synthesis of 4-(2-chloropropan-2-yl)-2-phenylthiazole:
To a heterogenous solution of 2-(2-phenylthiazol-4-yl)propan-2-ol (214 mg, 0.976 mmol) and 
sodium bicarbonate (517 mg, 4.88 mmol) in diethyl ether (5 mL) was added thionyl chloride 
(0.078 mL, 1.07 mmol). The reaction solution was stirred for 15 min, filtered through a pad of 
Celite and concentrated in vacuo at low temperature. The crude product was used directly in the 
following step due to instability of the tertiary chloride. HRMS-ESI (m/z) calcd for C12H13ClNS 
[M+H]+ 238.04572, found 238.04814.
1.5.11 General Method I – Synthesis of 2-substituted 2-((2-(thiazol-4-yl)propan-2-
yl)thio)pyrimidine-4,6-diamine Final NMc Compounds (NMc 5–16)
With appropriate 2-substituted 4-(2-chloropropan-2-yl) precursors, all final gem-dimethyl NMc 
compounds 5–16 were synthesized using the following General Method I for synthesis of 2-((2-
(2-phenylthiazol-4-yl)propan-2-yl)thio)pyrimidine-4,6-diamine (NMc-7):
To a solution of crude 4-(2-chloropropan-2-yl)-2-phenylthiazole (0.638 mmol) in DMF was 
added sodium 4,6-diaminopyrimidine-2-thiolate (105 mg, 0.638 mmol) and the resulting solution 
was stirred at room temperature for 3 hr. The reaction solution was then filtered through Celite, 
concentrated in vacuo and purified by flash column chromatography using an eluent gradient of 
3–5% methanol in DCM. Product obtained as an off-white solid (22 mg, 10% yield).  1H NMR 
(400 MHz, CDCl3) δ 7.94 (m, 2H), 7.40 (m, 3H), 7.22 (s, 1H), 5.16 (s, 1H), 4.58 (br s, 4H), 2.02 
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(s, 6H); 13C NMR (100 MHz, CDCl3) δ 170.1, 166.4, 162.8, 152.9, 134.2, 129.8, 128.9, 126.7, 
114.2, 80.9, 50.4, 29.2; 
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1.6 Experimental Details
4-Methoxy-3-(2-morpholinoethoxy)benzonitrile (I1)
To a heterogeneous solution of 4-methoxy-3-hydroxybenzonitrile (2.44 g, 16.4 mmol) and 
Cs2CO3 (10.68 g, 32.8 mmol) in N,N-dimethylformamide (DMF) and acetone (1:1, 60 mL) was 
added 4-(2-chloroethyl)morpholine hydrochloride (2.45 g, 16.4 mmol). The reaction solution 
was stirred under argon at 70 °C for 12 hr. The reaction solution was then filtered and the filtrate 
diluted with deionized water before extracting three times with ethyl acetate. The combined 
organic layers were dried over anhydrous MgSO4 and concentrated in vacuo before purification 
by flash chromatography over silica gel (2:3 ethyl acetate/ hexanes) to yield the desired product 
I1 (3.91 g, 91% yield). 
1H NMR (500 MHz, CDCl3) δ:
7.29 (dd, J = 8.4, 1.9 Hz, 1H)
7.13 (d, J = 1.9 Hz, 1H)
6.91 (d, J = 8.4 Hz, 1H)
4.16 (t, J = 5.9 Hz, 2H)
3.91 (s, 3H)
3.73 (t, J = 4.7 Hz, 4H)
2.85 (t, J = 5.9 Hz, 2H)
2.59 (t, J = 4.6 Hz, 4H). 
HRMS-ESI (m/z) calcd for C14H19N2O3 [M+H]+ 263.13957, found 263.14203.
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4-Methoxy-3-(2-morpholinoethoxy)benzothioamide (I2)
I2 was synthesized according to General Method A starting from precursor I1. 1.35 g, 79% yield. 
1H NMR (300 MHz, CDCl3) δ: 
7.75 (br s, 1H)
7.65 (d, J = 2.2 Hz, 1H)
7.41 (dd, J = 8.5, 2.2 Hz, 1H) 
7.36 (br s, 1H)
6.81 (d, J = 8.5 Hz, 1H) 
4.21 (t, J = 5.9 Hz, 2H) 
3.88 (s, 3H)
3.72 (t, J = 4.7 Hz, 4H)
2.85 (t, J = 5.9 Hz, 2H) 
2.59 (t, J = 4.6 Hz, 4H).
DART-MS: m/z calcd. for C14H21N2O3S [M + H]+ 297.12729; found 297.12241.
1-(2-(4-Methoxy-3-(2-morpholinoethoxy)phenyl)-5- methylthiazol-4-yl)ethan-1-one (I3)
I3 was synthesized according to General Method B starting from precursor I2. (90 mg, 54% 
yield. 
1H NMR (500 MHz, CDCl3) δ: 
7.50 (d, J = 2.0 Hz, 1H) 
7.47 (dd, J = 8.4, 2.1 Hz, 1H) 
6.90 (d, J = 8.4 Hz, 1H)
4.66 (t, J = 4.4 Hz, 2H) 
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4.30 (br m, 2H)
4.02 (br m, 2H) 
3.88 (s, 3H) 
3.72 (br m, 2H) 
3.55 (t, J = 4.3 Hz, 2H) 
3.22 (br m, 2H)
2.74 (s, 3H) 
2.68 (s, 3H). 
DART-MS: m/z calcd. for C19H25N2O4S [M + H]+ 377.15350; found 377.15920.
(S)-1-(2-(4-Methoxy-3-(2-morpholinoethoxy)phenyl)-5-methylthiazol-4-yl)ethan-1-ol (I4)
To a solution of (R)-(+)-2-methyl-CBS-oxazaborolidine (3.0 mL of a 1.0 M solution in toluene, 
3.0 mmol) in THF (13 mL) at −78 °C was added borane–THF complex (4.4 mL of a 1.0 M 
solution in THF, 4.4 mmol) followed by a solution of 3 (125 mg, 0.332 mmol) in THF (7 mL) by 
syringe pump over 6 hr while stirring at −78 °C. Upon completion of addition by syringe pump, 
the reaction solution was stirred for another 20 min before addition of DI water (10 mL) and 
methanol (5 mL) and warming to room temperature. The aqueous solution was extracted with 
ethyl acetate, and the resulting organic layer was dried over anhydrous MgSO4 and concentrated 
in vacuo. The resulting residue was purified by flash chromatography over silica gel (1:20 to 1:10 
methanol/DCM) to yield the desired alcohol 14 (50 mg, 40% yield). 
1H NMR (500 MHz, CDCl3) δ: 
7.49 (d, J = 2.1 Hz, 1H)
7.39 (dd, J = 8.4, 2.1 Hz, 1H)
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6.86 (d, J = 8.4 Hz, 1H)
4.93 (q, J = 6.4 Hz, 1H)
4.22 (t, J = 6.1 Hz, 2H)
3.88 (s, 3H)
3.74(t, J = 4.7 Hz, 4H)
2.86(t, J = 6.1 Hz, 2H)
2.60(t, J = 4.5 Hz, 4H)
2.40 (s, 3H)
1.53 (d, J = 6.5 Hz, 3H). 
DART-MS: m/z calcd. for C19H27N2O4S [M + H]+ 379.16915, found 379.17384.
(S)-1-(2-(4-Methoxy-3-(2-morpholinoethoxy)phenyl)-5- methylthiazol-4-yl)ethyl 2,2,2-
trifluoroacetate (I5)
I5 was synthesized according to General Method F starting from precursor I4.
1H NMR (500 MHz, CDCl3) δ:
7.50 (d, J = 1.9 Hz, 1H)
7.48 (dd, J = 8.4, 1.8 Hz, 1H)
6.91 (d, J = 8.4 Hz, 1H)
6.16 (q, J = 6.6 Hz, 1H)
4.48 (t, J = 4.4 Hz, 2H)
4.01 (t, J = 4.7 Hz, 4H)
3.88 (s, 3H)
3.51 (t, J = 4.2 Hz, 2H)
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3.41 (br m, 4H)
2.52 (s, 3H)
1.81 (d, J = 6.6 Hz, 3H).
HRMS-ESI (m/z) calcd for C21H26F3N2O5S [M+H]+ 475.15145, found 475.15481.
(R)-2-((1-(2-(4-Methoxy-3-(2-morpholinoethoxy) phenyl)-5-methylthiazol-4-
yl)ethyl)thio)pyrimidine-4,6-diamine (DI-87)
DI-87 was synthesized according to General Method G starting from precursor I5. 20 mg, 27% 
yield (two steps). 
1H NMR (400 MHz, CDCl3) δ: 
7.54 (d, J = 2.0 Hz, 1H)
7.37 (dd, J = 8.4, 2.0 Hz, 1H)
6.86 (d, J = 8.4, 1H)
5.24 (s, 1H)
5.22 (q, J = 7.0 Hz, 1H)
4.60 (s, 4H)
4.24 (t, J = 5.9 Hz, 2H)
3.88 (s, 3H)
3.76 (t, J = 4.7 Hz, 4H)
2.87 (t, J = 5.9 Hz, 2H)
2.61, (t, J = 4.5 Hz, 4H)
2.50 (s, 3H)
1.80 (d, J = 7.0 Hz, 3H). 
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13C NMR (100 MHz, CDCl3) δ 170.5, 163.8, 163.3, 153.5, 150.8, 148.4, 127.4, 126.9, 119.9, 
111.6, 111.3, 80.7, 67.0, 66.7, 57.6, 56.1, 54.2, 37.7, 22.1, 11.7.
HRMS-ESI (m/z) calcd for C23H31N6O3S2 [M+H]+ 503.18991, found 503.18727.
1-(5-Methyl-2-phenylthiazol-4-yl)ethan-1-one (I6)
I6 was synthesized according to General Method B starting from benzothioamide (2.804 g, 53% 
yield).
1H NMR (400 MHz, CDCl3) δ: 
7.91 (m, 2H)
7.44 (m, 3H)
2.80 (s, 3H)
2.72 (s, 3H).
13C NMR (100 MHz, CDCl3) δ 196.0, 162.6, 149.2, 143.7, 133.3, 130.3, 129.1, 126.5, 29.5, 
13.6.
HRMS-ESI (m/z) calcd for C12H12NOS [M+H]+ 218.06396, found 218.06825.
1-(5-Methyl-2-phenylthiazol-4-yl)ethan-1-ol (I7)
I7 was synthesized according to General Method D starting from precursor I6. 350 mg, 99% 
yield.
1H NMR (400 MHz, CDCl3) δ: 
7.90 (m, 2H)
7.41 (m, 3H)
4.96 (q, J = 6.5 Hz, 1H)
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3.03 (br s, 1H)
2.44 (s, 3H)
1.56 (d, J = 6.5 Hz, 3H).
HRMS-ESI (m/z) calcd for C12H12NOS [M+H]+ 220.07961, found 
220.08247.
1-(5-Methyl-2-phenylthiazol-4-yl)ethyl 2,2,2-trifluoroacetate (I8)
I8 was synthesized according to General Method F starting from precursor I7 and taken directly 
to the next step due to the instability of the trifluoroacetate.
HRMS-ESI (m/z) calcd for C14H13F3NO2S [M+H]+ 316.06191, 
found 316.06092.
2-((1-(5-Methyl-2-phenylthiazol-4-yl)ethyl)thio)pyrimidine-4,6-diamine (NMc-1)
NMc-1 was synthesized according to General Method G starting from precursor I8. 22 mg, 67% 
yield.
1H NMR (400 MHz, DMSO-d6) δ:
7.85 (m, 2H)
7.47 (m, 3H)
6.11 (br s, 4H)
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5.24 (q, J = 7.0 Hz, 1H)
5.16 (s, 1H)
2.50 (s, 3H)
1.70 (d, J = 7.0 Hz, 3H).
13C NMR (100 MHz, DMSO-d6) δ 168.0, 163.5, 162.9, 
154.1, 133.1, 129.8, 129.2, 127.6, 125.7, 79.1, 36.1, 22.2, 
11.2.
HRMS-ESI (m/z) calcd for C16H18N5S2 [M+H]+ 344.10036, 
found 344.10087.
Pyridine-2-carbothioamide (I9)
To a homogenous solution of 2-pyridinecarbonitrile (500 mg, 4.8 mmol) in methanol (48 mL) 
was added ammonium sulfide (20% aqueous solution, 1.72 mL, 5.04 mmol) and the resulting 
reaction solution was stirred at room temperature for 18 hr. Reaction solution was then 
concentrated in vacuo to a yellow solid which was taken up in a mixture of ethyl acetate and 
deionized water. This solution was extracted three times with ethyl acetate. The combined 
organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated in vacuo 
to give a I9 as a fine yellow powder (545 mg, 82% yield). 
1H NMR (400 MHz, CDCl3) δ:
9.52 (br s, 1H)
8.70 (dt, J = 8.0, 1.0 Hz, 1H)
8.52 (ddd, J = 4.7, 1.7, 0.9 Hz, 1H)
7.84 (ddd, J = 7.8, 7.8, 1.7 Hz, 1H)
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I9
7.79 (br s, 1H)
7.45 (ddd,  J = 7.6, 4.7, 1.2 Hz)
13C NMR (100 MHz, CDCl3) δ 195.9, 150.5, 147.2, 137.2, 126.4, 125.1.
HRMS-ESI (m/z) calcd for C6H7N2S [M+H]+ 139.03299, found 139.03345.
1-(5-Methyl-2-(pyridin-2-yl)thiazol-4-yl)ethan-1-one (I10)
I10 was synthesized according to General Method B starting from precursor I9. 225 mg, 49% 
yield.
1H NMR (400 MHz, CDCl3) δ:
8.59 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H)
8.19 (dt, J = 7.9, 1.1 Hz, 1H)
7.80 (ddd, J = 7.7, 7.7, 1.7 Hz, 1H)
7.33 (ddd, J = 7.5, 4.9, 1.2 Hz, 1H)
2.82 (s, 3H)
2.72 (s, 3H).
13C NMR (100 MHz, CDCl3) δ 195.9, 163.5, 151.2, 149.59, 149.55, 146.2, 137.2, 124.7, 119.6, 
29.3, 13.9.
HRMS-ESI (m/z) calcd for C11H11N2OS [M+H]+ 219.05921, found 219.06183.
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1-(5-Methyl-2-(pyridin-2-yl)thiazol-4-yl)ethan-1-ol (I11)
I11 was synthesized according to General Method D starting from 
precursor I10. The crude product taken directly to the  next step 
following confirmation by mass spectrometry. 
HRMS-ESI (m/z) calcd for C11H13N2OS [M+H]+ 221.07486, found 
221.06937.
1-(5-Methyl-2-(pyridin-2-yl)thiazol-4-yl)ethyl 2,2,2-trifluoroacetate (I12)
I12 was synthesized according to General Method F using precursor I11.
1H NMR (400 MHz, CDCl3) δ:
8.58 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H)
8.18 (dt, J = 7.9, 1.0 Hz, 1H)
7.78 (ddd, J = 7.6, 7.6, 1.7 Hz, 1H)
7.29 (ddd, J = 7.5, 4.9, 1.2 Hz, 1H)
6.19 (q, J = 6.6 Hz, 1H)
2.56 (s, 3H)
1.82 (d, J = 6.6 Hz, 3H).
HRMS-ESI (m/z) calcd for C13H12F3N2O2S [M+H]+ 317.05716, found 317.05442.
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2-((1-(5-Methyl-2-(pyridin-2-yl)thiazol-4-yl)ethyl)thio)pyrimidine-4,6-diamine (NMc-2)
NMc-2 was synthesized according to General Method G using precursor I12. 157 mg, 48% 
yield.
1H NMR (400 MHz, DMSO-d6) δ:
8.59 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H)
8.08 (dt, J = 7.9, 1.0 Hz, 1H)
7.93 (ddd, J = 7.6, 7.6, 1.7 Hz, 1H)
7.45 (ddd, J = 7.5, 4.8, 1.2 Hz, 1H)
6.11 (br s, 4H)
5.25 (q, J = 7.0 Hz, 1H)
5.16 (s, 1H)
2.51 (s, 3H)
1.71 (d, J = 7.0 Hz, 3H).
13C NMR (100 MHz, CDCl3) δ 168.0, 164.1, 163.5, 154.6, 150.6, 149.6, 137.6, 130.1, 124.7, 
118.7, 79.1, 36.1, 22.1, 11.4.
HRMS-ESI (m/z) calcd for C15H17N6S2 [M+H]+ 345.09561, found 345.09283.
Adamantane-1-carbothioamide (I13) 
I13 was synthesized according to General Method A from 
1-adamantanecarbonitrile. 2.3 g, 89% yield.
1H NMR (400 MHz, CDCl3) δ:
7.63 (br s, 1H)
7.02 (br s, 1H)
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I13
2.09 (m, 3H)
1.97 (m, 6H)
1.73 (m, 6H).
HRMS-ESI (m/z) calcd for C11H18NS [M+H]+ 196.11600, found 196.11483.
1-(2-(Adamantan-1-yl)-5-methylthiazol-4-yl)ethan-1-one (I14)
I14 was synthesized according to General Method B from 
precursor I13. 1.25g, 72% yield.
1H NMR (400 MHz, CDCl3) δ:
2.72 (s, 3H)
2.63 (s, 3H)
2.10 (m, 3H)
2.02 (m, 6H)
1.78 (m, 6H).
HRMS-ESI (m/z) calcd for C16H22NOS [M+H]+ 276.14221, found 276.13983.
1-(2-(Adamantan-1-yl)-5-methylthiazol-4-yl)ethan-1-ol (I15)
I15 was synthesized according to General Method D using 
precursor I14, though after aqueous workup crude product was 
taken on to next step without further purification. 878 mg, 70% 
crude yield.
HRMS-ESI (m/z) calcd for C16H24NOS [M+H]+ 278.15786, found 
278.15835.
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1-(2-(Adamantan-1-yl)-5-methylthiazol-4-yl)ethyl 2,2,2-trifluoroacetate (I16)
I16 was synthesized according to General Method F from crude I15. 1.066g, 92% crude yield.
1H NMR (400 MHz, CDCl3) δ:
6.11 (q, J = 6.6 Hz, 1H)
2.44 (s, 3H)
2.08 (m, 3H)
2.00 (m, 6H)
1.77 (m, 6H)
1.74 (d, J = 6.6 Hz, 3H).
13C NMR (100 MHz, CDCl3) δ 178.2, 157.4, 146.8, 130.2, 113.3, 71.7, 43.2, 39.5, 36.7, 28.7, 
19.7, 11.1.
2-((1-(2-Adamantan-1-yl)-5-methylthiazol-4-yl)ethyl)thio)pyrimidine-4,6-diamine (NMc-3)
NMc-3 was synthesized according to General Method G. 580 mg, 52% yield.
1H NMR (400 MHz, CDCl3) δ:
5.23 (s, 1H)
5.18 (q, J = 6.9 Hz, 1H)
4.56 (br s, 4H)
2.44 (s, 3H)
2.06 (m, 3H)
2.00 (m, 6H)
1.75 (m, 6H)
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1.74 (d, J = 7.0 Hz, 3H).
13C NMR (100 MHz, CDCl3) δ 177.0, 171.1, 163.3, 151.5, 125.1, 80.7, 43.2, 39.4, 38.1, 36.8, 
28.8, 22.2, 11.6.
HRMS-ESI (m/z) calcd for C20H28N5S2 [M+H]+ 402.17861, found 402.17482.
Butanethioamide (I17)
I17 was synthesized according to General Method A. 844 mg, 36% yield.
1H NMR (400 MHz, CDCl3) δ:
7.55 (br s, 1H)
6.84 (br s, 1H)
2.63 (t, J = 7.5 Hz, 2H)
1.81 (tq, J = 7.5, 7.4 Hz, 2H)
0.99 (t, J = 7.4 Hz, 3H).
13C NMR (100 MHz, CDCl3) δ 211.2, 47.5, 22.7, 13.5.
HRMS-ESI (m/z) calcd for C4H10NS [M+H]+ 104.05340, found 104.05300.
1-(5-Methyl-2-propylthiazol-4-yl)ethan-1-one (I18)
I18 was synthesized according to General Method B with precursor 
I17. 1.075g, 66% yield.
1H NMR (400 MHz, CDCl3) δ:
2.87 (t, J = 7.7 Hz, 2H)
2.69 (s, 3H)
2.61 (s, 3H)
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1.77 (tq, J = 7.5, 7.5 Hz, 2H)
1.00 (t, J = 7.4 Hz, 3H).
13C NMR (100 MHz, CDCl3) δ 195.8, 166.0, 148.0, 143.1, 35.3, 29.5, 23.3, 13.7, 13.4.
1-(5-Methyl-2-propylthiazol-4-yl)ethan-1-ol (I19)
I19 was synthesized according to General Procedure D with precursor I18. 491 mg, 68% yield.
1H NMR (400 MHz, CDCl3) δ:
4.88 (m, 1H)
2.86 (t, J = 7.6 Hz, 2H)
2.77 (br s, 1H)
2.35 (s, 3H)
1.75 (tq, J = 7.5, 7.5 Hz, 2H)
1.48 (d, J = 6.5 Hz, 3H)
0.99 (t, J = 7.4 Hz, 3H).
13C NMR (100 MHz, CDCl3) δ 168.1, 153.8, 125.5, 64.6, 35.4, 24.2, 23.5, 13.8, 10.9.
1-(5-Methyl-2-propylthiazol-4-yl)ethyl 2,2,2-trifluoroacetate (I20)
I20 was synthesized according to General Method F starting from 
precursor I19. 703 mg, 94% crude yield. The product was taken 
directly to next step due to the instability of the trifluoroacetate. 
HRMS-ESI (m/z) calcd for C11H15F3NO2S [M+H]+ 282.07756, found 
282.07472.
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2-((1-(5-Methyl-2-propylthiazol-4-yl)ethyl)thio)pyrimidine-4,6-diamine (NMc-4)
NMc-4 was synthesized according to General Method G from precursor I20. 204 mg, 25% yield. 
1H NMR (400 MHz, DMSO-d6) δ:
6.09 (br s, 4H)
5.14 (q, J = 7.0 Hz, 1H)
5.14 (s, 1H)
2.82 (t, J = 7.5 Hz, 2H)
2.39 (s, 3H)
1.67 (sext, J = 7.4 Hz, 2H)
1.60 (d, J = 7.0 Hz, 3H)
0.94 (t, J = 7.3 Hz, 3H).
13C NMR (100 MHz, DMSO-d6) δ 168.1, 166.5, 163.4, 151.9, 125.5, 79.0, 36.0, 34.5, 22.8, 22.3, 
13.4, 11.0.
HRMS-ESI (m/z) calcd for C13H20N5S2 [M+H]+ 310.11601, found 310.11396.
Morpholine-4-carbothioamide (I21)
I21 was synthesized according to General Method A from morpholine-4-carbonitrile. 1.316 g, 
91% yield.
1H NMR (400 MHz, DMSO-d6) δ:
7.49 (br s, 2H)
3.71 (t, J = 4.4 Hz, 4H)
3.56 (t, J = 4.9 Hz, 4H).
HRMS-ESI (m/z) calcd for C5H11N2OS [M+H]+ 147.05921, found 147.06193.
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1-(5-Methyl-2-morpholinothiazol-4-yl)ethan-1-one (I22)
I22 was synthesized according to General Method B from precursor 
I21. 42 mg, 19% yield.
1H NMR (400 MHz, CDCl3) δ:
3.81 (t, J = 4.9 Hz, 4H)
3.41 (t, J = 4.9 Hz, 4H)
2.61 (s, 3H)
2.52 (s, 3H).
13C NMR (100 MHz, CDCl3) δ 196.1, 166.0, 145.1, 133.3, 66.3, 48.6, 29.5, 13.1.
1-(5-Methyl-2-morpholinothiazol-4-yl)ethan-1-ol (I23)
I23 was synthesized according to General Method D starting
 from precursor I22. 24 mg, 57% yield.
HRMS-ESI (m/z) calcd for C10H17N2O2S [M+H]+ 229.10107, 
found 229.10375.
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1-(5-Methyl-2-morpholinothiazol-4-yl)ethyl 2,2,2-trifluoroacetate (I24)
I24 was synthesized according to General Method F from precursor 
I23. The crude product taken directly to the next step following workup 
due to the instability of the  trifluoroacetate. 
HRMS-ESI (m/z) calcd for C12H16F3N2O3S [M+H]+ 325.08337, 
found 325.08372.
2-((1-(5-Methyl-2-morpholinothiazol-4-yl)ethyl)thio)pyrimidine-4,6-diamine (NMc-5)
NMc-5 was synthesized according to General Method G. 22 mg, 59% yield. 
1H NMR (400 MHz, DMSO-d6) δ:
6.07 (br s, 4H)
5.13 (br s, 1H)
5.04 (q, J = 6.9 Hz, 1H)
3.68 (t, J = 4.8 Hz, 4H)
3.28 (t, J = 4.8 Hz, 4H)
2.27 (s, 3H)
1.55 (d, J = 7.0 Hz).
13C NMR (100 MHz, DMSO-d6) δ 168.3, 167.6, 163.5, 148.6, 
114.6, 79.0, 65.4, 48.0, 36.2, 22.2, 10.8.
HRMS-ESI (m/z) calcd for C14H21N6S2 [M+H]+ 353.12183, found 353.12249.
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2-(5-Methyl-2-phenylthiazol-4-yl)propan-2-ol (I25)
I25 was synthesized according to General Method E from precursor I6. 1.70 g, 75% yield.
1H NMR (400 MHz, CDCl3) δ:
7.87 (m, 2H)
7.40 (m, 3H)
3.97 (br s, 1H)
2.55 (s, 3H)
1.64 (s, 6H).
13C NMR (100 MHz, CDCl3) δ 162.0, 158.0, 133.4, 129.7, 128.9, 126.1, 125.8, 71.8, 30.1, 12.6.
HRMS-ESI (m/z) calcd for C13H16NOS [M+H]+ 234.09526, found 234.09582.
4-(2-Chloropropan-2-yl)-5-methyl-2-phenylthiazole (I26)
I26 was synthesized according to General Method H from 
precursor I25. It was taken directly to the next step due to the 
instability of the tertiary chloride. 
HRMS-ESI (m/z) calcd for C13H15ClNS [M+H]+ 252.06137, 
found 252.05949.
2-((2-(5-Methyl-2-phenylthiazol-4-yl)propan-2-yl)thio)pyrimidine-4,6-diamine (NMc-6)
NMc-6 was synthesized according to General Method I from crude precursor I26. 61 mg, 19% 
yield.
1H NMR (400 MHz, DMSO-d6) δ:
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7.83 (m, 2H)
7.46 (m, 3H)
5.92 (br s, 4H)
5.12 (s, 1H)
2.67 (s, 3H)
2.07 (s, 6H).
13C NMR (100 MHz, DMSO-d6) δ 169.2, 163.2, 159.7, 
155.2, 133.3, 129.6, 129.5, 129.1, 125.6, 79.3, 50.2, 
29.1, 13.4.
Ethyl 2-phenylthiazole-4-carboxylate (I27)
I27 was synthesized according to General Method C from precursor thiobenzamide. 1.40 g, 78% 
yield.
1H NMR (400 MHz, CDCl3) δ: 
8.13 (s, 1H)
7.98 (m, 2H)
7.42 (m, 3H)
4.42 (q, J = 7.1 Hz, 2H)
1.40 (t, J = 7.1 Hz, 3H).
13C NMR (100 MHz, CDCl3) δ 168.9, 161.5, 148.1, 132.8, 130.7, 129.0, 127.1, 127.0, 61.5, 
14.4.
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2-(2-Phenylthiazol-4-yl)propan-2-ol (I28)
I28 was synthesized according to General Method E from precursor I27. 322 mg, 70% yield. 
1H NMR (400 MHz, CDCl3) δ: 
7.95 (m, 2H)
7.42 (m, 3H)
7.08 (s, 1H)
3.04 (br s, 1H) 
1.65 (s, 6H).
13C NMR (100 MHz, CDCl3) δ 168.0, 165.0, 133.7, 130.1, 129.0, 126.7, 111.3, 71.3, 30.2.
HRMS-ESI (m/z) [M+H]+ calcd for C12H14NOS 220.07961, found 220.08266.
4-(2-Chloropropan-2-yl)-2-phenylthiazole (I29)
I29 was synthesized according to General Method H from 
precursor I28. The crude product was taken directly to the next step due 
to the instability of the tertiary chloride. 
HRMS-ESI (m/z) calcd for C12H13ClNS [M+H]+ 238.04572, 
found 238.04814.
2-((2-(2-Phenylthiazol-4-yl)propan-2-yl)thio)pyrimidine-4,6-diamine (NMc-7)
NMc-7 was synthesized according to General Method I from precursor I29. 22 mg, 10% yield 
(two steps).
1H NMR (400 MHz, CDCl3) δ:
	 82
NS
OH
I28
NS
Cl
I29
7.94 (m, 2H)
7.40 (m, 3H)
7.22 (s, 1H)
5.16 (s, 1H)
4.58 (br s, 4H) 
2.02 (s, 6H).
13C NMR (100 MHz, CDCl3) δ 170.1, 166.4, 162.8, 152.9, 
134.2, 129.8, 128.9, 126.7, 114.2, 80.9, 50.4, 29.2.
HRMS-ESI (m/z) calcd for C16H18N5S2 [M+H]+ 344.10036, 
found 344.10073.
Ethyl 2-(adamantan-1-yl)thiazole-4-carboxylate (I30)
I30 was synthesized according to General Method C from 
precursor I13. 530 mg, 68% yield.
1H NMR (400 MHz, CDCl3) δ:
8.02 (s, 1H)
4.39 (q, J = 7.1 Hz, 2H)
2.09 (br m, 9H)
1.77 (br m, 6H)
1.38 (t, J = 7.1 Hz, 3H).
13C NMR (100 MHz, CDCl3) δ 182.4, 161.8, 146.7, 126.0, 61.3, 43.1, 40.0, 36.5, 28.6, 14.5.
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2-((2-Adamantan-1-yl)thiazol-4-yl)propan-2-ol (I31)
I31 was synthesized according to General Method E from precursor 
I30. 435 mg, 96% yield. 
1H NMR (400 MHz, CDCl3) δ:
6.87 (s, 1H)
3.19 (br s, 1H)
2.04 (br m, 9H)
1.78 (br m, 6H)
1.57 (s, 6H).
13C NMR (100 MHz, CDCl3) δ 181.34, 163.1, 109.0, 70.9, 43.3, 36.7, 35.9, 30.1, 28.7.
HRMS-ESI (m/z) calcd for C16H24NOS [M+H]+ 278.15786, found 178.15738.
2-(Adamantan-1-yl)-4-(2-chloropropan-2-yl)thiazole (I32)
I32 was synthesized using General Method H from precursor I31. 
The crude product was taken directly to the next step due to the 
instability of the tertiary chloride.
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2-((2-(2-Adamantan-1-yl)thiazol-4-yl)propan-2-yl)thiopyrimidine-4,6-diamine (NMc-8)
NMc-8 was synthesized according to General Method I from crude precursor I32. 95 mg, 16% 
yield (two steps).
1H NMR (400 MHz, DMSO-d6) δ:
7.50 (s, 1H)
6.05 (br s, 4H)
5.10 (s, 1H)
2.04 (br m, 3H)
1.95 (br m, 6H)
1.94 (s, 6H)
1.73 (br m, 6H).
13C NMR (100 MHz, DMSO-d6) δ 178.2, 169.0, 162.9, 159.4, 113.6, 79.0, 49.1, 42.7, 38.8, 36.0, 
28.3, 28.0.
HRMS-ESI (m/z) calcd for C20H28N5S2 [M+H]+ 402.17861, found 402.17839.
Ethyl 2-(3-hydroxy-4-methoxyphenyl)thiazole-4-carboxylate (I33)
I33 was synthesized according to General Method A from 3-
hydroxy-4-methoxybenzothioamide. 1.0 g, 97% yield.
1H NMR (400 MHz, DMSO-d6) δ:
8.44 (s, 1H)
7.44 (d, J = 2.2 Hz, 1H)
7.37 (dd, J = 8.4, 2.2 Hz, 1H)
7.0 (d, J = 8.4 Hz, 1H)
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4.32 (q, J = 7.1 Hz, 2H)
3.82 (s, 3H)
1.32 (t, J = 7.1 Hz, 3H).
13C NMR (100 MHz, DMSO-d6) δ 167.9, 160.8, 150.2, 147.0, 146.7, 128.2, 125.3, 118.2, 113.0, 
112.4, 60.8, 55.7, 14.2.
Ethyl 2-(4-methoxy-3-((triisopropylsilyl)oxy)phenyl)thiazole-4-carboxylate (I34)
To a solution of I33 (1.0g, 3.58 mmol) in THF (14 mL) and DMF (0.5 mL) was added imidazole 
(730 mg, 10.7 mmol) and then TIPSCl (1.07 mL, 5.01 mL). The reaction was stirred for 18 hr 
and then concentrated in vacuo. The resulting residue was dissolved in ethyl acetate and washed 
with deionized water and brine before drying over Na2SO4. The organic layer was then 
concentrated in vacuo and the crude residue was purified by flash column chromatography on 
silica gel (20% ethyl acetate in hexanes. 1.192 g, 76% yield. 
1H NMR (400 MHz, CDCl3) δ:
8.07 (s, 1H)
7.61 (dd, J = 8.4, 2.2 Hz, 1H)
7.47 (d, J = 2.2 Hz, 1H)
6.88 (d, J = 8.5 Hz, 1H)
4.43 (q, J = 7.1 Hz, 2H)
3.85 (s, 3H)
1.42 (t, J = 7.1 Hz, 3H)
1.28 (m, 3H)
1.11 (d, J = 7.3 Hz, 18H).
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13C NMR (100 MHz, CDCl3) δ 169.0, 161.7, 153.3, 148.0, 145.8, 126.4, 126.0, 120.7, 119.2, 
111.9, 61.5, 55.6, 18.0, 14.5, 13.1.
2-(2-(4-Methoxy-3-((triisopropylsilyl)oxy)phenyl)thiazol-4-yl)propan-2-ol (I35)
I35 was synthesized according to General Procedure E from precursor I34. 860 mg, 98% yield.
1H NMR (400 MHz, CDCl3) δ:
7.52 (dd, J = 8.4, 2.1 Hz, 1H)
7.47 (d, J = 2.2 Hz, 1H)
6.98 (s, 1H)
6.87 (d, J = 8.4 Hz, 1H)
3.85 (s, 3H)
3.05 (br s, 1H)
1.63 (s, 6H)
1.28 (m, 3H)
1.12 (d, J = 7.2 Hz, 18H).
13C NMR (100 MHz, CDCl3) δ 167.9, 164.5, 152.7, 145.7, 126.5, 120.0, 118.6, 111.9, 110.1, 
71.1, 55.5, 30.1, 17.9, 12.9.
HRMS-ESI (m/z) calcd for C22H36NO3SSi [M+H]+ 421.21069, found 421.21028.
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4-(2-Chloropropan-2-yl)-2-(4-methoxy-3-((triisopropylsilyl)oxy)phenyl)thiazole (I36)
I36 was synthesized according to General Method H from precursor 
I35. The crude product was taken directly to the next step due to the 
instability of the tertiary chloride. 
2-((2-(2-(4-Methoxy-3-((triisopropylsilyl)oxy)phenyl)thiazol-4-
yl)propan-2-yl)thio)pyrimidine-4,6-diamine (I37)
I37 was synthesized according to General Method I with precursor I36. 
1H NMR (400 MHz, CDCl3) δ:
7.52 (dd, J = 8.3, 2.2 Hz, 1H)
7.46 (d, J = 2.1 Hz, 1H)
7.14 (s, 1H)
6.84 (d, J = 8.5 Hz, 1H)
5.18 (s, 1H)
4.68 (br s, 4H)
3.83 (s, 3H)
2.00 (s, 6H)
1.26 (m, 3H)
1.11 (d, J = 7.2 Hz, 18H).
HRMS-ESI (m/z) calcd for C22H40N5O2S2Si [M+H]+ 535.23144, found 535.23185.
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5-(4-(2-((4,6-Diaminopyrimidin-2-yl)thio)propan-2-yl)thiazol-2-yl)-2-methoxyphenol 
(NMc-10)
To a solution of I37 (58 mg, 0.1063 mmol) in THF (1.2 mL) at 0 °C was added TBAF (1.0 M in 
THF, 0.13 mL, 0.13 mmol) and the mixture was stirred for 2 hr before a second addition of 
TBAF (1.0 M in THF, 0.08 mL, 0.08 mmol). The reaction solution was stirred for an additional 
hour and then quenched with deionized water. The aqueous solution was then extracted four 
times with ethyl acetate. The combined organic layers were washed with saturated sodium 
bicarbonate solution, brine, dried over anhydrous Na2SO4 and concentrated in vacuo. The 
residue was purified by flash column chromatography over silica gel using 50–75% ethyl acetate 
in hexanes. 30 mg, 72% yield.
H NMR (400 MHz, DMSO-d6) δ:
9.36 (s, 1H)
7.59 (s, 1H)
7.39 (d, J = 2.0 Hz, 1H)
7.29 (dd, J = 8.4, 2.0 Hz, 1H)
7.00 (d, J = 8.4 Hz, 1H)
6.00 (m, 4H)
5.08 (s, 1H)
3.81 (s, 3H)
1.97 (s, 6H).
13C NMR (100 MHz, DMSO-d6) δ 169.0, 165.1, 163.1, 161.0, 149.4, 146.8, 126.3, 117.5, 114.9, 
112.7, 112.3, 79.0, 55.6, 48.8, 28.4.
HRMS-ESI (m/z) calcd for C17H20N5O2S2 [M+H]+ 390.1058, found 390.1043.
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2-((2-(2-(4-Methoxy-3-(2-morpholinoethoxy)phenyl)thiazol-4-yl)propan-2-
yl)thio)pyrimidine-4,6-diamine (NMc-9)
To a heterogenous solution of NMc-10 ( 22 mg, 0.0565 mmol) and K2CO3 (23.4 mg, 0.169 
mmol) in DMF was added 4-(2-chloroethyl)morpholine hydrochloride (11 mg, 0.0565 mmol) 
and the reaction was stirred at 70 °C for 12 hr. The reaction was then concentrated in vacuo and 
the residue purified by flash column chromatography over silica gel using 5% methanol in DCM 
as eluent. 21 mg, 75% yield. 
1H NMR (400 MHz, CDCl3) δ:
7.56 (d, J = 1.8 Hz, 1H)
7.47 (dd, J = 8.4, 1.9 Hz, 1H)
7.14 (s, 1H)
6.86 (d, J = 8.4 Hz, 1H)
5.15 (s, 1H)
4.56 (br s, 4H)
4.24 (t, J = 6.0 Hz, 2H)
3.88 (s, 3H)
3.74 (t, J = 9.2 Hz, 4H)
2.87 (t, J = 6.0 Hz, 2H)
2.62 (t, J = 8.6 Hz, 4H)
2.01 (s, 6H).
13C NMR (100 MHz, CDCl3) δ 170.4, 166.2, 162.9, 162.4, 151.1, 148.4, 127.4, 120.2, 113.4, 
111.8, 111.7, 80.9, 67.0, 66.9, 57.6, 56.1, 54.2, 50.3, 29.1.
HRMS-ESI (m/z) calcd for C23H31N6O3S2 [M+H]+ 503.18991, found 503.18724.
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Ethyl 2-(3,4-dimethoxyphenyl)thiazole-4-carboxylate (I38)
To a solution of I33 (560 mg, 2.00 mmol) and K2CO3 in DMF was added methyl triflate (0.33 
mL, 3.00 mmol) dropwise. The reaction was stirred for 12 hr and then concentrated in vacuo, the 
residue taken up in ethyl acetate and the organic layer consecutively washed with saturated 
sodium bicarbonate solution, water, and brine. The organic layer dried over anhydrous Na2SO4, 
concentrated in vacuo, and resulting crude product purified by flash chromatography over silica 
gel using 1% MeOH in DCM as the eluent. 421 mg, 72% yield.
1H NMR (400 MHz, CDCl3) δ:
8.09 (s, 1H)
7.60 (d, J = 2.1 Hz, 1H)
7.50 (dd, J = 8.3, 2.1 Hz, 1H)
6.90 (d, J = 8.4 Hz, 1H)
4.44 (q, J = 7.1 Hz, 2H)
3.99 (s, 3H)
3.93 (s, 3H)
1.42 (t, J = 7.1 Hz, 3H).
13C NMR (100 MHz, CDCl3) δ 169.0, 161.6, 151.4, 149.4, 147.9, 126.6, 126.1, 120.4, 111.1, 
109.7, 61.6, 56.3, 56.1, 14.5.
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2-(2-(3,4-Dimethoxyphenyl)thiazol-4-yl)propan-2-ol (I39)
I39 was synthesized according to General Method E from precursor I38. 300 mg, 82% yield.
1H NMR (400 MHz, CDCl3) δ:
7.51 (d, J = 2.0 Hz, 1H)
7.47 (dd, J = 8.3, 2.1 Hz, 1H)
7.00 (s, 1H)
6.89 (d, J = 8.4 Hz, 1H)
3.97 (s, 3H)
3.92 (s, 3H)
3.04 (br s, 1H)
1.64 (s, 6H).
13C NMR (100 MHz, CDCl3) δ 167.9, 164.6, 150.8, 149.2, 126.8, 119.7, 111.1, 110.4, 109.3, 
71.1, 56.1, 56.0, 30.1.
4-(2-Chloropropan-2-yl)-2-(3,4-dimethoxyphenyl)thiazole (I40)
I40 was synthesized according to General Method H. The crude 
product was taken directly to the next step due to the instability of 
the tertiary chloride. 
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2-((2-(2-(3,4-Dimethoxyphenyl)thiazol-4-yl)propan-2-yl)thio)pyrimidine-4,6-diamine 
(NMc-11)
NMc-11 was synthesized according to General Method I from crude precursor I40. 39 mg, 7% 
yield.
1H NMR (400 MHz, CDCl3) δ:
7.53 (d, J = 2.0 Hz, 1H)
7.47 (dd, J = 8.3, 2.0 Hz, 1H)
7.16 (s, 1H)
6.87 (d, J = 8.4 Hz, 1H)
5.17 (s, 1H)
4.53 (br s, 4H)
3.97 (s, 3H)
3.92 (s, 3H)
2.03 (s, 6H).
13C NMR (100 MHz, CDCl3) δ 166.5, 162.7, 162.4, 162.1, 150.6, 149.3, 127.4, 119.7, 113.5, 
111.2, 109.5, 80.7, 56.2, 56.1, 50.69, 29.1.
HRMS-ESI (m/z) calcd for C18H22N5O2S2 [M+H]+ 404.12149, found 404.12186.
Ethyl 2-(4-fluorophenyl)thiazole-4-carboxylate (I41)
I41 was synthesized according to General Method C starting from 4-fluorothiobenzoamide. 478 
mg, 68% yield.
1H NMR (400 MHz, CDCl3) δ:
8.13 (s, 1H)
	 93
OMe
OMe
NS
S
NMc-11
N
N
H2N
NH2
7.99 (m, 2H)
7.13 (m, 2H)
4.44 (q, J = 7.1 Hz, 2H)
1.42 (t, J = 7.1 Hz, 3H).
13C NMR (100 MHz, CDCl3) δ 166.68 (JC–F = 213.8 Hz), 163.12, 
161.5, 148.3, 129.3 (d, JC–F = 3.3 Hz), 129.1 (d, JC–F = 8.6 Hz), 
127.1, 116.2 (d, JC–F = 22.2 Hz), 61.7, 14.5.
2-(2-(4-Fluorophenyl)thiazol-4-yl)propan-2-ol (I42)
I42 was synthesized according to General Method E from 
precursor I41. 101 mg, 92% yield.
1H NMR (400 MHz, CDCl3) δ:
7.94 (m, 2H)
7.12 (m, 2H)
7.08 (s, 1H)
2.86 (br s, 1H)
1.65 (s, 6H).
HRMS-ESI (m/z) calcd for C12H13FNOS [M+H]+ 238.07019, found 238.07284.
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4-(2-Chloropropan-2-yl)-2-(4-fluorophenyl)thiazole (I43)
I43 was synthesized according to General Method H from 
precursor I42. The crude product was taken directly to the next step due 
to the instability of the tertiary chloride.
2-((2-(2-(4-Fluorophenyl)thiazol-4-yl)propan-2-yl)thio)pyrimidine-4,6-diamine (NMc-12)
NMc-12 was synthesized according to General Method I 
from crude precursor I43. 
1H NMR (400 MHz, DMSO-d6) δ:
7.95 (m, 2H)
7.75 (s, 1H)
7.32 (m, 2H)
6.28 (br s, 4H)
5.12 (s, 1H)
1.98 (s, 6H).
HRMS-ESI (m/z) calcd for C16H17FN5S2 [M+H]+ 362.0909, found 362.08878.
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2,4-Difluorobenzothioamide (I44)
I44 was synthesized according to General Method A from 2,4-difluorobenzonitrile. 487 mg, 58% 
yield.
1H NMR (400 MHz, CDCl3) δ:
8.42 (td, J = 13.9, 6.6 Hz, 1H)
8.08 (br s, 1H)
7.73 (br s, 1H)
6.97 (m, 1H)
6.84 (ddd, J = 12.5, 8.3, 2.5 Hz, 1H).
13C NMR (100 MHz, CDCl3) δ 195.8, 165.3 (JC–F = 257.3, 13.0), 159.0 (JC–F = 252.9, 12.4 
Hz), 137.2 (dd, JC–F = 10.1, 2.3 Hz), 121.7 (dd, JC–F = 9.8, 4.0 Hz), 112.5 (dd, JC–F = 21.1, 
3.4 Hz), 104.2 (dd, JC–F = 28.5, 25.9 Hz).
Ethyl 2-(2,4-difluorophenyl)thiazole-4-carboxylate (I45)
I45 was synthesized according to General Method C from precursor I44. 478 mg, 68% yield. 
1H NMR (400 MHz, CDCl3) δ:
8.40 (td, J = 13.0, 6.5 Hz, 1H)
8.24 (s, 1H)
7.01 (m, 1H)
6.95 (ddd, J = 11.1, 8.6, 2.5 Hz, 1H)
4.44 (q, J = 7.1 Hz, 2H)
1.42 (t, J = 7.1 Hz, 3H).
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13C NMR (100 MHz, CDCl3) δ 164.1 (dd, JC–F = 254.2, 12.2 Hz), 161.5, 160.5 (dd, JC–F = 
254.5, 12.1 Hz), 160.5 (d, JC–F = 5.1 Hz), 147.1, 130.9 (dd, JC–F = 9.9, 4.0 Hz), 128.0 (d, JC–F 
= 8.9 Hz), 117.4 (dd, JC–F = 11.6, 3.9 Hz), 112.5 (dd, JC–F = 21.7, 3.4 Hz), 104.5 (t, JC–F = 
25.8 Hz), 61.7, 14.5.
2-(2-(2,4-Difluorophenyl)thiazol-4-yl)propan-2-ol (I46)
I46 was synthesized according to General Method E from precursor I45. 354 mg, 84% yield.
1H NMR (400 MHz, CDCl3) δ:
8.30 (td, J = 13.0, 6.5 Hz, 1H)
7.21 (s, 1H)
7.00 (m, 1H)
6.94 (ddd, J = 11.1, 8.6, 2.5 Hz, 1H)
2.88 (br s, 1H)
1.65 (s, 6H).
HRMS-ESI (m/z) calcd for C12H12F2NOS [M+H]+ 256.06077, found 256.06389.
4-(2-Chloropropan-2-yl)-2-(2,4-difluorophenyl)thiazole (I47)
I47 was synthesized according to General Method H from 
precursor I46. The crude product was taken directly to the next 
step due to the instability of the tertiary chloride. 
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2-((2-(2-(2,4-Difluorophenyl)thiazol-4-yl)propan-2-yl)thio)pyrimidine-4,6-diamine 
(NMc-13)
NMc-13 was synthesized according to General Method I. 
41 mg, 16% yield. The 4 amine protons of the 4,6-
diaminopyrimidine ring exchanged in the NMR solvent 
(CD3OD).
1H NMR (400 MHz, CD3OD) δ:
8.30 (m, 1H)
7.60 (s, 1H)
7.09 (m, 2H)
5.23 (s, 1H)
2.03 (s, 6H).
HRMS-ESI (m/z) calcd for C16H16F2N5S2 [M+H]+ 379.07369, found 379.07728.
Cyclopropanecarbothioamide (I48)
I48 was synthesized according to General Method A from cyclopropanecarbonitrile. 545 mg, 
40% yield.
1H NMR (400 MHz, CDCl3) δ:
7.57 (br s, 1H)
7.11 (br s, 1H)
1.89 (m, 1H)
1.27 (m, 2H)
1.01 (m, 2H).
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13C NMR (100 MHz, CDCl3) δ: 212.5, 23.6, 13.5.
Ethyl 2-cyclopropylthiazole-4-carboxylate (I49)
I49 was synthesized according to General Method C from precursor I48. 273 mg, 15% yield.
1H NMR (400 MHz, CDCl3) δ:
7.93 (d, J = 0.5 Hz, 1H)
4.40 (q, J = 7.1 Hz, 2H)
2.40 (m, 1H)
1.39 (t, J = 7.1 Hz, 3H)
1.17 (m, 2H)
1.07 (m, 2H).
HRMS-ESI (m/z) calcd for C9H12NO2S [M+H]+ 198.05887, found 198.06382.
2-(2-Cyclopropylthiazol-4-yl)propan-2-ol (I50)
I50 was synthesized according to General Method E from precursor I49. 180 mg, 73% yield.
1H NMR (400 MHz, CDCl3) δ: 
6.80 (s, 1H)
2.85 (br s, 1H)
2.30 (m, 1H)
1.57 (s, 6H)
1.11 (m, 2H)
1.04 (m, 2H).
HRMS-ESI (m/z) calcd for C9H14NOS [M+H]+ 184.07961, found 184.08291.
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4-(2-Chloropropan-2-yl)-2-cyclopropylthiazole (I51)
I51 was synthesized according to General Method H from 
precursor I50. The crude product was taken directly to the next step 
due to the instability of the tertiary chloride. 
2-((2-(2-Cyclopropylthiazol-4-yl)propan-2-yl)thio)pyrimidine-4,6-diamine (NMc-14)
NMc-14 was synthesized according to General Method I from crude precursor I51. 31 mg, 11% 
yield. The 4 amine protons of the 4,6-diaminopyrimidine ring exchanged in the NMR solvent 
(CD3OD). 
1H NMR (400 MHz, CD3OD) δ:
7.19 (s, 1H)
5.25 (s, 1H)
2.33 (m, 1H)
1.95 (s, 6H)
1.12 (m, 2H)
0.91 (m, 2H).
13C NMR (100 MHz, CD3OD) δ: 174.7, 169.7, 164.3, 161.3, 113.6, 80.5, 51.1, 29.1, 15.2, 11.4.
HRMS-ESI (m/z) calcd for C13H15N5S2 [M+H]+ 309.10036, found 309.0993.
	 100
I51
NS
Cl
Figure 8
NS
S
N
N
H2N
NH2
NMc-6 
IC50 = 924.5 nM
NS
S
N
N
H2N
NH2
NMc-7 
IC50 = 305.1 nM
NS
S
N
N
H2N
NH2
NMc-8 
IC50 = 160.8 nM
NS
S
N
N
H2N
NH2
OMe
OH
NMc-10 
IC50 = 37.2 nM
NS
S
N
N
H2N
NH2
OMe
O
N
O
NMc-9 
IC50 = 145.0 nM
A
B
NS
S
N
N
H2N
NH2
OMe
OMe
NMc-11 
IC50 = 104.0 nM
NS
S
N
N
H2N
NH2
F
NMc-12 
IC50 = 552.5 nM
NS
S
N
N
H2N
NH2
F
F
NMc-13 
IC50 = 548.8 nM
NS
S
N
N
H2N
NH2
NMc-14 
IC50 = 104.4 nM
NS
S
N
N
H2N
NH2
NMc-15 
IC50 = >1 µM
NS
S
N
N
H2N
NH2
N
O
N
NMc-16 
IC50 = 283.9 nM
Ethyl 2-methylthiazole-4-carboxylate (I52)
I52 was synthesized according to General Method C from thioacetamide. 380 mg, 73% yield.
1H NMR (400 MHz, CDCl3) δ: 
8.03 (s, 1H)
4.42 (q, J = 7.1 Hz, 2H)
2.76 (s, 3H)
1.40 (t, J = 7.1 Hz, 3H).
13C NMR (100 MHz, CDCl3) δ: 166.9, 161.6, 147.0, 127.4, 61.6, 19.5, 
14.5.
2-(2-Methylthiazol-4-yl)propan-2-ol (I53)
I53 was synthesized according to General Method E from 
precursor I52. 
HRMS-ESI (m/z) calcd for C7H12NOS [M+H]+ 158.06396, 
found 158.06924.
4-(2-Chloropropan-2-yl)-2-methylthiazole (I54)
I54 was synthesized according to General Method H using precursor 
I53. The crude product was taken directly to the next step due to the 
instability of the tertiary chloride. 
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2-((2-(2-Methylthiazol-4-yl)propan-2-yl)thio)pyrimidine-4,6-diamine (NMc-15)
NMc-15 was synthesized according to General Method I from crude precursor I54. 
1H NMR (400 MHz, DMSO-d6) δ:
7.44 (s, 1H)
5.99 (br s, 4H)
5.07 (s, 1H)
2.60 (s, 3H)
1.91 (s, 6H).
13C NMR (100 MHz, DMSO-d6) δ: 169.0, 163.2, 163.1, 159.8, 115.0, 79.1, 48.8, 28.4, 18.9.
2-Hydroxyethanethioamide (I55)
To a solution of ethyl thiooxamate (965 mg, 7.25 mmol) in THF (15 mL) and ethanol (15 mL) at 
0 °C was added NaBH4 (685 mg, 18.1 mmol) portion wise over five min. The reaction was 
stirred at 0 °C for 3 hr, at which point the reaction was quenched by careful addition of saturated 
ammonium chloride solution. The aqueous solution was extracted three times with ethyl acetate, 
and three times with DCM. The combined organic layers were dried over anhydrous Na2SO4 and 
then concentrated in vacuo. The product was taken on to next step without further purification. 
485 mg, 73% yield. 
1H NMR (400 MHz, DMSO-d6) δ:
9.84 (br s, 1H)
9.05 (br s, 1H)
5.77 (t, J = 5.9 Hz, 1H)
4.07 (d, J = 5.8 Hz, 2H).
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Ethyl 2-(hydroxymethyl)thiazole-4-carboxylate (I56)
I56 was synthesized according to General Method C from precursor I56. 675 mg, 70% yield. 
1H NMR (400 MHz, CDCl3) δ:
8.15 (s, 1H)
5.00 (s, 2H)
4.41 (q, J = 7.1 Hz, 2H)
2.62 (br s, 1H)
1.40 (t, J = 7.1 Hz, 3H).
13C NMR (100 MHz, CDCl3) δ: 172.7, 161.5, 147.2, 127.7, 62.4, 61.7, 14.5.
2-(2-(Hydroxymethyl)thiazol-4-yl)propan-2-ol (I57)
I57 was synthesized according to General Method E from precursor I56. 331 mg, 67% yield.
1H NMR (400 MHz, CDCl3) δ:
7.08 (s, 1H)
4.91 (s, 2H)
2.61 (br s, 1H)
1.60 (s, 6H).
13C NMR (100 MHz, CDCl3) δ: 170.9, 163.9, 111.9, 71.2, 62.2, 30.1.
HRMS-ESI (m/z) calcd for C7H12NO2S [M+H]+ 174.05887, found 174.05274.
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4-(2-Hydroxypropan-2-yl)thiazole-2-carbaldehyde (I58)
To a solution of I57 (173 mg, 1.0 mmol) in acetonitrile (2 mL) was added a solution of 
tetrakis(acetonitrile)copper(I) hexafluorophosphate (18.6 mg, 0.05 mmol) in acetonitrile (1 mL). 
A solution of bipyridine (7.8 mg, 0.05 mmol) in acetonitrile (1 mL) was then added, followed by 
TEMPO (7.8 mg, 0.05 mmol) in acetonitrile (1 mL) and N-methylimidazole (0.008 mL, 0.1 
mmol) in acetonitrile (1 mL). The reaction solution was then stirred vigorously while open to air 
for three hr before concentrating in vacuo. The resulting residue was purified by flash column 
chromatography over silica gel using 40% ethyl acetate in hexanes as the eluent. 156 mg, 91% 
yield. 
1H NMR (400 MHz, CDCl3) δ:
9.97 (d, J = 1.2 Hz, 1H)
7.61 (d, J = 1.3 Hz, 1H)
2.53 (br s, 1H)
1.66 (s, 6H).
13C NMR (100 MHz, CDCl3) δ: 183.9, 167.5, 165.7, 119.6, 71.7, 30.5.
(E)-4-(2-Hydroxypropan-2-yl)thiazole-2-carbaldehyde oxime (I59)
To a solution of I58 (141 mg, 0.824 mmol) and sodium acetate (108 mg, 1.32 mmol) in methanol 
(3 mL) was added hydroxylamine hydrochloride (86 mg, 1.24 mmol). The reaction solution was 
stirred for 40 min and then concentrated in vacuo. The resulting solid was partitioned between 
ethyl acetate and deionized water, the aqueous layer was extracted three times with ethyl acetate, 
and the combined organic layers dried over anhydrous sodium sulfate. The organic layer was 
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then concentrated in vacuo to yield the desired product as a 1:1 mixture of the E and Z isomers. 
1H NMR taken in DMSO-d6, 13C NMR taken in CDCl3.
1H NMR (400 MHz, DMSO-d6) δ:
12.70 (s, 1H)
11.89 (s, 1H)
8.28 (d, J = 0.8 Hz, 1H)
7.95 (d, J = 1.0 Hz, 1H)
7.62 (d, J = 1.0 Hz, 1H)
7.36 (d, J = 0.9 Hz, 1H)
1.46 (s, 6H)
1.44 (s, 6H).
13C NMR (100 MHz, CDCl3) δ: 164.7, 163.9, 161.9, 154.7, 145.1, 141.0, 116.9, 113.2, 71.33, 
71.28, 30.3, 30.1.
HRMS-ESI (m/z) calcd for C7H11N2O2S [M+H]+ 187.05412, found 187.05468.
4-(2-Hydroxypropan-2-yl)thiazole-2-carbonitrile (I60)
To a solution of I59 (135 mg, 0.832 mmol) in acetonitrile (3 ml) was added copper(II) acetate 
(15.1 mg, 0.0832 mmol) and the reaction heated to reflux for 15 min. The reaction solution was 
then concentrated in vacuo and the residue purified by flash column 
chromatography over silica gel using 40–66% ethyl acetate in hexanes 
as the eluent. 40 mg, 29% yield. 
1H NMR (400 MHz, CDCl3) δ:
7.56 (s, 1H)
	 105
N
I59
NS
OH
OH
N
NS
OH
OH
CN
I60
NS
OH
2.43 (br s, 1H)
1.63 (s, 6H).
13C NMR (100 MHz, CDCl3) δ: 167.3, 136.2, 118.4, 112.9, 72.0, 30.5.
HRMS-ESI (m/z) calcd for C7H9N2OS [M+H]+ 169.0436, found 169.04254.
N’-Hydroxy-4-(2-hydroxypropan-2-yl)thiazole-2-carboximidamide (I61)
To a solution of I60 (170 mg, 1.01 mmol) in ethanol (3 ml) was added hydroxylamine (50% 
aqueous solution, 0.11 mL, 2.02 mmol) and the reaction solution was heated to 98 °C for two hr. 
The reaction solution was then concentrated in vacuo, yielding a crystalline solid. The solid was 
dissolved in ethanol and concentrated once more. The product was obtained as a white crystalline 
solid. 200 mg, 99% yield. 
1H NMR (400 MHz, DMSO-d6) δ:
10.04 (s, 1H)
7.31 (s, 1H)
5.81 (s, 2H)
5.14 (s, 1H)
1.46 (s, 6H).
13C NMR (100 MHz, DMSO-d6) δ: 164.7, 160.3, 146.9, 113.0, 70.3, 30.4.
HRMS-ESI (m/z) calcd for C7H12N3O2S [M+H]+ 202.0650, found 202.06370.
N’-Acetoxy-4-(2-hydroxypropan-2-yl)thiazole-2-carboximidamide (I62)
To a solution of I61 (143 mg, 0.711 mmol) and triethylamine (0.18 ml, 1.28 mmol) in THF (4.3 
ml) was added acetyl chloride (1.0 M solution in THF, 0.782 ml, 0.782 mmol) dropwise. The 
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reaction solution was stirred for 70 min and then concentrated in vacuo. The resulting solution 
was partitioned between ethyl acetate and saturated ammonium chloride solution. The aqueous 
solution was extracted three times with ethyl acetate and the combined organic layers were dried 
over anhydrous sodium sulfate before being concentrated in vacuo to give an oil which 
crystallized upon standing. 164 mg, 95% yield.
1H NMR (400 MHz, CDCl3) δ:
7.25 (s, 1H)
5.65 (br s, 2H)
2.50 (br s, 1H)
2.26 (s, 3H)
1.62 (s, 6H).
13C NMR (100 MHz, CDCl3) δ: 168.5, 164.3, 158.1, 150.4, 115.1, 71.4, 30.3, 19.9.
2-(2-(5-Methyl-1,2,4-oxadiazol-3-yl)thiazol-4-yl)propan-2-ol (I63)
To a solution of I62 (205 mg, 0.843 mmol) in THF (25 ml) at 0 °C was added 
tetrabutylammonium fluoride (TBAF, 1.0 M solution in THF, 0.17 ml, 0.17 mmol). The reaction 
vessel was removed from ice bath and stirred at room temperature following addition of TBAF. 
After two hr the reaction was quenched by addition of deionized water. Brine was added to the 
aqueous solution, which was then extracted with ethyl acetate four times. The combined organic 
layers were dried over anhydrous sodium sulfate, concentrated in vacuo to give a yellow oil, 
which was purified by flash column chromatography over silica using 1:1 ethyl acetate:hexanes 
as the eluent. 188 mg, 99% yield. 
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1H NMR (400 MHz, CDCl3) δ:
7.39 (s, 1H)
2.77 (br s, 1H)
2.70 (s, 3H)
1.67 (s, 6H).
13C NMR (100 MHz, CDCl3) δ: 177.8, 166.7, 164.1, 153.8, 115.4, 
71.6, 30.3, 12.6.
HRMS-ESI (m/z) calcd for C9H12N3O2S [M+H]+ 226.0650, found 226.0674.
3-(4-(2-Chloropropan-2-yl)thiazol-2-yl)-5-methyl-1,2,4-oxadiazole (I64)
I64 was synthesized according to General Method H using precursor I63. 
The crude product was taken directly to the next step due to the instability 
of the tertiary chloride.
HRMS-ESI (m/z) calcd for C9H11ClN3OS [M+H]+ 244.03114,
found 244.03247.
2-((2-(2-(5-Methyl-1,2,4-oxadiazol-3-yl)thiazol-4-yl)propan-2-yl)thio)pyrimidine-4,6-
diamine (NMc-16)
NMc-16 was synthesized according to General Method I from precursor I64. 
1H NMR (400 MHz, CDCl3) δ:
7.55 (s, 1H)
5.17 (s, 1H)
4.46 (br s, 4H)
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2.68 (s, 3H)
2.01 (s, 6H).
13C NMR (100 MHz, CDCl3) δ: 177.6, 170.1, 165.1, 164.3, 
162.9, 151.8, 118.1, 80.9, 49.8, 29.6, 12.6.
HRMS-ESI (m/z) calcd for C13H16N7OS2 [M+H]+ 350.0858, 
found 350.0828.
	 109
NS
S
N
O
N
NMc-16
N
N
H2N
NH2
1.7 References
1. Hess, J. R.; Greenberg, N. A. The role of nucleotides in the immune and gastrointestinal 
systems: potential clinical applications. Nutr. Clin. Pract. 2012, 27, 281–294.
2. Carver, J. D.; Walker, W. A. The role of nucleotides in human nutrition. J. Nutr. Biochem. 
1995, 6, 58–72.
3. Pai,  C. C.;  Kearsey,  S.  E.  A Critical  Balance: dNTPs and the Maintenance of Genome 
Stability. Genes 2017, 57, 1–14.
4. Reichard, P.  Interactions Between Deoxyribonucleotide and DNA Synthesis.  Annu. Rev. 
Biochem. 1988, 57, 349–374.
5. Evans, D. R.; Guy, H. I. Mammalian pyrimidine biosynthesis: fresh insights into an ancient 
pathway. J. Biol. Chem. 2004, 32, 33035–33038.
6. Arner, E. S. J.; Eriksson, S. Mammalian Deoxyribonucleoside Kinases. Pharmacol. Ther. 
1995, 2, 155–186.
7. Eriksson, S.; Munch-Petersen, B.; Johansson, K.; Ecklund, H. Structure and function of 
cellular deoxyribonucleoside kinases. Cell. Mol. Life Sci. 2002, 59, 1327–1346 (2002).
8. Toy, G.;, Austin, W. R.; Liao, H.; Cheng, D.; Singh, A.; Campbell, D. O.; Ishikawa, T.; 
Lehmann, L. W.; Satyamurthy, N.; Phelps, M. E.; Herschmann, H. R.; Czernin, J.; Witte, O. 
N.;  Radu,  C.  G.  Requirement  for  deoxycytidine  kinase  in  T  and  B  lymphocyte 
development. Proc. Natl. Acad. Sci. 2010, 12, 5551–5556.
9. Smal, C.; Vertommen, D.; Bertrand, L.; Ntamashimikiro, S.; Rider, M. H.; Van Den Neste, 
E.; Bontemps, F. Identification of Phosphorylation Sites on Human Deoxycytidine Kinase: 
Role of Ser-74 in the Control of Enzyme Activity. J. Biol. Chem. 2006, 8, 4887-4893.
	 110
10. Hazra, S.; Szewczak, A.; Ort, S.; Konrad, M.; Lavie, A. Post-translational phosphorylation 
of  serine  74  of  human  deoxycytidine  kinase  favors  the  enzyme  adopting  the  open 
conformation making it competent for nucleoside binding and release. Biochemistry 2011, 
14,  2870-2880.
11. Sabini,  E.;  Hazra,  S.;  Ort,  S.;  Konrad,  M.;  Lavie,  A.  Structural  basis  for  substrate 
promiscuity of dCK. J. Mol. Biol. 2008, 3, 607-621.
12. Van Rompay, A. R.; Johansson, M.; Karlsson, A. Substrate specificity and phosphorylation 
of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases 
and ribonucleoside kinases. Pharmacol. Ther. 2003, 2, 119-139.
13. Aird, K. M.; Zhang, R. Nucleotide metabolism, oncogene-induced senescence and cancer. 
Cancer Lett. 2015, 2, 204-210.
14. Kohnken, R.; Kodigepalli,  K. M.; Wu, L. Regulation of deoxynucleotide metabolism in 
cancer: novel mechanisms and therapeutic implications. Mol. Cancer. 2015, 14, 176-187.
15. Madaan, K.; Kaushik, D.; Verma, T. Hydroxyurea: a key player in cancer chemotherapy. 
Expert Rev. Anticancer Ther. 2012, 12, 19-29.
16. Kunos, C. A.; Chu, E.; Beumer, J. H.; Sznol, M.; Ivy, S. P. Phase I trial of daily triapine in 
combination  with  cisplatin  chemotherapy  for  advanced-stage  malignancies.  Cancer 
Chemother. Pharmacol. 2017, 1, 201-207.
17. Nathanson, D. A.; Armijo, A. L.; Tom, M.; Li, Z.; Dimitrova, E.; Austin, W. R.; Nomme, J.; 
Campbell, D. O.; Ta, L.; Le, T. M.; Lee, J. T.; Darvish, R.; Gordin, A.; Wei, L.; Liao, H.; 
Wilks, M.; Martin, C.; Sadeghi, S.; Murphy, J. M.; Boulos, N.; Phelphs, M. E.; Faull, K. F.; 
Herschman,  H.  R.;  Jung,  M.  E.;  Czernin,  J.;  Lavie,  A.;  Radu,  C.  G.  Co-targeting  of 
	 111
convergent nucleotide biosynthetic pathways for leukemia eradication. J. Exp. Med. 2014, 
3, 473-486.
18. Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B. E.; Sumer, S. O.; Aksoy, B. A.; Jacobsen, A.; 
Byrne, C. J.; Heuer, M. L.; Larsson, E.; Antipin, Y.; Reva, B.; Goldberg, A. P.; Sander, C.; 
Schultz,  N.  The  cBio  cancer  genomics  portal:  an  open  platform  for  exploring 
multidimensional cancer genomics data. Cancer Discov. 2012, 2, 401-404.
19. Austin, W. R.; Armijo, A. L.; Campbell, D. O.; Singh, A. S.; Hsieh, T.; Nathanson, D.; 
Herschman, H. R.; Phelps, M. E.; Czernin, J.; Radu, C. G. Nucleoside salvage pathway 
kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress. J. 
Exp. Med. 2012, 12, 2215-2228.
20. Yang, C.; Lee, M.; Hao, J.; Cui, X.; Guo, X.; Smal, C.; Bontemps, F.; Ma, S.; Liu, X.; 
Engler,  D.;  Parker,  W. B.;  Xu, B. Deoxycytidine kinase regulates the G2/M checkpoint 
through interaction with cyclin-dependent kinase 1 in response to DNA damage. Nucleic 
Acids Research 2012, 19, 9621-9632.
21. Murphy, J. M.; Armijo, A. L.; Nomme, J.; Lee, C. H.; Smith, Q. A.; Li, Z.; Campbell, D. 
O.; Liao, H.; Nathanson, D. A.; Austin, W. R.; Lee, J. T.; Darvish, R.; Wei, L.; Wang, J.; Su, 
Y.;  Damoiseaux,  R.;  Sadeghi,  S.;  Phelps,  M.  E.;  Herschman,  H.  R.;  Czernin,  J.; 
Alexandrova,  A.  N.;  Jung,  M.  E.;  Lavie,  A.;  Radu,  C.  G.  Development  of  New 
Deoxycytidine  Kinase  Inhibitors  and  Noninvasive  in  Vivo  Evaluation  Using  Positron 
Emission Tomography. J. Med. Chem. 2013, 17, 6696-6708 (2013).
22. Nomme, J.; Li, Z.; Gipson, R. M.; Wang, J.; Armijo, A. L.; Le, T. M.; Poddar, S.; Smith, T.; 
Santarsiero, B. D.; Nguyen, H.; Czernin, J.; Alexandrova, A. N.; Jung, M. E.; Radu, C. G.; 
	 112
Lavie,  A.  Structure-Guided  Development  of  Deoxycytidine  Kinase  Inhibitors  with 
Nanomolar Affinity and Improved Metabolic Stability. J. Med. Chem. 2014, 22, 9480-9494.
23. Gambhir, S. S. Molecular imaging of cancer with positron emission tomography. Nat. Rev. 
Cancer 2002, 9, 683-693.
24. Czernin, J.; Benz, M. R.; Allen-Auerbach, M. S. PET/CT imaging: The incremental value 
of  assessing  the  glucose  metabolic  phenotype  and  the  structure  of  cancers  in  a  single 
examination. Eur. J. Radiol. 2010, 3, 470-480.
25. Hargreaves, R. J. The Role of Molecular Imaging in Drug Discovery and Development. 
Clin. Pharmacol. Ther. 2008, 2, 349-353.
26. Phelps,  M.  E.  Positron emission tomography provides  molecular  imaging of  biological 
processes. Proc. Natl. Acad. Sci. 2000, 16, 9226-9233.
27. Wagner, C. C.; Muller, M.; Lappin, G.; Langer, O. Positron emission tomography for use in 
microdosing studies. Curr. Opin. Drug Discov. Devel. 2008, 1, 104-110.
28. Kim, W.; Le, T. M.; Wei, L.; Poddar, S.; Bazzy, J. Wang, X.; Uong, N. T.; Abt, E.R. Capri, 
J. R.; Austin, W. R.; Van Valkenburgh, J. S.; Steele, D.; Gipson, R. M.; Slavik, R.; Cabebe, 
A. E.; Taechariyakul, T.; Yaghoubi, S. S.; Lee, J. T.; Sadeghi, S.; Lavie, A.; Faull, K. F.; 
Witte, O. N.; Donahue, T. R.; Phelps, M. E.; Herschman, H. R.; Herrmann, K.; Czernin, J.; 
Radu, C.G. [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine 
kinase activity. Proc. Natl. Acad. Sci. 2017, 15, 4027-4032.
29. Laing, R. E.; Walter, M. A.; Campbell, D. O.; Herschman, H. R.; Satyamurthy, N.; Phelphs, 
M. E.; Czernin, J.; Witte, O. N.; Radu, C. G. Noninvasive prediction of tumor responses to 
gemcitabine  using  positron  emission  tomography.  Proc.  Natl.  Acad.  Sci.  2009,  8, 
2847-2852.
	 113
30. Radu, C. G.; Shu, C. J.; Nair-Gill, E.; Shelly, S. M.; Barrio, J. R.; Satyamurthy, N.; Phelps, 
M. E.;  Witte,  O.  N.  Molecular  imaging of  lymphoid organs and immune activation by 
positron  emission  tomography  with  a  new [18F]-labeled  2ʹ-deoxycytidine  analog.  Nat. 
Med. 2008, 7, 783-788.
31. Tzara, A.; Xanthopoulos, D.;  Kourounakis, A. P. Morpholine As a Scaffold in Medicinal 
Chemistry: An Update on Synthetic Strategies. Chem. Med. Chem. 2020, 5, 392-403.
32. Gobburu,  J.  V.;  Jusko,  W.  J.  Role  of  dosage  regimen  in  controlling  indirect 
pharmacodynamic responses. Adv. Drug Deliv. Rev. 2001, 46, 45-57.
33. Matthews, P. M.; Rabiner, E. A.; Passchier, J.; Gunn, R. N. Positron emission tomography 
molecular  imaging  for  drug  development:  PET  for  drug  development.  Br.  J.  Clin. 
Pharmacol. 2012, 2, 175-186.
34. 18F-Clofarabine  PET/CT  in  Imaging  Cancer  Patients  Before  and  After  Interventions. 
https://clinicaltrials.gov/ct2/show/NCT02888301 (2020).
35. Valkenburgh, J. V. Development of Small-Molecule Modulators of Nucleotide Metabolism 
Enzymes. [Doctoral dissertation, University of California, Los Angeles], 2019.
36. Nomme, J.; Murphy, J. M.; Su, Y.; Sansone, N. D.; Armijo, A. L.; Olson, S. T.; Radu, C. G.; 
Lavie, A. Structural characterization of new deoxycytidine kinase inhibitors rationalizes the 
affinity-determining  moieties  of  the  molecules.  Acta.  Crystallogr.  D.  Biol.  Crystallogr. 
2014, 1, 68-78.
37. Lipinski,  C.  A.;  Lombardo,  F.;  Dominy,  B.  W.;  Feeney,  P.  J.  Experimental  and 
computational approaches to estimate solubility and permeability in drug discovery and 
development settings. Adv. Drug. Deliv. Rev. 2001, 1–3, 3-26.
	 114
38. Benet, L. Z.; Hosey, C. M.; Ursu, O.; Oprea, T. I. BDDCS, the Rule of 5 and drugability. 
Adv. Drug Deliv. Rev. 2016, 101, 89-98.
39. Poddar, S.; Capparelli, E. V.; Rosser, E. W.; Gipson, R. M.; Wei, L.; Le, T. M.; Jung, M. E.; 
Radu, C. R.; Nikanjam, M. Development and preclinical pharmacology of a novel dCK 
inhibitor, DI-87. Biochem. Pharmacol. 2020, 172, 113742.
40. Creary, X.; Zhu, C.; Jiang, Z. Carbocations in the β ︎-Lactam and β ︎︎-Thiolactam Series. J. 
Am. Chem. Soc. 1996, 49, 12331-12338.
41. Kornblum, N. D.; Thomas M.; Earl, G. W.; Holy, N. L.; Kerber, R. C.; Musser, M. T.; 
Snow, D. H. New and facile substitution reactions at tertiary carbon. J. Am. Chem. Soc. 
1967, 3, 727.
42. Hiroyoshi, H.; Ingaki, M.;  Kawamato, S.; Sasaki, Y. Isoquinolinesulfonamides, Novel and 
Potent Inhibitors of Cyclic Nucleotide Dependent Protein Kinase and Protein Kinase C. 
Biochemistry 1984, 23, 5036-5041.
43. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors. 
Nat. Rev. Cancer 2009, 9, 28-39.
44. Gross,  S.;  Rahal,  R.;  Stransky,  N.;  Lengauer,  C.;  Hoeflich,  K. P.  Targeting cancer with 
kinase inhibitors. J. Clin. Invest. 2015, 5, 1780-1789.
45. Manning, G.; Whyte, D. B.; Martinez, R., Hunter, T.; Sudarsanam, S. The protein kinase 
complement of the human genome. Science 2002, 5600, 1912-1934.
46. Traxler, P.; Furet, P. Strategies toward the design of novel and selective protein tyrosine 
kinase inhibitors. Pharmacol. Ther. 1999, 2–3, 195-206.
47. Abt, E. R.; Rosser, E. W.; Durst, M. A.; Lok, V.; Poddar, S.; Le, T. M.; Cho, A.; Kim, W.; 
Wei, L.; Song, J.; Capri, J. R.; Xu, S.; Wu, N.; Slavik, R.; Jung, M. E.; Damoiseaux, R.; 
	 115
Czernin, J.; Donahue, T. R.; Lavie, A.; Radu, C. G. Metabolic Modifier Screen Reveals 
Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism. Cell Chem. 
Biol. 2020, 2, 197-205.
48. Fernandez-Banet,  J.;  Esposito,  A. Coffin, S.;  Horvath, I.  B.;  Estrella,  H.;  Schefzick, S.; 
Deng, S.; Wang, K.; AChing, K.; Ding, Y.; Roberts, P.; Rejito, P. A.; Kan, Z. OASIS: web-
based platform for exploring cancer multi-omics data. Nat. Methods 2016, 1, 8-9.
49. Van Rompay, A. R.; Norda, A.; Linden, K.; Johansson, M.; Karlsson, A. Phosphorylation of 
Uridine and Cytidine Nucleoside Analogs by Two Human Uridine-Cytidine Kinases. Mol. 
Pharmacol. 2001, 59, 1181-1186 (2001).
50. Peters,  G.  J.;  Smid,  K.;  Vecchi,  L.;  Kathmann,  L.;  Sarkisjan,  D.;  Honeywell,  R.  J.; 
Losekoot, N.; Ohne, O.; Orbach, A.; Blaugrund, E.; Jeong, L. S.; Lee, Y. B.; Ahn, C.; Kim, 
D.  J.  Metabolism,  mechanism  of  action  and  sensitivity  profile  of 
fluorocyclopentenylcytosine (RX-3117; TV-1360). Invest. New Drugs 2013, 6, 1444-1457.
51. Siegel, R. L.; Miller, K. D.; Jemal, A. Cancer Statistics, 2020. CA. Cancer J. Clin. 2020,  1, 
7-30.
52. Derle, A.; De Santis, M. C.; Gozzelino, L.; Ratto, E.; Martini, M. The role of metabolic 
adaptation to nutrient stress in pancreatic cancer. Cell Stress 2018, 12, 332-339.
53. Bryant, K. L.; Mancias, J. D.; Kimmelman, A. C.; Der, C. J. KRAS: feeding pancreatic 
cancer proliferation. Trends Biochem. Sci. 2014, 2, 91-100.
54. Vanzo, R.;, Bartkova, J.; Merchut-Maya, J. M.; Hall, A.; Bouchal, J.; Dyrskjot, L.; Frankel, 
L.  B.;  Gorgoulis,  V.;  Maya-Mendoza,  A.;  Jaattela,  M.;  Bartek,  J.  Autophagy role(s)  in 
response to oncogenes and DNA replication stress. Cell Death Differ. 2020, 3, 1134-1153.
	 116
55. Terai, C.; Wasson, D. B.; Carrera, C. J.; Carson, D. A. Dependence of cell survival on DNA 
repair in human mononuclear phagocytes. J. Immunol. 1991, 12, 4302-4306.
56. Huang, S.; Li, J.; Tam, N. L.; Sun, C.; Hou, Y.; Hughes, B.; Wang, Z.; Zhou, Q.; He, X.; 
Wu, L. Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular 
carcinoma and is associated with cancer aggressiveness. Mol. Carcinog. 2019, 4, 603-615.
57. Lim,  M.;  Moyer,  J.  D.;  Cysyk,  R.  L.;  Marquez,  V.  E.  Cyclopentenyluridine  and 
Cyclopentenylcytidine Analogues as Inhibitors of Uridine-Cytidine Kinase. J. Med. Chem. 
1984, 12, 1536-1538.
58. Cysyk, R. L.; Malinowski, N.; Marquez, V.; Zaharevitz, D.; August, E. M.; Moyer, J. D. 
Cyclopentenyl  Uracil:  An  Effective  Inhibitor  of  Uridine  Salvage  In  Vivo.  Biochem. 
Pharmacol. 1995, 2, 203-207.
59. White,  R.  M.;  Cech,  J.;  Ratanasirintrawoot,  S.;  Lin,  C.  Y.;  Rahl,  P.  B.;  Burke,  C.  J.; 
Langdon, E.; Tomlinson, M. L.; Mosher, J.; Kaufman, C.; Chen, F.; Long, H. K.; Kramer, 
M.; Datta, S.; Neuberg, D.; Granter, S.; Young, R. A.; Morrison, S.; Wheeler, G. N.; Zon, L. 
I. DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 
2011, 7339, 518-522.
60. McLean, J. E.; Neidhardt, E. A.; Grossman, T. H.;  Hedstrom, L. Multiple inhibitor analysis 
of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase. 
Biochemistry 2001, 7, 2194-2200.
61. Munier-Lehmann,  H.;  Vidalain,  P.  O.;  Tangy,  F.;  Janin,  Y.  L.  On  dihydroorotate 
dehydrogenases and their inhibitors and uses. J. Med. Chem. 2013, 8, 3148-3167.
62.    Le, T. M.; Poddar, S.; Capri, J. R.; Abt, E. R.; Kim, W.; Wei, L.; Uong, N. T.; Cheng, C. M.; 
Braas, D.; Nikanjam, M.; Rix, P.; Merkurjev, D.; Zaretsky, J.; Kornblum, H. I.; Ribas, A.; 
	 117
Herschman, H. R.; Whitelegge, J.; Faull, K. F.; Donahue, T. R.; Czernin, J.; Radu, C. G. 
ATR  inhibition  facilitates  targeting  of  leukemia  dependence  on  convergent  nucleotide 
biosynthetic pathways. Nat. Commun. 2017, 5600, 1912-1934.
63.    Shu, C.J.;Campbell, D. O.; Lee, J. T.; Tran, A. Q.; Wengrod, J. C.; Witte, O. N.; Phelps, M. 
E.; Satyamurthy, N.; Czernin, J.; Radu, C. G. Novel PET probes specific for deoxycytidine 
kinase. J. Nucl. Med. 2010, 7, 1092–1098. 
64.    Upton, R. N.; Mould, D. R. Basic concepts in population modeling, simulation, and model-
based drug development: part 3-introduction to pharmacodynamic modeling methods, CPT 
Pharmacometrics Syst. Pharmacol. 2014, 1, e88.  
 
	 118
CHAPTER TWO
Identification of Small Molecule Modulators of Pyrimidine Nucleotide Metabolism
Adapted from: Evan R. Abt*,  Ethan W. Rosser*, Matthew A. Durst*, Soumya Poddar, Vincent 
Lok, Liu Wei, Woosuk Kim, Janet Song, Joseph R. Capri, Thuc M. Le, Roger Slavik, Michael E. 
Jung, Robert Damoiseaux, Johannes Czernin, Timothy R. Donahue, Arnon Lavie, Caius G. Radu. 
Cell Chem Biol. 2019, 27(2), 197-205. (*These authors contributed equally).
2.1 Introduction
The redundant and plastic nature of metabolic networks represents a significant obstacle 
in the pharmacological targeting of cancer metabolism. This redundancy manifests in two ways, 
the first being the expression of multiple enzymes that perform ostensibly identical biochemical 
reactions, such as the hexokinase isozymes which each phosphorylate glucose.1 The second is 
the existence of convergent metabolic pathways that produce a common metabolite from unique 
precursors. Generally, these parallel networks consist of de novo and scavenging pathways that 
synthesize  or  recycle  (either  from  the  extracellular  environment  or  by  breakdown  of 
macromolecules) their common metabolite, respectively. Such convergent metabolic nodes have 
been noted in nucleotide,2 lipid (cholesterol),3 and amino acid (aspartate)4 metabolism.
Despite these difficulties, the development of metabolism modifiers remains a robust area 
of research. One such therapeutically relevant target is pyrimidine nucleotide biosynthesis, which 
consists of nucleoside salvage (NSP) and de novo (DNP) pathways that converge to generate 
uridine monophosphate (UMP), the common precursor for all pyrimidine nucleotides.5 The NSP 
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allows for the scavenging of uridine from the extracellular environment, shuttling it into the cell 
via  nucleoside transporters where it  is  phosphorylated by uridine-cytidine kinases (UCKs) to 
produce UMP. UCK2 is thought to be the primary NSP kinase, given its 20-fold higher catalytic 
efficiency compared to UCK1.6 The DNP is a six-step process that utilizes glutamine, aspartate, 
bicarbonate,  and glucose to produce UMP through the action of three enzymes: trifunctional 
CAD, electron transport chain-linked dihydroorotate dehydrogenase (DHODH), and bifunctional 
UMP synthase (UMPS).  Among the DNP enzymes,  DHODH in particular has emerged as a 
therapeutic target in multiple cancers including pancreatic ductal adenocarcinoma (PDAC).7–9 
Additionally, over 90 patent applications involving DHODH inhibition have been filed in the last 
decade.10 
In this study, we show that the pyrimidine NSP and DNP are interchangeable in their 
ability to sustain cancer cell proliferation and that a synthetic lethal phenotype can be achieved 
through their  simultaneous  inhibition.  We leverage this  observation to  construct  a  metabolic 
modifier  screen  that  allows  for  the  identification  of  selective  modulators  of  NSP and  DNP 
pathways. In screening a library of protein kinase inhibitors, we identified multiple compounds 
with previously uncharacterized nucleotide metabolism-modifying activity. We show that the c-
Jun N-terminal kinase (JNK) inhibitor JNK-IN-8 is a potent inhibitor of uridine transport which 
is vital for NSP function, and that the 3-phosphoinositide-dependent protein kinase 1 (PDK1) 
inhibitor OSU-03012 (also known as AR-12) and the pan-RAF inhibitor TAK-632 both bind and 
inhibit the pyrimidine DNP enzyme DHODH.
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2.2  Design  of  a  Differential  Metabolic  Modifier  Screen  for  Identification  of  Novel 
Modulators of Pyrimidine Nucleotide Metabolism
While  the  UMP-DNP and  -NSP are  interchangeable  in  their  ability  to  sustain  cell 
proliferation, their relative activity at baseline (when both pathways are functional) is poorly 
defined. De novo pyrimidine biosynthesis is allosterically inactivated by its end product, UTP, 
which is also produced by the uridine (rU) NSP.12 This allosteric control functions at the level of 
the CPSase activity of the trifunctional protein CAD, which performs the first committed step in 
de  novo  pyrimidine  biosynthesis  (Figure  S2.1A).  To  quantitatively  evaluate  the  discrete 
activities of the pyrimidine de novo and salvage pathways, we modified and applied a LC-MS/
MS  assay  previously  used  by  our  group  to  track  the  contribution  of  stable  isotope-labeled 
glucose and deoxycytidine to newly replicated DNA.2 In this assay, cells are cultured in the 
presence of  [13C6]glucose (to track DNP activity)  and 10 µM [13C9;  15N2]rU (to track NSP 
activity).  Their  DNA is  then extracted and hydrolyzed and the abundance of  stable  isotope-
labeled nucleosides is evaluated using LC-MS/MS in the multiple reaction monitoring (MRM) 
mode (Figure S2.1B).  We applied this  assay to a  panel  of  cancer  cell  lines and observed a 
heterogenous  degree  of  total  labeling ([13C6]glucose  + [13C9;  15N2]rU)  in  the  deoxycytidine 
compartment of DNA (DNA-C) after 24 hr (Figure S2.1C). Consistent with the aforementioned 
model in which UTP produced by uridine savage allosterically impairs de novo biosynthesis, we 
found that the fractional contribution of [13C9; 15N2]rU exceeded that of [13C6]glucose in all 
models tested (Figure S2.1D). Interestingly, we found heterogeneity in the relative contribution 
of [13C6]glucose and [13C9; 15N2]rU to DNA-C across the cell line panel, which likely reflects 
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differential  expression  or  regulation  of  the  various  transporters,  kinases,  nucleotidases,  and 
phosphorylases  involved  in  rU  salvage.  Importantly,  we  confirmed  that  the  contribution  of 
[13C6]glucose to DNA-C could be blocked by NITD-982, an established DHODH inhibitor, and 
likewise the contribution of [13C9; 15N2]rU could be prevented by the FDA-approved nucleoside 
transport inhibitor dipyridamole (DPA) (Figure S2.1E). Collectively, these results indicate that, 
under the conditions tested, both the UMP-DNP and -NSP pathways are simultaneously, but not 
equally, active.
Although redundant routes for UMP biosynthesis can complicate targeting, impaired 
cellular proliferation resulting from simultaneous restriction of both de novo (DNP) and salvage 
(NSP)  pathways  can  be  leveraged  for  the  identification  of  selective  DNP or  NSP activity 
modifiers (Figure S2.1F). A metabolic modifier screen was developed for the discovery of small 
molecule modulators of UMP production by leveraging this biosynthetic redundancy. This cell-
based platform concurrently tests the effects of small molecule compounds on the proliferation of 
cells  cultured  in  baseline  (both  NSP and  DNP active),  NSP-only,  and  DNP-only  conditions 
(Figure 2.1A). Baseline conditions were those in which cells were incubated in standard media 
supplemented with physiological levels of uridine. To promote DNP-only conditions, cells were 
grown in standard media without uridine,  effectively abrogating the activity of the NSP and 
forcing cells to rely upon the DNP for UMP production. To achieve NSP-only conditions, cells 
were  incubated  in  standard  media  with  physiological  levels  of  uridine  in  the  presence  of 
NITD-982, a potent and selective small molecule inhibitor of DHODH which prevents the DNP-
synthesis  of  pyrimidine  nucleotides.11  Compounds  which  inhibit  proliferation  in  baseline 
conditions are classified as non-specific inhibitors, those which inhibit proliferation in NSP-only 
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conditions are NSP inhibitors, while those that inhibit growth in DNP-only conditions are DNP 
inhibitors. The screen design was validated using NITD-982 and the FDA-approved nucleoside 
transport  inhibitor  dipyridamole  (DPA),  with  Cell  Titer  Glo  (CTG)  utilized  to  evaluate 
proliferation impairment (Figure S2.1G).11
Figure 2.1 | Identification of nucleotide metabolism modulators in a small molecule protein 
kinase inhibitor library. (A) Phenotypic screening strategy. The impact of 430 protein kinase 
inhibitors on cell proliferation was evaluated in MIAPACA2 cells plated in 3 distinct culture 
conditions; 1) NSP + DNP (media +10 µM uridine (rU)); 2) NSP only (media +10 µM rU +1 µM 
NITD-982); or 3) DNP only (media alone). % proliferation values were calculated using Cell 
Titer  Glo (CTG) following 72 hr  treatment  (7-point  dose response;  n=2).  (B)  Waterfall  plot 
ranking library compounds based on NSP pathway selectivity score. (C) Summary of NSP and 
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trypan blue exclusion cell scoring in a second cancer cell line,
JURKAT, to confirm hit selectivity (Figures S3I and S3J).
In addition to its non-redundant role in de novo pyrimidine
nucleotide biosynthesis, DHODH functions as an electron donor
in the mitochondrial electron transport chain (Fang et al., 2013).
To exclude the possibility that the selective activity of JNK-IN-8
reflects an interaction with NITD-982 at the level of electron
transport chain modulation, we synthesized and evaluated
N-phosphonacetyl-L-aspartate (PALA), an inhibitor of CAD,
which functions upstream of DHODH (Collins and Stark, 1971;
Peters, 2018). We determined that JNK-IN-8 inhibits JURKAT
cell proliferation when both PALA and rU are present in the cul-
ture media, supporting that its selective activity results from the
inhibition of uridine salvage (Figure S4A).
We next applied our LC-MS/MS stable isotope tracking
approach to evaluate the impact of JNK-IN-8, OSU-03012, and
TAK-632 on the incorporation of [13C6]glucose and [
13C9;
15N2]
rU into newly replicated DNA (Figure 1I). In MIAPACA2 cells,
we found that JNK-IN-8 blocked the NSP contribution while
triggering a compensatory upregulation of the DNP. Conversely,
OSU-03012 and TAK-632 selectively impaired DNP contribution
(Figure 1J). Similar selectivity was observed in JURKAT cells,
where both OSU-03012 and TAK-632 blocked DNP contribu-
tion while inducing compensatory upregulation of the NSP
(Figure 1K).
JNK-IN-8 Inhibits Nucleoside Uptake
Although three protein kinase inhibitors were identified as selec-
tive inhibitors of the pyrimidine NSP, JNK-IN-8 was exceptionally
potent, with NSP-condition IC50 values in the low nanomolar
range. We reasoned that the activity of JNK-IN-8 could arise
from either the inhibition of nucleoside shuttling across the
plasma membrane, which is achieved by nucleoside trans-
porters, or through the inhibition of nucleoside phosphorylation
A B C D
E F G H
I J K
Figure 1. Identification of Nucleotide Metabolism Modulators in a Small Molecule Protein Kinase Inhibitor Library
(A) Phenotypic screening strategy. The impact of 430 protein kinase inhibitors on cell proliferation was evaluated in MIAPACA2 cells cultured in 3 distinct
conditions; (i) NSP + DNP (medium + 10 mM rU); (ii) NSP only (medium +10 mM rU + 1 mMNITD-982); or (iii) DNP only (medium alone). Proliferation vinhibition was
evaluated using Cell Titer Glo (CTG) following 72 h treatment (library compounds were tested at 7-point dose response; n = 2).
(B) Waterfall plot ranking library compounds by NSP pathway selectivity score.
(C) Summary of NSP and DNP selectivity scores across library compounds annotated as JNK inhibitors.
(D) Structure of JNK-IN-8.
(E) Waterfall plot ranking library compounds by DNP pathway selectivity score.
(F and G) Summary of NSP and DNP selectivity scores across library compounds annotated as PDK1 (F) or RAF (G) inhibitors .
(H) Structures of OSU-03012 and TAK-632.
(I) Experimental design to track contribution of UMP-DNP and -NSP pathways to newly replicated DNA using stable isotope-labeled metabolite tracers.
(J and K) LC-MS/MS analysis of [13C6]glucose (5.5 mM) and [
13C9;
15N2] rU (10 mM) utilization for DNA-C replication in MIAPACA2 (J) or JURKAT (K) cells treated +
1 mM JNK-IN-8 + 5 mM OSU-03012 or + 5 mM TAK-632 for 24 h (NT, not-treated; mean ± SD; n = 3; unpaired t test; **p < 0.01, ****p < 0.0001).
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DNP selectivity scores across library compounds annotated as JNK inhibitors. (D) Structure of 
JNK-IN-8.  (E)  Waterfall  plot  ranking library  compounds  based  on  DNP pathway selectivity 
score. (F,G) Summary of NSP and DNP selectivity scores across library compounds annotated as 
PDK1 (F) or RAF inhibitors (G). (H) Structures OSU-03012 and TAK-632. (I) Experimental 
design  to  track  contribution  of  UMP-DNP and -NSP to  newly  replicated  DNA using  stable 
isotope-labeled metabolite tracers.  (J,K) LC-MS/MS analysis of [13C6]glucose (5.5 mM) and 
[13C9; 15N2] rU (10 µM) utilization for DNA-C replication in MIAPACA2 (J) or JURKAT (K) 
cells treated +1 µM JNK-IN-8 +5 µM OSU-03012 or +5 µM TAK-632 for 24 hr (NT: not-
treated; mean±SD; n=3; unpaired T-test; ** P < 0.01, **** P < 0.0001).
Cancer cell  lines exhibited varying degrees of sensitivity to DHODH inhibition (as 
determined by doubling-time-normalized proliferation inhibition) and were all  rescued by rU 
supplementation (Figure S2.2).13 MIAPACA2 PDAC cells were utilized for the screen due to 
their ability to maintain baseline proliferation levels in NSP-only or DNP-only conditions, while 
also exhibiting a significant decrease in proliferation upon simultaneous NSP and DNP inhibition 
(Figure  S2.3A).  A library  of  430  protein  kinase  inhibitors  was  chosen  for  evaluation,  the 
rationale being twofold. First, it was hypothesized that our synthetic lethality screen may identify 
compounds that indirectly target pyrimidine metabolism through regulatory signal transduction 
pathway inhibition. Second, because a substantial fraction of kinase inhibitors are ATP-mimetics 
and  therefore  resemble  nucleotides,  we  predicted  that  protein  kinase  inhibitors  may possess 
secondary,  non-canonical  targets  within  nucleotide  metabolism.  Consistently,  several  protein 
kinase  inhibitors,  specifically  those  exhibiting  similarities  with  imatinib's  phenylamino 
pyrimidine  (PAP)  scaffold,  and  a  subset  of  p38  MAPK  inhibitors,  exhibit  activity  against 
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nucleoside transporters.14,15 This kinase inhibitor library was screened at 7-point dose response 
in  duplicate.  Composite  NSP and  DNP pathway  selectivity  scores  were  calculated  for  each 
compound  as  the  sum  of  condition-specific  anti-proliferative  effects  across  the  dose  range 
(Figure S2.3B).  Phenotypic  screen quality  was monitored using the Z-factor  metric  (Figure 
S2.3C)16.
The JNK inhibitor JNK-IN-8, the BTK inhibitor CNX-774, and the VEGFR inhibitor 
AMG-706 were active  in  the  NSP-only condition,  exhibiting positive  NSP-selectivity  scores 
(Figure 2.1B). The selectivity of these hits for the NSP was unique among inhibitors of JNK 
(Figures 2.1C, 2.1D), BTK, and VEGFR (Figures S2.3D–F), indicating this phenotype likely 
did not result from on-target effects. The PDK1 inhibitor OSU-03012 (also known as AR-12) and 
the pan-RAF inhibitor TAK-632 elicited potent and selective inhibition of proliferation in the 
DNP-only condition (Figure 2.1E).17,18 Among the four PDK1 inhibitors and 14 RAF inhibitors 
tested, OSU-03012 and TAK-632 were unique in their ability to selectively inhibit  the DNP, 
again suggesting that this effect was not the consequence of on-target activity (Figures 2.1F–H).
Microplate immunofluorescence microscopy nuclei scoring analysis of MIAPACA2 cells 
stained with Hoechst 33342 was performed as an orthogonal approach. These studies confirmed 
the culture-condition selectivity of our hits and validated the results of the CTG-based screen 
(Figures S2.3G, S2.3H). Additionally, we performed CTG analysis and trypan-blue exclusion 
cell  scoring in  a  second cancer  cell  line,  JURKAT, to  confirm hit  selectivity  (Figure S2.3I, 
S2.3J). 
In  addition  to  its  non-redundant  role  in  de  novo  pyrimidine  nucleotide  biosynthesis, 
DHODH functions  as  an  electron  donor  in  the  mitochondrial  electron  transport  chain.19  To 
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exclude  the  possibility  that  the  selective  activity  of  JNK-IN-8  reflects  an  interaction  with 
NITD-982 at the level of electron transport chain modulation, we synthesized and evaluated N-
phosphonacetyl-L-aspartate (PALA), an inhibitor of CAD which functions upstream of DHODH.
20,21 We determined that JNK-IN-8 inhibits JURKAT cell proliferation when both PALA and rU 
are present in the culture media, supporting that its selective activity results from the inhibition 
of uridine salvage (Figure S2.4A).
We next applied our LC-MS/MS stable isotope tracking approach to evaluate the impact 
of  JNK-IN-8,  OSU-03012,  and  TAK-632  on  the  incorporation  of  [13C6]glucose  and  [13C9; 
15N2]rU into newly replicated DNA (Figure 2.1I). In MIAPACA2 cells, we found that JNK-IN-8 
blocked  the  NSP  contribution  while  triggering  a  compensatory  upregulation  of  the  DNP. 
Conversely,  OSU-03012 and TAK-632 selectively impaired DNP contribution (Figure 2.1J). 
Similar  selectivity  was  observed  in  JURKAT  cells,  where  both  OSU-03012  and  TAK-632 
blocked  DNP contribution  while  inducing  compensatory  up-regulation  of  the  NSP (Figure 
2.1K).
2.3 JNK-IN-8 Inhibits Nucleoside Uptake
While  three  protein  kinase  inhibitors  were  identified  as  selective  inhibitors  of  the 
pyrimidine NSP, the JNK inhibitor JNK-IN-8 was exceptionally potent, with IC50 values in the 
low nanomolar range. We reasoned that the activity of JNK-IN-8 could arise from either the 
inhibition of nucleoside shuttling across the plasma membrane, which is achieved by nucleoside 
transporters, or through the inhibition of nucleoside phosphorylation by nucleoside kinases. To 
determine the level at which JNK-IN-8 is active, we determined the effects of JNK-IN-8 upon 
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the uptake of a panel of 3H-labeled purine (dA, dG) and pyrimidine nucleosides (rU, dC) in 
MIAPACA2 cells. These nucleosides rely upon the same nucleoside transporters to enter the cell 
but  require  unique  kinases  for  conversion  into  their  respective  monophosphate  forms  and 
intracellular accumulation. UCKs are required for the phosphorylation of rU while deoxycytidine 
kinase  (dCK)  is  required  for  the  phosphorylation  of  both  purine  and  pyrimidine 
deoxyribonucleosides including dC, dA, and dG (Figure 2.2A).2 
Figure 2.2 | JNK-IN-8 inhibits nucleoside uptake. (A) Uridine salvage pathway activity can be 
prevented  by  inhibition  of  either  nucleoside  transporters  or  kinases.  (B)  Uptake  of  [3H]rU, 
[3H]dC, [3H]dA (+10 µM dCF) and [3H]dG (+1 µM BCX-1777) in MIAPACA2 cells following 
2 hr incubation ± 1 µM JNK-IN-8 or 1 µM dipyridamole (DPA; 18.5 kBq; mean±SD; n=3; one-
way ANOVA corrected for  multiple  comparisons  by Bonferroni  adjustment;  ** P<0.01;  *** 
P<0.001; **** P<0.0001).
We found that JNK-IN-8 prevented the uptake of all nucleosides tested, but exhibited 
greater potency toward rU and dC. Importantly, JNK-IN-8 exhibits a selectivity pattern similar to 
the established ENT1 inhibitor DPA (Figure 2.2B). We confirmed JNK-IN-8 inhibited the uptake 
of both rU and dC with similar potency (33 nM and 31 nM, respectively), further suggesting that 
the compound inhibits nucleoside transport (Figure S2.4C). Additionally, JNK-IN-8 treatment 
prevented  the  anti-proliferative  effects  of  gemcitabine  (dFdC),  a  dCK-dependent  nucleoside 
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by nucleoside kinases. To determine the level at which JNK-IN-8
is active, we determined the effects of JNK-IN-8 on the uptake of
a panel of [3H]-labeled purine (dA, dG) and pyrimidine nucleo-
sides (rU, dC) in MIAPACA2 cells. These nucleosides rely upon
the same nucleoside transporters to enter the cell but require
unique kinases for conversion into their respective monophos-
phate forms and intracellular accumulation. UCKs are required
for the phosphorylation of rU while deoxycytidine kinase (dCK)
is required for the phosphorylation of both purine and pyrimidine
deoxyribonucleosides including dC, dA, and dG (Figure 2A) (Le
et al., 2017). We found that JNK-IN-8 prevented the uptake of
all nucleosides tested, but exhibited greater potency toward rU
and dC. Importantly, JNK-IN-8 exhibits a selectivity pattern
similar to the established ENT1 inhibitor DPA (Figure 2B). We
confirmed JNK-IN-8 inhibited the uptake of both rU and dC
with similar potency (33 and 31 nM, respectively), further sug-
gesting that the compound inhibits nucleoside transport (Fig-
ure S4C). In addition, JNK-IN-8 treat ent prevented the anti-
proliferative effects of gemcitabine (dFdC), a dCK-dependent
nucleoside analog prodrug which relies upon nucleoside trans-
porters for its activation, in a dose-dependent manner (Fig-
ure S4D) (Mackey et al., 1998). A similar pattern of dA, dG, rU,
and dC uptake inhibition by JNK-IN-8 and DPA was observed
in a second cell line, the murine pancreatic cancer model
KP4662 (Figures S4E and S4F) (Byrne et al., 2016).
Seven nucleoside transporters have been described and cate-
gorized into two families. Concentrative nucleoside transporters
(CNT1-3; SLC28A1-3) are unidirectional inward transporters that
co-transport Na+. Equilibrative nucleoside transporters (ENT1-4;
SLC29A1-4) are bidirectional, energy-independent, and accept
a broad range of purine and pyrimidine nucleosides (Young
et al., 2013). We evaluated the expression of these transporters
in MIAPACA2 and JURKAT cells and found that ENT1 (SLC29A1)
is the predominantly expressed transporter in both models (Fig-
ure S4G) (Fernandez-Banet et al., 2016). ENT1 is an established
transporter of a variety of nucleosides including natural purine
and pyrimidine nucleosides as well as therapeutic analogs
such as dFdC (Young et al., 2013). We next utilized the cellular
thermal shift assay (CETSA), an approach that leverages the
altered thermostability of proteins following ligand binding, to
confirm ENT1 engagement by JNK-IN-8 (Figure S4H) (Martinez
Molina and Nordlund, 2016). Collectively, these results suggest
that JNK-IN-8 inhibits UMP-NSP activity by interfering with the
transport of rU.
OSU-03012 and TAK-632 Target De Novo UMP
Biosynthesis and Activate the DNA Replication Stress
Response Pathway
Two protein kinase inhibitors, TAK-632 and OSU-03012, were
identified as potent and selective inhibitors of MIAPACA2 prolif-
eration in the DNP-only culture condition (Figure 1E). We
reasoned that these compounds could restrict pyrimidine
biosynthesis by targeting CAD, DHODH, or UMPS–the three
enzymes essential for de novo UMP biosynthesis (Figure 3A).
In MIAPACA2 cell cultur d in he DNP-only conditi n both
OSU-03012 and TAK-632 induced S-phase arrest, a phenotype
associated with dNTP biosynthesis levels insufficient to sustain
DNA replication and is the result of activation of intra-S-phase
cell-cycle signaling checkpoints (Figure 3B). This effect was
rescued by orotate (the product of DHODH) supplementation
and completely reversed by rU supplementation (Figures 3B
and 3C). These data implicated DHODH as a likely target of
both OSU-03012 and TAK-632. DHODH catalyzes one of three
committed steps within the DNP and is an established druggable
protein (Madak et al., 2019). In addition, both OSU-03012 and
TAK-632 possess fluorine substituents, which have been shown
to stabilize bioactive conformations of DHODH inhibitors (Bo-
nomo et al., 2013; Baumgartner et al., 2006). In an in vitro color-
imetric recombinant humanDHODH activity assay, TAK-632 and
OSU-03012 both inhibited DHODH activity in a dose-dependent
manner (Figure 3D) (Baumgartner et al., 2006). Importantly, the
response to TAK-632 or OSU-03012 correlated with the
response to a knownDHODH inhibitor in a panel of 25 pancreatic
cancer cell lines (Figure 3E).
OSU-03012 was recently reported to synergize with replica-
tion stress response kinase inhibitors in RSK-subtype mutant
KRAS cancer models (Yuan et al., 2018). However, after confirm-
ing that OSU-03012 binds DHODH, we hypothesized that the
observed synergy resulted from DHODH inhibition rather than
PDK1 inhibition. Immunoblot analysis of S6K and S6 phosphor-
ylation, PDK1 downstream targets, confirmed that GSK-
2334470, a known PDK1 inhibitor, potently blocked PDK1 while
OSU-03012 triggered S345 CHEK1 phosphorylation, a replica-
tion stress biomarker, only in the absence of rU (Figure 3F).
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Figure 2. JNK-IN-8 Inhibits Nucleoside Uptake
(A) Uridine salvage pathway activity can be prevented by inhibition of either nucleoside transporters or kinases.
(B) Uptake of [3H]rU, [3H]dC, [3H]dA (+ 10 mM dCF), and [3H]dG (+ 1 mM BCX-1777) in MIAPACA2 cells following 2 h incubation ± 1 mM JNK-IN-8 or 1 mM di-
pyridamole (DPA) (18.5 kBq; mean ± SD; n = 3; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment; **p < 0.01, ***p < 0.001,
****p < 0.0001).
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analog prodrug which relies upon nucleoside transporters for its activation, in a dose-dependent 
manner (Figure S2.4D).22 A similar pattern of dA, dG, rU and dC uptake inhibition by JNK-
IN-8 and DPA was observed in a second cell line, the murine pancreatic cancer model KP4662 
(Figures S2.4E, S2.4F).23
Seven nucleoside transporters have been described and categorized into two families. 
Concentrative  nucleoside  transporters  (CNT1-3;  SLC28A1-3)  are  unidirectional  inward 
transporters  which  co-transport  Na+.  Equilibrative  nucleoside  transporters  (ENT1-4; 
SLC29A1-4)  are  bidirectional,  energy-independent,  and  accept  a  broad  range  of  purine  and 
pyrimidine  nucleosides  and  nucleoside  analogs.24  We  evaluated  the  expression  of  these 
transporters  in  MIAPACA2  and  JURKAT  cells  and  found  that  ENT1  (SLC29A1)  is  the 
predominantly expressed transporter in both models (Figure S2.4G).25 ENT1 is an established 
transporter  of  a  variety  of  nucleosides  including natural  purines  and pyrimidines  as  well  as 
therapeutic  analogs  such  as  gemcitabine.24  We  next  utilized  a  cellular  thermal  shift  assay 
(CETSA), an approach that leverages the altered thermostability of proteins following ligand 
binding, to confirm ENT1 engagement by JNK-IN-8 (Figure S2.4H).26 The assay showed that 
upon  incubation  with  JNK-IN-8,  ENT1  demonstrated  increased  thermostability,  relative  to 
incubation with vehicle only. Collectively, these results indicate that JNK-IN-8 inhibits UMP-
NSP activity by blocking ENT1 and interfering with the transport of rU.
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2.4  OSU-03012 and TAK-632 Target  de novo  UMP Biosynthesis  and Activate  the  DNA 
Replication Response Pathway
Two protein kinase inhibitors, TAK-632 and OSU-03012, were identified as potent and 
selective  inhibitors  of  MIAPACA2  proliferation  in  the  DNP-only  culture  condition  (Figure 
2.1E).  We reasoned that  these  compounds could inhibit  de novo  pyrimidine biosynthesis  by 
targeting either CAD, DHODH, or UMPS – the three enzymes essential for the six-step de novo 
biosynthesis of UMP (Figure 2.3A). Both OSU-03012 and TAK-632 induced S-phase arrest in 
MIAPACA2  cells  cultured  in  the  DNP-only  condition  (Figure  2.3B).  S-phase  arrest  is  a 
phenotype associated with dNTP biosynthesis levels insufficient to sustain DNA replication, and 
is  the  result  of  activation  of  intra-S-phase  cell  cycle  signaling  checkpoints.  This  effect  was 
rescued by orotate (the product of DHODH) supplementation and could be completely reversed 
by rU supplementation (Figures 2.3B, 2.3C). These data implicated DHODH as a likely target of 
both OSU-03012 and TAK-632.  DHODH catalyzes one of  three committed steps within the 
UMP-DNP and is an established druggable protein.7 In addition, both OSU-03012 and TAK-632 
possess fluorine substituents,  which have been shown to stabilize bioactive conformations of 
DHODH inhibitors  within  the  ubiquinone transport  tunnel  of  the  protein.27,28  In  an in  vitro 
colorimetric  recombinant  human  DHODH  activity  assay,  TAK-632  and  OSU-03012  both 
inhibited  DHODH  activity  in  a  dose-dependent  manner  (Figure  2.3D).28  Additionally,  the 
response to TAK-632 or OSU-03012 correlated with the response to a known DHODH inhibitor 
in a panel of 25 pancreatic cancer cell lines (Figure 2.3E).
OSU-03012 was recently reported to synergize with replication stress response kinase 
inhibitors  in  RSK-subtype  mutant  KRAS  cancer  models.29  However,  after  confirming  that 
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OSU-03012 binds DHODH, we hypothesized that the observed synergy resulted from DHODH 
inhibition rather than from inhibition of PDK1, the canonical target of OSU-03012. Immunoblot 
analysis of S6K and S6 phosphorylation, PDK1 downstream targets, confirmed that the known 
PDK1  inhibitor  GSK-2334470  potently  blocked  PDK1  while  OSU-03012  triggered  S345 
CHEK1 phosphorylation, a replication stress biomarker, only in the absence of rU (Figure 2.3F). 
Similarly, TAK-632 only triggered CHEK1 phosphorylation in the absence of rU whereas an 
established pan-RAF inhibitor which does not exhibit paradoxical RAF activation, LY3009120, 
down-regulated ERK1/2 phosphorylation but had no impact on CHEK1 phosphorylation (Figure 
2.3G).30  Consistently,  we found that  neither  GSK-2334470 nor  LY3009120 induced S-phase 
arrest at doses where we observed down-regulation of their target substrates, whereas a known 
DHODH inhibitor induced potent  S-phase accumulation that  was completely reversed by rU 
supplementation (Figures S2.4I, S2.4J). 
To complement our evaluation of replication stress response biomarker induction,  we 
performed an  assessment  of  DNA damage induced by  OSU-03012,  TAK-632,  and  the  ATR 
inhibitor  VE-822 as  a  positive control  using γ-H2A.X flow cytometry.  We found that  while 
OSU-03012  and  TAK-632  trigger  activation  of  the  replication  stress  response,  they  do  not 
significantly induce γ-H2A.X. We hypothesize that activation of the replication stress response 
pathway  by  OSU-03012  or  TAK-632  limits  DNA double-strand  breaks  by  preventing  the 
collapse of stalled replication forks (Figure S2.4K).31
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Figure 2.3 | OSU-03012 and TAK-632 inhibit DHODH and activate the DNA replication 
stress  response pathway.  (A)  Schematic  of  UMP biosynthesis  via  the de novo  and salvage 
pathways. (B) Propidium iodide cell cycle analysis of MIAPACA2 PDAC cells treated ± 5 µM 
TAK-632 or ± 5 µM OSU-03012 and supplemented with 50 µM orotate (OA) or 10 µM rU 
(N.S.: no supplement). Insert indicates % S-phase cells. (C) Summary of fold changes in S-phase 
cells  from  B  (mean±SD;  n=2;  one-way  ANOVA  corrected  for  multiple  comparisons  by 
Bonferroni adjustment, ns: not significant; * P<0.05; ** P<0.01). (D) in vitro DHODH enzyme 
assay performed in the presence of OSU-03012 or TAK-632. (E) Correlation between DHODH 
inhibitor (1 µM NITD-982) and OSU-03012 (3.17 µM) or TAK-632 (3.17 µM) response across a 
panel  of  25  PDAC  cell  lines  determined  using  CTG  following  72  hr  treatment.  Response 
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Similarly, TAK-632 only triggered CHEK1 phosphorylation in the
absence of rU, whereas an established pan-RAF inhibitor,
LY3009120, which does not trigger paradoxical RAF activation,
downregulated ERK1/2 phosphorylation but had no impact on
CHEK1 phosphorylation (Figure 3G) (Peng et al., 2015). Consis-
tently, we found that neither GSK-2334470 nor LY3009120
induced S-phase arrest at doses where we observed downregu-
lation of their target substrates, whereas a known DHODH inhib-
itor induced potent S-phase accumulation that was completely
reversed by rU supplementation (Figures S4I and S4J). To com-
plement our evaluation of replication stress response biomarker
induction we performed an assessment of DNA damag induced
byOSU-03012, TAK-632, and the ATR inhibitor VE-822 as a pos-
itive control using g-H2A.X flow cytometry. We found that while
OSU-03012 and TAK-632 trigger activation of the replication
stress response, they do not significantly induce g-H2A.X. We
hypothesize that activation of the replication stress response
pathway by OSU-03012 or TAK-632 limits DNA double-strand
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Figure 3. OSU-03012 and TAK-632 Inhibit DHODH and Activate the DNA Replication Stress Response Pathway
(A) Schematic of UMP biosynthesis via de novo and salvage pathways.
(B) Propidium iodide cell-cycle analysis of MIAPACA2 PDAC cells treated ± 5 mM TAK-632 or ± 5 mM OSU-03012 and supplemented with 50 mM orotate (OA) or
10 mM rU (N.S., no supplement). Insert indicates percent of S-phase cells.
(C) Summary of fold changes in S-phase cells from (B) (mean ± SD; n = 2; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment, ns, not
significant; *p < 0.05, **p < 0.01).
(D) In vitro DHODH enzyme assay performed in the presence of OSU-03012 or TAK-632.
(E) Correlation between DHODH inhibitor (1 mM NITD-982) and OSU-03012 (3.17 mM) or TAK-632 (3.17 mM) response across a panel of 25 PDAC cell lines
determined using CTG following 72 h treatment. Response calculated as doubling time normalized proliferation inhibition. Pearson correlation coefficient is
indicated.
(F) Immunoblot analysis of MIAPACA2 cells treated ± 1 mM PDK1 inhibitor GSK-2334470 (GSK) ±1 mM OSU-03012 (OSU) ± 10 mM rU for 24 h.
(G) Immunoblot analysis of MIAPACA2 cells treated ± 10 mM RAF inhibitor LY3009120 (LY) ± 10 mM TAK-632 (TAK) ± 10 mM rU for 24 h.
(H) Annexin V/PI flow cyto etry analysis of MIAPACA2 PDAC cells treated ± 1 mM OSU-03012 (OSU) or 1 mM GSK-2334470 (GSK) ± 500 nM VE-822 (ATRi) ±
25 mM rU for 72 h (mean ± SD; n = 2; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment; ns, not significant; **p < 0.01, ***p < 0.001).
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calculated as doubling time normalized proliferation inhibition. Pearson correlation coefficient is 
indicated.  (F)  Immunoblot  analysis  of  MIAPACA2  cells  treated  ±  1  µM  PDK1  inhibitor 
GSK-2334470 (GSK)  ±  1  µM OSU-03012 (OSU)  ±  10  µM rU for  24  h.  (G)  Immunoblot 
analysis  of  MIAPACA2  cells  treated  ±  10  µM  RAF  inhibitor  LY3009120  (LY)  ±  10  µM 
TAK-632  (TAK)  ±  10  µM  rU  for  24  h.  (H)  Annexin  V/PI  flow  cytometry  analysis  of 
MIAPACA2 PDAC cells treated ± 1 µM OSU-03012 or 1 µM GSK-2334470 (GSK) ± 500 nM 
VE-822 (ATRi) ± 25 µM rU for 72 hr (mean ± SD; n=2; one-way ANOVA corrected for multiple 
comparisons by Bonferroni adjustment; ns: not significant; ** P<0.01; *** P<0.001).
To  investigate  the  interaction  between  OSU-03012  and  replication  stress  response 
inhibitors, we treated MIAPACA2 cells with VE-822, an inhibitor of the proximal replication 
stress response kinase ATR, and either OSU-03012 or GSK-2334470 for 72 hr. A synergistic 
increase in cell death was observed when OSU-03012 and the ATR inhibitor were combined, 
whereas the combination of  potent  PDK1 inhibitor  GSK-2334470 and VE-822 demonstrated 
only a nominal increase in cell death as determined by AnnexinV/PI flow cytometry (Figure 
2.3H). Taken together, these data indicate that replication stress triggered by OSU-03012 is the 
consequence of DHODH inhibition rather than inhibition of its canonical target PDK1.
2.5 Co-Crystal Structures of OSU-03012 and TAK-632 in Complex with Human DHODH
 To determine the molecular interactions between the protein and its putative inhibitors, 
complete DHODH co-crystallization data sets were obtained and processed to 1.4 Å and 2.7 Å 
for  OSU-03012  and  TAK-632,  respectively  (Table  S2.1).28  Both  compounds  bind  in  a 
hydrophobic channel composed by two N-domain α-helices through which ubiquinone travels, a 
mechanism consistent  with  previously  identified  DHODH inhibitors.  A long-range  hydrogen 
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bond between Arg 69 and OSU-03012 helps  orient  the molecule  to  the hydrophobic  pocket 
where the phenanthrene moiety inserts, while the remainder of the molecule lies on the outer 
surface of DHODH, blocking the hydrophobic channel (Figures 2.4A, S2.4A). Three hydrogen 
bonds stabilize TAK-632 in the same hydrophobic pocket: two with Tyr 37 and Leu 66 help 
stabilize the inhibitor at the opening of the channel, while a third with Gln 46 helps pull the 
inhibitor deep into the pocket (Figures 42.B, S2.4B).
Figure 2.4 | OSU-03012 and TAK-632 bind DHODH. (A, B) Crystal Structure of DHODH 
with compounds OSU-03012 (A) or TAK-632 (B). 2mFo-DFc electron density for OSU-03012 
(carbons  in  yellow)  or  TAK-632  (carbons  in  green)  contoured  at  1  σ.  Dashed  black  lines 
represent hydrogen bonds between DHODH and its ligands. Interacting residues as predicted by 
LigPlot+ are shown and labeled. 
2.6 Discussion
Our screening strategy expands upon previously described “nutrient-sensitized” genetic 
and  small  molecule  cell-based  screening  approaches  that  leveraged  the  production  of  a 
proliferation-enabling  metabolite  by  parallel  and  redundant  metabolic  networks  to  identify 
selective metabolism modifiers.32,33 UMP biosynthesis (i.e. pyrimidine metabolism) proved to be 
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breaks by preventing the collapse of stalled replication forks
(Figure S4K) (Zeman and Cimprich, 2014).
To investigate the interactions between DHODH, PDK1 and
replication stress response inhibitors, we treated MIAPACA2
cells with VE-822 (Le et al., 2017), an inhibitor of the replication
stress response kinase ataxia telangiectasia and Rad3-
related (ATR), and either OSU-03012 or GSK-2334470 for 72 h.
A synergistic increase in apoptotic cells was observed when
OSU-03012 and an ATR inhibitor were combined, whereas the
combination of GSK-2334470 and VE-822 demonstrated only
a nominal increase as determined by annexin V/propi ium iodide
(PI) flow cytometry (Figure 3H). Taken together, these data sug-
gest that replication stress trigger d byOSU-03012 is the conse-
quence of DHODH inhibition rather than inhibition of its canonical
target.
Co-crystal Structures of OSU-03012 and TAK-632 in
Complex with Human DHODH
To determine the molecular interactions between DHODH and
its putative inhibitors, complete co-crystallization datasets
were obtained and processed to 1.4 and 2.7 A˚ for OSU-03012
and TAK-632, respectively (Table S1). Both compounds bind in
a hydrophobic channel composed by two N-domain a helices
through which ubiquinone travels, a mechanism consistent
with previously identified DHODH inhibitors (Baumgartner
et al., 2006). A long-range hydrogen bond between Arg 69 and
OSU-03012 helps orient themolecule to the hydrophobic pocket
where the phenanthrene moiety inserts, while the remainder of
the molecule lies on the outer surface of DHODH, blocking the
hydrophobic channel (Figure 4A) (PDB: 6OC0). Three hydrogen
bonds stabilize TAK-632 in the same hydrophobic pocket: two
with Tyr 37 and Leu 66 help stabilize the inhibitor at the opening
of the channel, while a third with Gln 46 helps pull the inhibitor
deep into the pocket (Figure 4B) (PDB: 6OC1).
DISCUSSION
Our screening strategy expands upon previously described
‘‘nutrient-sensitized’’ genetic and small-molecule cell-based
screening approaches which leveraged the production of a pro-
liferation-enabling metabolite by parallel and redundant meta-
bolic networks to identify selective metabolismmodifiers (Arroyo
et al., 2016; Gohil et al., 2010). UMP biosynthesis (i.e., pyrimidine
metabolism) proved to be compatible with this screening frame-
work as UMP is produced by convergent (de novo and salvage)
pathways, and UMP depletion triggers a quantifiable change in
cellular proliferation.
JNK-IN-8, developed as an irreversible inhibitor of c-Jun
N-terminal kinases 1, 2, and 3 with low-nanomolar affinity, was
the most potent of three uridine salvage inhibitors identified
(Zhang et al., 2012). Our data demonstrate that JNK-IN-8 also
fun tions as potent inhibitor of uridine and deoxycytidine trans-
port and engages the nucleoside transporter ENT1 (SLC29A1).
We conclude that JNK-IN-8 should not be used in conjunction
with compounds which rely upon nucleoside transport, such
as the anticancer agent gemcitabine, in research or therapy
s tt ngs.
In addition to their role in pyrimidine salvage, equilibrative
nucleoside transporters are well studied for their ability to regu-
late levels of the immuno-modulatory metabolite adenosine.
ENT1 inhibitors increase extracellular adenosine levels that
signal through the P1 purinergic receptor and are used clinically
for the treatment of hypertension, among other disorders (Young
et al., 2013). Thus, the development of potent and selective in-
hibitors of ENT1 is an active area of investigation.
The recently reported co-crystal structure of ENT1 in complex
with two small-molecule inhibitors (NBMPR and dilazep) pro-
vided new insight into the molecular mechanism of nucleoside
transport and suggested that structurally diverse ENT1 inhibitors
possess unique modes of inhibition (Wright and Lee, 2019).
ENT1 contains ten cysteine residues and ENT1-mediated uridine
transport can be inhibited by covalent modification of Cys416 by
N-ethylmaleimide (Yao et al., 2018). Intriguingly, the two highest-
scoring NSP inhibitors in our screen, JNK-IN-8 and the BTK in-
hibitor CNX-774, each contain a reactive acrylamide group and
are cysteine-targeting drugs. Future work will explore the mech-
anism of ENT1 inhibition by JNK-IN-8 with a specific focus on the
contribution of covalent interactions.
Figure 4. OSU-03012 and TAK-632 bind DHODH
Crystal Structure of DHODHwith compoundsOSU-03012 (A) or TAK-632 (B). 2mFo-DFc electron density for OSU-03012 (carbons in yellow) or TAK-632 (carbons
in green) contoured at 1s. Dashed black lines represent hydrogen bonds between DHODH and its ligands. Interacting residues as predicted by LigPlot+ are
shown and labeled.
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compatible with this screening framework, as UMP is produced by convergent (de novo  and 
salvage) pathways, and UMP depletion triggers a quantifiable change in cellular proliferation.
JNK-IN-8, developed as an irreversible inhibitor of c-Jun N-terminal kinases 1, 2, and 3 
with low-nanomolar affinity, was the most potent of three uridine salvage inhibitors identified in 
our study.34 Our data confirm that JNK-IN-8 also functions as a potent inhibitor of uridine and 
deoxycytidine transport and engages the nucleoside transporter SLC29A1 (ENT1). We conclude 
that JNK-IN-8 should not be used in conjunction with compounds which rely upon nucleoside 
transport, such as the anticancer agent gemcitabine, in research or therapy settings. JNK-IN-8 
was synthesized by the Gray group at  the Dana Farber  Cancer  Institute  as  part  of  series  of 
molecules for targeting JNK. We have started a collaboration with their group and are currently 
identifying additional compounds within their chemical library which possess ENT1-inhibiting 
ability. 
In addition to their role in pyrimidine salvage, equilibrative nucleoside transporters are 
well studied for their ability to regulate levels of the immuno-modulatory metabolite adenosine. 
ENT1 inhibitors increase extracellular adenosine levels which signal through the P1 purinergic 
receptor  and  are  used  clinically  for  the  treatment  of  hypertension,  among other  disorders.35 
ENT1 inhibitors have been shown to increase vasodilation and can exert cardioprotective effects 
upon ischemic cardiovascular tissue.34 Additionally, due to the immunosuppressive effects of 
increased  extracellular  adenosine  levels,  ENT1  inhibitors  could  find  utility  in  mitigating 
excessive  late-stage  immune  responses  which  contribute  to  dangerous  pathology  related  to 
cytokine  storms  and  acute  respiratory  distress  syndrome.  Given  the  prevalence  of  these 
conditions in influence and the current COVID-19 pandemics, these therapeutic considerations 
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are particularly intriguing.34  Thus, the development of potent and selective inhibitors of ENT1 is 
an active area of investigation with opportunity for clinical application.
The  recently  reported  co-crystal  structure  of  ENT1  in  complex  with  two  small 
molecule inhibitors (NBMPR and dilazep) provided new insight into the molecular mechanism 
of nucleoside transport and suggested that structurally diverse ENT1 inhibitors possess unique 
modes of inhibition.36 ENT1 contains ten cysteine residues and ENT1-mediated uridine transport 
can be inhibited by covalent modification of Cys416 by N-ethylmaleimide.37 Intriguingly, the 
two highest scoring NSP inhibitors in our screen, JNK-IN-8 and the BTK inhibitor CNX-774, 
both contain a  reactive acrylamide group and are  cysteine-targeting drugs.  Future work will 
explore  the  mechanism  of  ENT1  inhibition  by  JNK-IN-8  with  a  specific  focus  on  the 
contribution  of  covalent  interactions,  with  additional  efforts  focused  upon  decoupling  JNK 
affinity from ENT1 inhibition. 
Positron  emission  tomography  (PET)  imaging  is  a  powerful  approach  to  monitor 
cellular metabolism in vivo, and several nucleoside analog PET probes have been developed 
including  both  pyrimidine  ([18F]FAC,  [18F]FLT)  and  purine  analogs  ([18F]CFA).38–40 
Interestingly,  ENT1-knockout  mice  exhibit  significantly  higher  plasma  thymidine  but  also 
paradoxically higher levels of thymidine analog [18F]FLT uptake in the spleen and bone marrow 
compared to wild type controls.41 Discrepancies between in vitro and in vivo  findings could 
result from shifts in nucleoside gradients or differential expression of nucleoside transporters 
mediated  by factors  absent  from traditional  cell  culture  systems.  Future  work will  focus  on 
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exploring  the  utility  of  nucleoside  analog  PET as  a  pharmacodynamic  biomarker  for  ENT 
inhibitor activity in vivo.
The structurally and functionally unrelated OSU-03012 and TAK-632 were identified 
as inhibitors of the pyrimidine DNP. A recent report described the ability of OSU-03012 and 
analogs  to  inhibit  virus  propagation  via  pyrimidine  nucleotide  biosynthesis  inhibition, 
specifically implicating modulation of DHODH activity.42 Our work substantiates these findings 
and confirms engagement of  DHODH by OSU-03012 and TAK-632 through crystallography 
studies. Notably, our studies show that OSU-03012 and TAK-632 bind in the same hydrophobic 
tunnel of DHODH as known inhibitors brequinar and teriflunomide (the active metabolite of 
leflunomide). This suggests that these two protein kinase inhibitors compete with ubiquinone, a 
redox partner  of  DHODH which traverses  this  hydrophobic tunnel  to  regenerate  FMN from 
FMNH2.  By  competitively  inhibiting  the  binding  of  ubiquinone,  these  compounds  prevent 
DHODH from completing its redox cycle and effectively abrogate its activity. 
OSU-03012  has  orphan  drug  designation  in  the  European  Union  for  treatment  of 
tularaemia and cryptococcosis. We hypothesize that its effectiveness in these indications stems 
from its ability to inhibit DHODH, rather than from ‘on-target’ effects against PDK1. Indeed, 
DHODH  inhibitors  have  demonstrated  efficacy  against  viruses  such  as  dengue  virus  and 
respiratory syncytial virus.11,42,43 Our results should encourage the further study and application 
of  OSU-03012,  and  DHODH  inhibitors  in  general,  in  antimicrobial  therapy.  In  anticancer 
settings, OSU-03012 was recently demonstrated to synergize with CHK1 inhibitors in KRAS-
mutant cancers,29 which was initially attributed to its ability to inhibit PDK1. However, our data 
show  that  GSK-2334470,  a  PDK1  inhibitor  more  potent  than  OSU-03012,  displayed  little 
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synergy with ATR inhibition. In light of this and our crystallographic data, we conclude that the 
synergy observed between OSU-03012 and ATR inhibition is likely a result of the DHODH-
inhibitory ability of the former. Taken together, our data suggest that DHODH inhibitors may 
have utility in oncology, particularly if used in conjunction with ATR inhibitors or other DNA-
damage response/replication stress response pathway inhibitors.2
While a small  library of 430 protein kinase inhibitors was assessed in this study, the 
design of our screen allows for much larger high-throughput screening campaigns which could 
be utilized for identification of hit compounds with the ability to modulate pyrimidine nucleotide 
metabolism. This may be beneficial for research groups or pharmaceutical companies who wish 
to  screen  small-molecule  libraries  to  identify  new  hit  compounds,  or  could  be  used  to 
characterize  the  “off-target”  effects  of  existing  drugs.  The  utility  of  characterizing  a  drug’s 
effects  upon  pyrimidine  nucleotide  metabolism  is  high,  as  off-target  effects  within  these 
pathways  can  lead  to  misattribution  of  beneficial  activities.  This  is  demonstrated  by  the 
attribution of OSU-03012-mediated PDK1 inhibition as synergizing with CHK1 inhibition – this 
conclusion was made without the knowledge of the DHODH-inhibiting ability of OSU-03012, 
and could have led researchers to spend precious resources studying this supposed link. 
In  summary,  we  designed  and  applied  a  metabolic  modifier  screen  which  identified 
multiple protein kinase inhibitors as having non-canonical targets within pyrimidine metabolism. 
Similarly constructed phenotypic screens designed against other metabolic networks containing 
convergent nodes may find use in drug discovery campaigns or in repurposing screens using 
existing compounds.
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2.7 Experimental Section
2.7.1 Methods and Materials
Cell culture
All cell cultures were between passages 3 and 20 and maintained in antibiotic free DMEM or 
RPMI  +10%  dialyzed  FBS,  at  37ºC  in  5%  CO2.  We  routinely  monitored  for  mycoplasma 
contamination  using  the  PCR-based  Venor  Mycoplasma kit.  PDAC cell  lines  were  acquired 
either  from a  commercial  vendor  (ATCC,  DSMZ)  or  from collaborators  (KP4662  from Dr. 
Vonderheide, UPenn). Cell line identity was independently authenticated by PCR.
Drugs
Drug  stocks  were  prepared  in  DMSO  or  H2O  and  diluted  fresh  in  cell  culture  media  for 
treatments.  NITD-98243  and  N-phosphonacetyl-L-aspartate  (PALA)44  were  synthesized  as 
previously described.
In vivo mouse studies
All animal studies were approved by the UCLA Animal Research Committee (ARC). 4-6 week-
old  male  NCG  mice  obtained  from  Charles  River  Laboratories  (CRL 572),  were  injected 
subcutaneously  in  the  flank  with  2x106  CCRF-CEM  cells  suspended  in  100  µL  1:1  in 
PBS:matrigel.  4-6 week-old male C57BL/6 mice,  obtained from UCLA Radiation Oncology, 
were injected subcutaneously on bilateral flanks with 0.3x106 KP4662 cells suspended in 100 µL 
PBS. 14 days following inoculation treatment was initiated. JNK-IN-8 was suspended in 2% 
ethanol and 5% Tween-80 in PBS and administered by intraperitoneal (i.p.) injection at 50 mg/
kg.
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Method Details
Protein kinase inhibitor phenotypic screen
A library of 430 protein kinase inhibitors was arrayed in polypropylene 384-well plates at 200x 
concentrations covering a 7-point concentration range (corresponding to 1x concentrations: 5 
µM, 1.65 µM, 550 nM, 185 nM, 61.5 nM, 20.6 nM, 6.85 nM). 25 µl per well of condition-
specific growth media (DNP + NSP: media + 10 µM rU; DNP: media alone; NSP: media +10 
µM rU + 1 µM NITD-982) was plated in opaque-white 384-well plates using a BioTek multidrop 
liquid handler. Protein kinase inhibitors were added by 250 nL pin-tool transfer (BioMek FX, 
Beckman-Coulter) and inhibitor/media mixtures were incubated at room temperature for 30 m. 
25 µL of a 40,000 cells/mL MIAPACA2 suspension (for 1000 cells / well) was subsequently 
added to each well. After 72 h, 50 µL of Cell Titer Glo reagent diluted 1:4 in deionized H2O was 
added to each well and luminescence was measured using a Wallac plate reader (Perkin Elmer). 
Each condition was assayed in duplicate (n=2) and % proliferation values were calculated by 
normalizing  experimental  wells  to  plate  negative  controls  and  averaging  replicate  values. 
Composite pathway selectivity synergy scores for each test compound were defined as the sum 
of the excess over additivity (% proliferation inhibition observed - % proliferation inhibition 
expected)  between  individual  protein  kinase  inhibitor  concentrations  across  the  7-point 
concentration  range.  Z  factor  scores  for  individual  assay  plates  were  calculated  using  eight 
positive and eight negative control wells on each plate as previously described.16 All plates gave 
a Z factor > 0.5 (Figure S2.3C).
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Cell Titer Glo viability analysis
Cells were plated at 1x103 cells / well at 50 µl / well in white opaque 384-well plates and treated 
as described. Following incubation 50 µl of Cell Titer. Glo reagent (Diluted 1:5 in deionized 
H2O) was added to each well, plates incubated at room temperature for 5 min and luminescence 
was  measured using a  BioTek microplate  luminescence  reader.  Proliferation  rate  normalized 
growth inhibition was calculated using the previously described GR metric.13
Trypan blue exclusion cell viability
Trypan blue exclusion cell viability analysis was performed using a ViCell analyzer following 72 
hr of treatment. Trypan blue-negative population counts are reported.
Microplate immunofluorescence microscopy cell scoring
MIAPACA2 cells were plated at 1000 cells/well in black-walled clear-bottom 384 well plates in 
50 µL of media and treated as indicated with n=4 replicate wells per condition. After 72 hr of 
drug exposure 50 µL of 10 µg/mL Hoechst 33342 dye diluted in culture media was added to 
microplate  wells.  Following  a  30  min  incubation  at  37C  images  were  acquired  using  a 
ImageXpress Micro Confocal High-Content Imaging System at 10x magnification and 1 image/
well.  Analysis was performed using the Cell  Scoring Application Module  in the MetaXpress 
analysis software. Nuclei counts for treatment groups were normalized to control wells.
Mass spectrometry
For analysis of stable isotope-labeled metabolite incorporation into newly replicated DNA, cells 
were  cultured  in  glucose-free  DMEM (for  MIAPACA2 cells)  or  RPMI (for  JURKAT cells) 
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media supplemented with 10% dialyzed FBS, 4 mM glutamine, 1 g/L [13C6]glucose, 10 µM 
[13C9; 15N2]rU and treated as indicated.
Genomic DNA was extracted using the Quick-gDNA MiniPrep kit and hydrolyzed to nucleosides 
using the DNA Degradase Plus kit,  following manufacturer-supplied instructions. In the final 
step of DNA extraction, 50 μL of water was used to elute the DNA into 1.5 mL microcentrifuge 
tubes. A nuclease solution (5 μL; 10X buffer/DNA Degradase PlusTM/water, 2.5/1/1.5, v/v/v) 
was added to 20 μL of the eluted genomic DNA in an HPLC injector vial. The samples were 
incubated overnight at 37 ºC.
Hydrolyzed DNA was diluted 1/1 with solvent A (water/acetonitrile/formic acid, 95/5/0.1, v/v) 
and analyzed using a modified version of a previously reported method2,45 in which aliquots of 
the solution (15 µL) were injected onto a porous graphitic carbon column (Thermo Hypercarb, 
100 x 2.1 mm, 5 micron particle size) equilibrated in solvent A and eluted (300 µL/min) with an 
increasing  concentration  of  solvent  B  (acetonitrile/water/formic  acid,  90/10/0.1).  The  HPLC 
timetable, in terms of min/%B, is the following: 0/0, 5/0, 12/20, 15/30, 17/50, 19/50, 20/0, 24/0. 
The effluent from the column was directed to Agilent Jet Stream connected Agilent 6460 QQQ 
operating in the positive ion MRM mode. After verification of retention times using authentic 
standards, the peak areas of the protonated nucleoside/protonated base fragment ion transitions 
for each of the nucleosides were recorded with instrument manufacturer-supplied software.
3H-labeled metabolite uptake assays
Radioactive probe uptake assays were conducted as previously described.46 Briefly, cells were 
pretreated with JNK-IN-8 or DPA for 2 hr before incubation with 18.5 kBq of 3H-labeled probe 
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for 2 h. For purine uptake assays, cells were cultured in the presence of 10 µM dCF (for 3H-dA) 
or 1 µM BCX-1777 (for 3H-dG) to prevent nucleoside catabolism. Following incubation, cells 
were washed with PBS and lysed. Cell lysate radioactivity was measured using a beta-counter 
(Perkin-Elmer).
Flow cytometry
All  flow cytometry data  were acquired on five-laser  BD LSRII,  and analyzed using FlowJo 
software.
AnnexinV/PI: Treated PDAC cells were washed with PBS and incubated with AnnexinV and 
propidium iodide diluted in 1x Annexin binding buffer. 20,000 events were collected per sample.
Propidium  iodide  cell  cycle  analysis:  Treated  PDAC  cells  were  washed  with  PBS  and 
suspended in propidium iodide cell cycle staining solution (100 µg/ml propidium iodide; 20 µg/
ml Ribonuclease A). 10,000 events were collected per sample.
pH2A.XS139  flow cytometry:  Treated  cells  were  collected  by trypsinization,  incubated  with 
Cytofix/Cytoperm  reagent  for  15  min  at  4C,  washed  with  PBS  and  incubated  in  100  µL 
PermWash  buffer  for  15  min  at  4C.  Cells  were  washed  with  1  mL  Perm/Wash  buffer, 
resuspended  in  50  µL of  staining  solution  (1:800  dilution  of  FITC-conjugated  pH2AXS139 
antibody diluted in Perm/Wash buffer) and incubated for 20 min at 25C protected from light. 
Stained cells were washed and incubated in 500 µL of DAPI staining solution (1 µg/mL DAPI in 
PBS) before acquisition.
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Gene cloning, protein expression, and purification of DHODH in E.coli cells
P r i m e r s  w e r e  o r d e r e d  t o  a d d  N d e I 
(AGAGAACAGATTGGTGGTCATATGATGGCCACGGGAGATGAG) upstream of residue 29 
(after  the  mitochondrial  membrane  associated  loop)  and  BamHI 
(TCGGGCTTTGTTAGCAGCCGGATCCTTACCTCCGATGATCTGCTCC)  after  the  stop 
codon  to  insert  into  N-terminal  His-Sumo  pET 14b  vector.  This  clone,  His-Sumo-DHODH 
29-395 (subsequently referred to as DHODH) was successfully inserted into the vector in XL1-
blue cells for vector propagation.
The vector was transformed into C41(DE3) cells for productions. Cells were grown at 37 °C in 
2xYT medium supplemented with 100 μg/mL ampicillin (Amp), treated with 0.1 mM isopropyl 
β-D-1-thiogalactopyranoside  (IPTG)  at  an  OD600  nm  of  0.6-0.8,  and  then  cultured  for  an 
additional 18 hr at 18 °C.  Cells were harvested by centrifugation, washed with 200 mM NaCl 
and 25 mM Tris pH 7.5, and pelleted at 5000 rpm for 20 min before storage at -20°C. 6.7g/L of 
cell pellet was obtained.
DHODH  was  purified  according  to  known  purification  conditions.28  The  cell  pellet  was 
resuspended  in  lysis  buffer  (50  mM Tris  pH  7.5;  600  mM NaCl;  0.33% w/v  Thesit;  10% 
Glycerol; 1 mM PMSF) and lysed by sonication on ice. Lysed cells were centrifuged at 58,500 
RCF for 45 min at 4°C, and the supernatant was filtered through a 0.45 µM filter and loaded onto 
a 5-mL His-Trap column pre-equilibrated with buffer A (50 mM Tris pH 7.4; 600 mM NaCl; 
0.05% w/v Thesit; 10% Glycerol). The column was washed with buffer A for 70 mL, buffer A 
with 25 mM imidazole for 50 mL, and buffer A with 50 mM imidazole for 50 mL. The protein 
was eluted with buffer  A with 250 mM imidazole.  The eluted fraction was diluted 1:1 with 
Buffer A. Sumo protease was added and the protein was dialyzed overnight at 4°C against 1L of 
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Buffer A. The dialyzed protein was loaded back onto the His-Trap column equilibrated with 
buffer A. The cut-DHODH was eluted with buffer A with 50 mM imidazole. The purified protein 
was  concentrated  to  5  mL and  injected  onto  S-200  gel  filtration  column  (GE  Healthcare) 
equilibrated with: 50 mM HEPES pH 7.7, 400 mM NaCl, 10% Glycerol, 1mM EDTA, 0.05 % w/
v  Thesit.  Eluted  fractions  consistent  with  monomer  size  were  collected,  concentrated,  flash 
frozen, and stored at -80°C.
Recombinant DHODH enzyme assay
Evaluation of DHODH inhibition was performed as previously described.28 The standard assay 
mixture  contained  50  μM  decyclo-ubiquinone,  100  μM  dihydroorotate,  and  60  μM  2,6-
dichloroindophenol  (DCIP).  The amount  of  DHODH was 337.4 ng/mL. Measurements  were 
conducted in 50 mM TrisHCl, 150 mM KCl, 0.1% Triton X-100, pH 8.0, at 30 °C in a final 
volume  of  1  mL.  The  components  were  mixed,  and  the  reaction  was  started  by  adding 
dihydroorotate. The reaction was followed spectrophotometrically by measuring the decrease in 
absorption at  600 nm for  2.5 min at  30 second intervals.  The assay was linear  in  time and 
enzyme concentration.  Inhibitory studies were conducted in a standard assay with additional 
variable amounts of inhibitor.
Crystallization of DHODH with OSU-03012 and TAK-632 compounds
For  co-crystallizaion  of  DHODH  and  OSU-03012,  crystals  were  obtained  using  the  same 
conditions  reported  in  previously  published DHODH structures28,47–60,  namely  1.6  –  2.6  M 
ammonium sulfate and 5-30% glycerol in the well in pH 4.5, with 20 mg/mL DHODH with 2 
mM dihydroorotate (DHO),  20.8 mM dodecyldimethyl-N-amineoxide (DDAO), and 400 µM 
inhibitor.  Protein  was  mixed  1:1  with  mother  liquor  and  hanging  drops  were  used  at  room 
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temperature. Crystals appeared after 48 hr and reached maximal size within one week. Molecular 
replacement  used  4OQV  as  the  starting  model.61  Interestingly,  DHODH-TAK-632  crystals 
grown in similar conditions to those used for the DHODH-OSU-03012 complex did not show 
TAK-632 density. As a result,  novel DHODH crystallization conditions were identified using 
commercial screens. For co-crystallization of DHODH with TAK-632, crystals were obtained in 
conditions of 1.4-1.6 M sodium phosphate, pH 8.2. Protein solution (20 mg/mL DHODH with 2 
mM DHO, 20.8 mM DDAO, and 400 µM inhibitor) was mixed 1:1 with mother liquor and 
hanging  drops  were  used  at  room  temperature.  Crystals  appeared  after  48  hr  and  reached 
maximal  size  within  one  week.  The  lack  of  density  of  the  TAK-632 structure  in  the  initial 
crystallography condition is most likely due to the difference in pH between the conditions, pH 
4.5 and pH 8.2 for the OSU-03012 and the TAK-632 structure, respectively. There are multiple 
hydrogen bonds and potentially labile hydrogens on the TAK-632 structure that at low pH could 
be protonated and charged, potentially preventing their insertion into the hydrophobic tunnel. 
Ligplot+ was used to determine hydrophilic and hydrophobic interactions between inhibitors and 
DHODH molecules.62,63
Immunoblot analysis
PBS-washed cell pellets were resuspended in cold RIPA buffer supplemented with protease and 
phosphatase inhibitors. Protein lysates were normalized using BCA assay, diluted using RIPA 
and  4x  laemmli  loading  dye,  resolved  on  4-12%  Bis-Tris  gels  and  electro-transferred  to 
nitrocellulose membranes. After blocking with 5% nonfat milk in TBS + 0.1% Tween-20 (TBS-
T),  membranes  were  incubated  overnight  in  primary  antibodies  diluted  (per  manufacturers 
instructions) in 5% BSA in TBS-T. Membranes were washed with TBST-T and incubated with 
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HRP-linked secondary antibodies prepared at a 1:2500 dilution in 5% nonfat dry milk / TBS-T. 
HRP  was  activated  by  incubating  membranes  with  a  mixture  of  SuperSignal  Pico  and 
SuperSignal Femto ECL reagents (100:1 ratio). Exposure of autoradiography film was used for 
detection.
CETSA
MIAPACA2 cells  were  cultured  in  10  cm plates,  washed  with  PBS,  and  harvested  by  cell 
scraping following addition of 4 mL of lysis buffer (100 mM ammonium sulfate, 400 mM NaCl, 
10% glycerol, 0.5% DDM and 1x protease inhibitor cocktail). The cell lysate was collected in a 
15 mL conical tube, incubated on ice for 20 m, centrifuged at 5,000xg for 20 min at 4C and 
protein content of the supernatant was measured. 30 µL of protein lysate was aliquoted into 1.5 
mL Eppendorf tubes and treated with either DMSO, JNK-IN-8 or dipyridamole for 30 min on 
ice.  Lysates  were  subsequently  heated  at  the  indicated  temperatures  using  an  Eppendorf 
Thermomixer for 6 m, cooled to room temperature for 3 min and transferred to ice.  Heated 
lysates  were  centrifuged  at  12,000xg  for  40  min  to  pellet  the  insoluble  protein  fraction. 
Supernatants were processed for immunoblot analysis.
Statistical analyses
Data are presented as mean ± SD with number of biological replicates indicated. Comparisons of 
two groups were calculated using indicated unpaired two-tailed Student’s t-test and P values less 
than 0.05 were considered significant. Comparisons of more than two groups were calculated 
using one-way ANOVA followed by Bonferroni’s multiple comparison tests, and P values less 
than 0.05/m, where m is the total number of possible comparisons, were considered significant.  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2.8 Supplementary Figures
Figure S2.1 | Validation of UMP as a critical, convergent metabolic node in cancer cells. 
Related to Figure 2.1. (A) Schematic of CAD regulation by NSP produced UTP. (B) Schematic 
of the LC-MS/MS methodology used to determine the fractional contribution of UMP-DNP or -
NSP specific stable isotope-labeled metabolite tracers to deoxycytidine (dC) in DNA (DNA-C). 
(C) Total % DNA-C labeling ([13C6]glucose + [13C9; 15N2]uridine (rU) contribution) across a 
panel of cancer cell lines cultured for 24 hr determined by LC-MS/MS. (D) Relative contribution 
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Figure S1 | Validation of UMP as a critical, convergent metabolic node in cancer cells. Related to Figure 1. (A) Schematic of 
CAD regulation by NSP produced UTP. (B) Schematic of the LC-MS/MS methodology used to determine the fractional contribution of 
UMP-DNP or -NSP specific stable isotope-labeled metabolite tracers to deoxycytidine (dC) in DNA (DNA-C). (C) Total % DNA-C 
labeling ([13C6]glucose + [13C9; 15N2]uridine (rU) contribution) across a panel of cancer cell lines cultured for 24 h determined by LC-MS/
MS. (D) Relative contrib tion of DNP and NSP pathways to DNA biosynthesis as determined by LC-MS/MS following 24  treatment 
(n=3). % contribution values are normalized to total % labeling in E. (E) LC-MS/MS analysis DNP([13C6]glucose) and NSP([13C9; 
15N2]rU) contribution to DNA-C in JURKAT cells cultured for 24 h in media containing 5.5 mM [13C6]glucose and 10 µM [13C9; 15N2]rU 
treated ±1 µM NITD-982 or ±1 µM dipyridamole (DPA; mean±SD; n=3). (F) UMP can be produced by a de novo pathway (DNP) from 
glucose, glutamine, bicarbonate and aspartate or from extracellular rU by a nucleoside transporter and kinase-dependent salvage 
pathway (NSP). (G) Dose response curves of DHODH inhibitor NITD-982 and nucleoside transport inhibitor (NTi) dipyridamole (DPA) 
in JURKAT cells cultured in NSP+DNP (media +10 µM rU), NSP only (media +10 µM rU +1 µM NITD-982), or NP only (media alone) 
for 72 h as determined by Cell Titer Glo (mean±SD; n=4). 
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of DNP and NSP pathways to DNA biosynthesis as determined by LC-MS/MS following 24 hr 
treatment (n=3). % contribution values are normalized to total % labeling in E. (E) LC-MS/MS 
analysis DNP([13C6]glucose) and NSP([13C9; 15N2]rU) contribution to DNA-C in JURKAT cells 
cultured for 24 hr in media containing 5.5 mM [13C6]glucose and 10 µM [13C9; 15N2]rU treated 
±1 µM NITD-982 or ±1 µM dipyridamole (DPA; mean±SD; n=3). (F) UMP can be produced by 
a  de  novo  pathway  (DNP)  from  glucose,  glutamine,  bicarbonate  and  aspartate  or  from 
extracellular rU by a nucleoside transporter and kinase-dependent salvage pathway (NSP). (G) 
Dose response curves of DHODH inhibitor NITD-982 and nucleoside transport inhibitor (NTi) 
dipyridamole (DPA) in JURKAT cells cultured in NSP+DNP  (media +10 µM rU), NSP  only 
(media +10 µM rU +1 µM NITD-982), or DNP only (media alone) for 72 hr as determined by 
Cell Titer Glo (mean±SD; n=4). 
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Figure S2.2 | UMP-DNP and NSP are interchangeable in sustaining proliferation across a 
panel of cancer cell lines. Related to Figure 2.1. Uridine titration in cancer cell lines cultured 
±1  µM  NITD-982  (mean±SD;  n=4).  Relative  proliferation  rate  (GR)  was  calculated  by 
normalizing % proliferation values at 72 hr to cell line proliferation rate. Proliferation rates were 
calculated utilizing CTG measurements at the time of treatment and vehicle-treated controls at 
72 hr.
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Figure S2 | UMP-DNP and NSP are interchangeable in sustaining proliferation across a panel of cancer cell lines. Related to 
Figure 1. Uridine titration in cancer cell lines cultured ±1 µM NITD-982 (mean±SD; n=4). Relative proliferation rate (GR) was calculated 
by normalizing % proliferation values at 72 h to cell line proliferation rate. Proliferation rates were calculated utilizing CTG 
measurements at the time of treatment and vehicle-treated controls at 72 h.
rU titration alone 
NITD-982 + rU titration 
Figure S2.3 | Evaluation of UMP-NSP and -DNP inhibitor potency and selectivity. Related 
to Figure 2.1. (A) Cell Titer Glo analysis of MIAPACA2 cells cultured in NSP+DNP (media 
+10 µM rU), DNP (media alone),  NSP (media +10 µM rU +1 µM NITD-982) or starvation 
conditions (media + 1 µM NITD-982) for 72 hr (mean±SD; n=4; one-way ANOVA corrected for 
multiple comparisons by Bonferroni adjustment, ** P < 0.01; *** P < 0.001). (B) Methodology 
applied to determine UMP-DNP and -NSP selectivity scores (screen performed at n=2). (C) Z’-
scores  calculated  for  individual  assay plates  from experiment  in  Figure 2.1.  (D)  Selectivity 
scores for BTK inhibitors included in the screen. (E) Selectivity scores for VEGFR inhibitors 
included in the screen. (F) Structures of hit compounds. (G) Immuno-fluorescence microscopy 
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Figure S3 | Evaluation of UMP-NSP and -DNP inhibitor potency and selectivity. Related to Figure 1. (A) Cell Titer Glo analysis of 
MIAPACA2 cells cultured in NSP+DNP (media +10 µM rU), DNP (media alone), NSP (media +10 µM rU +1 µM NITD-982) or starvation 
conditions (media + 1 µM NITD-982) for 72 h (mean±SD; n=4; one-way ANOVA corrected for multiple comparisons by Bonferroni 
adjustment, ** P < 0.01; *** P < 0.001). (B) Methodology applied to determine UMP-DNP and -NSP selectivity scores (screen 
performed at n=2). (C) Z’-scores calculated for individual assay plates from experiment in Figure 1. (D) Selectivity scores for BTK 
inhibitors included in the screen. (E) Selectivity scores for VEGFR inhibitors included in the screen. (F) Structures of hit compounds. 
(G) Immuno-fluorescence microscopy nuclei counts of MIAPACA2 cells stained with Hoechst 33342 cultured in NSP+DNP (media +10 
µM rU), DNP only (media alone) or NSP only (media +10 µM rU +1 µM NITD-982) conditions for 72 h (mean±SD; n=4). (H) Calculation 
of IC50 values from experiment in G. (I) Calculation of JNK-IN-8, OSU-03012 and TAK-632 IC50 in JURKAT cells treated for 72 h 
determined using Cell Titer Glo. (J) JURKAT cell counts using trypan-blue exclusion following treatment ±100 nM JNK-IN-8 ±1 µM 
OSU-03012 ±1 µM TAK-632 for 72 h (mean±SD; n=4; one-way ANOVA corrected for multiple comparisons by Bonferroni 
adjustment,**** P < 0.0001).
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nuclei counts of MIAPACA2 cells stained with Hoechst 33342 cultured in NSP+DNP (media 
+10 µM rU),  DNP only (media alone) or NSP only (media +10 µM rU +1 µM NITD-982) 
conditions for 72 hr (mean±SD; n=4). (H) Calculation of IC50 values from experiment in G. (I) 
Calculation of JNK-IN-8, OSU-03012 and TAK-632 IC50 in JURKAT cells treated for 72 hr 
determined using Cell Titer Glo. (J) JURKAT cell counts using trypan-blue exclusion following 
treatment ±100 nM JNK-IN-8 ±1 µM OSU-03012 ±1 µM TAK-632 for 72 hr (mean±SD; n=4; 
one-way  ANOVA corrected  for  multiple  comparisons  by  Bonferroni  adjustment,****  P  < 
0.0001).
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Figure S2.4 | Characterization of JNK-IN-8, OSU-03012 and TAK-632. Related to Figures 
2.2 and 2.3. (A) JURKAT cell counts using trypan-blue exclusion following treatment ±200 µM 
PALA ±10 µM rU ±100 nM JNK-IN-8 for 72 hr (mean±SD; n=3; one-way ANOVA corrected for 
multiple comparisons by Bonferroni  adjustment,  **** P<0.0001).  (B)  Uptake of  [3H]labeled 
nucleosides in vehicle control condition from experiment in Figure 2.2B. Values represent % 
injected dose (%ID; n=3;  18.5 kBq).  (C)  Uptake of  [3H]rU or  [3H]dC in CCRF-CEM cells 
following 2 hr incubation ± JNK-IN-8 (mean±SD; n=2; 18.5 kBq). IC50 values are indicated. (D) 
Cell Titer Glo analysis of JURKAT cells treated ±10 nM dFdC ± JNK-IN-8 for 72 hr (mean±SD; 
n=4). Insert indicates JNK-IN-8 EC50 value. (E) Uptake of [3H]rU, [3H]dC, [3H]dA (+10 µM 
	 152
Figure S4
Figure S4 | Characterization of JNK-IN-8, OSU-03012 and TAK-632. Related to Figures 2 and 3. (A) JURKAT cell counts using 
trypan-blue exclusion following treatment ±200 µM PALA ±10 µM rU ±100 nM JNK-IN-8 for 72 h (mean±SD; n=3; one-way ANOVA 
corrected for multiple comparisons by Bonferroni adjustment, **** P<0.0001). (B) Uptake of [3H]labeled nucleosides in vehicle control 
condition from experiment in Figure 2B. Values represent % injected dose (%ID; n=3; 18.5 kBq). (C) Uptake of [3H]rU or [3H]dC in 
CCRF-CEM cells following 2 h incubation ± JNK-IN-8 (mean±SD; n=2; 18.5 kBq). IC50 values are indicated. (D) Cell Titer Glo analysis 
of JURKAT cells treated ±10 nM dFdC ± JNK-IN-8 for 72 h (mean±SD; n=4). Insert indicates JNK-IN-8 EC50 value. (E) Uptake of 
[3H]rU, [3H]dC, [3H]dA (+10 µM dCF), [3H]dG (+1 µM BCX-1777) in KP4662 cells following 2 h incubation ±1 µM JNK-IN-8 or 1 µM 
dipyridamole (DPA; 18.5 kBq; mean±SD; n=3; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment; ns: not 
significant; ** P<0.01; *** P<0.001; **** P<0.0001). (F) Uptake of [3H]-labeled nucleosides in vehicle control condition from experiment 
in E. Values are expressed as % injected dose (%ID; n=3; 18.5 kBq). (G) Summary of nucleoside transporter expression (RNA-seq; 
data obtained from oasis-genomics.org). (H) CETSA for ENT1 (SLC29A1) engagement in MIAPACA2 protein lysates. Lysates were 
incubated +10 µM JNK-IN-8 or +10 µM DPA for 2 h, subsequently heat treated at the indicated temperatures nd analyzed by 
immunoblot analysis. (I) Propidium iodide cell cycle analysis of MIAPACA2 PDAC cells treated ±1 µM NITD-982 (NITD) ±5 µM 
GSK-2334470 (GSK) or ±10 µM LY3009120 (LY) supplemented ±10 µM rU (N.S.: no supplement). Insert indicates % S-phase cells. (J) 
Summary of fold change in S-phase cells from I (mean±SD; n=2; one-way ANOVA corrected for multiple comparisons by Bonferroni 
adjustment, ns: not significant; **** P<0.0001). (K) pH2A.XS139 flow cytometry analysis of MIAPACA2 cells treated ±5 µM OSU-03012 
±5 µM TAK-632 ±500 nM VE-822 (ATRi) for 48 h (mean±SD; n=2; one-way ANOVA corrected for multiple comparisons by Bonferroni 
adjustment, ns: not significant; **** P<0.0001).
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dCF), [3H]dG (+1 µM BCX-1777) in KP4662 cells following 2 hr incubation ±1 µM JNK-IN-8 
or 1 µM dipyridamole (DPA; 18.5 kBq; mean±SD; n=3; one-way ANOVA corrected for multiple 
comparisons  by  Bonferroni  adjustment;  ns:  not  significant;  **  P<0.01;  ***  P<0.001;  **** 
P<0.0001). (F) Uptake of [3H]-labeled nucleosides in vehicle control condition from experiment 
in E. Values are expressed as % injected dose (%ID; n=3; 18.5 kBq). (G) Summary of nucleoside 
transporter  expression  (RNA-seq;  data  obtained  from  oasis-genomics.org).  (H)  CETSA for 
ENT1 (SLC29A1) engagement in MIAPACA2 protein lysates. Lysates were incubated +10 µM 
JNK-IN-8 or +10 µM DPA for 2 h, subsequently heat treated at the indicated temperatures and 
analyzed by immunoblot analysis. (I) Propidium iodide cell cycle analysis of MIAPACA2 PDAC 
cells treated ±1 µM NITD-982 (NITD) ±5 µM GSK-2334470 (GSK) or ±10 µM LY3009120 
(LY) supplemented ±10 µM rU (N.S.:  no supplement).  Insert  indicates  % S-phase cells.  (J) 
Summary of fold change in S-phase cells from I (mean±SD; n=2; one-way ANOVA corrected for 
multiple  comparisons  by  Bonferroni  adjustment,  ns:  not  significant;  ****  P<0.0001).  (K) 
pH2A.XS139 flow cytometry analysis of MIAPACA2 cells treated ±5 µM OSU-03012 ±5 µM 
TAK-632 ±500 nM VE-822 (ATRi) for 48 hr (mean±SD; n=2; one-way ANOVA corrected for 
multiple comparisons by Bonferroni adjustment, ns: not significant; **** P<0.0001).
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Table S2.1 | Crystallographic data collection and refinement statistics. Related to Figure 
2.4.
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Structure DHODH + OSU-03012 DHODH + TAK-632
PDB codes 6OC0 6OC1
Data collection statistics
X-ray source and detector
LS-CAT 21-ID-D LS-CAT 21-ID-G
Dectris Eiger x 9M MARCCD 300
Wavelength (Å) 0.99987 0.97872
Temperature (K) 100 100
Resolutiona (Å) 1.40 (1.48-1.40) 2.7 (2.85-2.7)
Number of Reflections
Observed 1,090,019 (113,565) 306,440 (48,502)
Unique 114,363 (17,418) 13,751 (2,169)
Completeness (%) 99.0 (94.2) 99.9 (99.8)
Rmeas (%) 7.0 (54.5) 17.0 (183.3)
CC1/2 (%) 99.9 (87.8) 99.9 (71.1)
Average I/σ(I) 19.2 (2.8) 21.6 (2.1)
Space group P 32 2 1 P 21 3
Unit cell: a, b, c (Å) 90.01, 90.01, 123.07 113.67, 113.67, 113.67
Unit cell: α, β, γ (°) 90, 90, 120 90, 90, 90
Wilson B-factors (Å2) 13.9 66.4
Refinement statistics
Refinement program REFMAC5 REFMAC5
     Rwork (%) 15.7 23.4
     Rfree (%) 19.1 29.1
Resolution range (Å) 48.55-1.40 46.45-2.70
Protein molecules per a.u. 1 1
Number of atoms:
     Protein 2845 2769
     Water molecules 232 36
     ORO + FMN 42 42
     Inhibitor 34 39
R.m.s. deviation from ideal:
     Bond length (Å) 0.009 0.0021
     Bond angles (°) 1.7114 1.264
Average B-factors (Å2)
     Protein 23.9 73.0
     Water molecules 32.6 44.7
     ORO + FMN 12.2 56.6
     Inhibitor 29.3 73.0
Ramachandran plot statistics (%)
     Most favored regions 97 86
     Additionally allowed regions 3 14
     Outlier regions 0 1
aHigh resolution shell in parenthesis; r.m.s., root-mean-square; a.u., asymmetric unit.
Table S1 | Crystallographic data collection and refinement statistics. Related to Figure 4.
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